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Altersbedingte Erkrankungen wie Osteoporose werden in Europa in den nächsten 
Jahren stark zunehmen. Die Knochenkrankheit geht mit einem erhöhten Frakturrisiko 
einher und ist mit hohen Kosten und einer unter Umständen stark verminderten 
Lebensqualität verbunden. Ausgehend von diesen Fakten wird die Wichtigkeit der 
Einführung und Einhaltung eines evidenzbasierten hochwertigen Standards für 
Prävention, Früherkennung und Therapie deutlich. Die Einführung eines so genannten 
„Medication Assessment Tool“ (MAT) durch Pharmazeuten, kann dabei helfen die 
Qualität der Verschreibungspraxis auf dem Gebiet der Osteoporosetherapie zu 
ermitteln.  
 
Im Rahmen des vorliegenden Projektes wurde eine retrospektive Studie an GPASS®- 
Daten aus drei allgemeinmedizinischen Praxen in Glasgow durchgeführt (n= 319 
Patienten; A= 154, B= 62, C= 103). Eingeschlossen wurden Patienten, die im 
genannten System als osteoporotisch oder osteopenisch registriert waren. MATosteo 
besteht aus 19 Kriterien- jedes davon stellt eine Guidelineempfehlung dar. Das 
Werkzeug selbst wurde von anerkannten, lokal tätigen, Osteoporoseexperten im 
Rahmen von Interviews evaluiert.  
 
Zwei unabhängige Forscher prüften MATosteo hinsichtlich seiner Zuverlässigkeit und 
erzielten dabei eine Übereinstimmung in ihren Ergebnissen von 99.6% (Minimum 
95.0%). Die Einhaltung der Guidelines wurde als „Guidelines Adherence“ in Prozent  
ausgedrückt und als niedrig (<50%), mittel (50-69.9%) oder hoch (>69.9%) eingestuft. 
Die Analyse ergab für alle drei Patientenkollektive eine mittlere Guidelineadherence 
von durchschnittlich 61.7% (CI 95% 59.8, 63.6). 148/260 (56.9%) 
Osteoporosepatienten wurden mit einem Bisphosphonat behandelt. Nur drei Patienten 
wurde ein Alternativmedikament verschrieben (Strontiumranelat). 35/260 (13.5%) 
erhielten nur Calcium und/oder Vitamin D. 110/260 (42.3%) wurden, trotz gestellter 
Diagnose, nicht behandelt.   
 
MATosteo ist ein systematisches und zuverlässiges Instrument. Ergebnisse, die eine 
mittlere oder gar niedrige Guidelineadherence aufzeigen, können als Ausgangspunkt 
für informelle Diskussionen mit dem Verschreiber genutzt werden und der Entwicklung 
von Initiativen zur Verbesserung der Verschreibungspraxis dienen.   
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ABSTRACT 
 
A pharmaceutical Care Model on Osteoporosis: Targeting patients groups 
 
Background 
As Europe's population is ageing the implementation of an evidence based standard for 
screening, diagnosis and treatment, especially for age associated diseases, like osteoporosis, 
will become more and more important. A Medication Assessment Tool (MATosteo) developed 
and used by pharmacists is now supposed to help to improve osteoporosis care in Scotland by 
identifying weak points in prescribing.  
 
Objectives 
To test a Medication Assessment Tool used for the application to GPASS® data and to 
demonstrate it's use in the evaluation of the level of adherence to guidelines and as a clinical 
audit tool. To find a method to analyse a large amount of data in an accurate and reproducible 
way. 
 
Design  
Retrospective Survey with a tool designed for medication assessment consisting of 19 criteria, 
each representing a guideline recommendation.   
 
Setting 
Patients (n=319) registered as osteopenic (n= 59) or osteoporotic (n= 260) on the GPASS® 
database of three general medicinal practices in Glasgow; A (n= 154), B(n= 62) and C (n= 103). 
Interviewees who have been nominated and accepted the invitation. 
 
Results 
The inter-rater reliability testing of the MATosteo by two independent researchers showed mean 
agreements of 99.6% (minimum 95% with 100% shown in 18/21). Adherence to guidelines was 
rated intermediate in all 3 practices and in total; A= 65.8% (CI 95% 62.3, 69.3); B= 52.1% (CI 
95% 47.8, 56.4); C=61.4% (CI 95% 57.7, 65.1) Total=61.7% (CI 95% 59.8, 63.6). Some 148/260 
(56.9%) patients with osteoporosis received a bisphosphonate. Overall only 3/112 (2.7%) 
patients not treated with a bisphosphonate were treated with an alternative (all 3 with Strontium 
ranelate).110/260 (42.3%) were untreated. 35/260 (13.5%) received only calcium and vitamin D. 
 
Conclusion 
MATosteo is a systematic and reliable audit tool for measuring quality of prescribing if full 
access to data is provided and the standard applied is most up to date and evidence based. 
Results ranked as intermediate (50- 69.9%) or low (< 50%) adherence to guidelines can be 
used as a starting-point for the development of pharmaceutical care initiatives.  
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1. INTRODUCTION 
 
1.1 Definition 
 
Osteoporosis is the most common bone disease in humans and defined as 
follows below (Mauck and Clarke 2006): 
“Osteoporosis is a systemic skeletal disorder characterized by a low BMD and 
microarchitectural deterioration of bone tissue, leading to enhance bone fragility 
and a consequent increase of fracture risk.” (Brown J.P and Fortier M. 2006) 
 
There are primary and secondary causes of osteoporosis (Mauck and Clarke 
2006). Both forms affect women and men (Scottish Intercollegiate Guideline 
Network 2003). In primary osteoporosis the bone loss is associated with the 
ageing process. Secondary causes for the disease can be nutritional deficiency, 
certain medications and medical conditions (Mauck and Clarke 2006).  
 
Osteoporosis is a chronic and progressive disease. Mostly there are no 
symptoms until the first fractures occur (Mauck and Clarke 2006; International 
Osteoporosis Foundation 2008). Those are however of notable concern as their 
impact on healthcare budgets, mortality, morbidity and patient’s quality of life is 
enormous (International Osteoporosis Foundation 2008). The most common 
sites for fractures due to osteoporosis are the vertebrae, hip and wrist 
(International Osteoporosis Foundation 2008; National Osteoporosis 
Foundation 2008). 
 
Osteopenia is a condition of low bone density and a marker for the risk of 
fractures (Torpy, Lynm et al. 2006). It is the preliminary stage of osteoporosis.   
 
1.2 Epidemiology 
 
The prevalence of osteoporosis increases with age. As it is particularly common 
in postmenopausal women, one could conclude it is a disease of elderly women 
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(Scottish Intercollegiate Guideline Network 2003). Nevertheless, clinicians 
should be aware of the fact that  men and younger people can also be affected 
for several reasons (National Osteoporosis Guideline Group 2008).  
 
In the European Union, someone suffers an osteoporotic fracture every 30 
seconds (International Osteoporosis Foundation 2008). In Scotland around 
240000 people are affected by the disease. Over the age of 50 one in three 
women and one in twelve men suffer an osteoporotic fracture (Scottish 
Intercollegiate Guideline Network 2003). As the population ages in Europe the 
scope of the problem will increase enormously within the next few years 
(National Osteoporosis Foundation 2008).  
 
Previous studies show clearly that different ethnic groups show different levels 
of bone density. Nevertheless, the role of ethnicity is still discussed 
controversially. In 1997 US researchers found out that the prevalence for 
osteoporosis is higher in non-Hispanic white women than in Mexican Americans 
and non- Hispanic black women (Looker, Orwoll et al. 1997). However recently 
a study was published where other conclusions were drawn. The researcher 
restricted data analysis to women with similar weight but belonging to different 
ethnic groups and demonstrated that ethnicity does not have an effect on rates 
of bone loss (Finkelstein, Brockwell et al. 2008).  
 
Among men 30 to 60 percent of cases of demonstrable osteoporosis are 
associated with secondary causes, like hypogonadism, use of glucocorticoids 
and alcoholism. Around 50% of the cases of osteoporosis in perimenopausal 
women can be classified as secondary osteoporosis. The prevalence of 
secondary causes among postmenopausal women is supposed to be lower, 
though the numbers are not known for sure (Mauck and Clarke 2006).  
 
1.3 Aetiology 
 
As osteoporosis remains asymptomatic until the first fractures occur, knowledge 
about risk factors and causes is especially important for health care 
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professionals in order to screen sufficiently the population and identify patients 
as soon and quickly as possible (Mauck and Clarke 2006). Several strategies 
and assessment tools had been developed within the last years, but still this 
disease remains dramatically under-diagnosed and under-treated (International 
Osteoporosis Foundation 2008).  Therefore, further work has to be done in 
order find out about the reasons for this phenomenon and to raise awareness of 
this problem equally among health care professionals and patients.  
 
1.4 Bone function and structure 
 
Bones form the skeleton of all vertebrates. Their mechanical purpose is to 
protect the internal organs, to make movements possible and to pass on 
sounds. Apart from these functions bones also take part in blood formation and 
have several metabolic tasks, like storing minerals or buffering the blood against 
excessive pH changes. Human bone mass increases during childhood and 
youth, reaches its' plateau when adults are young and starts to decrease 
around the age of 35 (Frost 1997). 
 
Bone matrix consists of organic and mineral parts. The mineral part is mainly 
hydroxyl apatite, the organic one collagen type 1, which forms fibrils.   
 
There are three main types of bone cells: osteocytes, osteoblasts and 
osteoclasts. Osteocytes transduce mechanical stimuli, which seem to activate 
osteoblasts (Parveen and Clark 2002). Osteoclasts and osteoblasts carry out 
the process of bone remodelling (Parfitt 1984).  
 
1.4.1 Bone remodelling 
 
Bones are subject to a permanent turnover. This process of bone remodelling is 
necessary to repair microdamage and to keep up other physiological functions 
of the human body. Bone resorption and bone formation are two closely linked 
functions. As long as they are well balanced, bone stays healthy and strong. 
Once equilibrium redeploys to resorption bone loss occurs.   
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Bone formation and bone resorption are linked together. BMUs (basic 
multicellular units) consist of mainly osteoclasts and osteoblasts (Frost 2000). 
The bone remodelling sequence can be represented  as a multilevel process 
(Parfitt 1984). Microdamage in bone means that also osteocytes are damaged 
(Heino, Kurata et al. 2009). As well as factors like PTH, certain interleukins and 
certain prostaglandins, microdamage leads to release of factors to which 
osteoblasts respond by releasing RANK-L and MCS-F and reducing 
osteoprotegerin (Aktories, Foerstermann et al. 2005). Osteoclasts are now 
directed chemotactically to the resorption area. Osteoclastic activity leads to 
release of calcium by secreting proteases and hydrochloric acids. Inhibitors limit 
activity of osteoclasts and growth factors initiate osteoblast formation from stem 
cells. Osteoid is produced and mineralization takes place (Parveen and Clark 
2002) (Aktories, Foerstermann et al. 2005). Osteoblasts are the so-called bone 
forming cells.  
 
1.4.2 The role of bones in calcium and phosphorus 
homoeostasis 
 
In the human body almost all of the calcium is stored in the bones. Only a small 
amount circulates in blood. Around 40 % of the plasma calcium are bound to 
albumin and has to be set free first, before it can be used for any physiological 
action (Hope, Longmore et al. 1993).  
 
Phosphate takes part in most of the biochemical reactions of the human body. 
Around 80 % are stored in the bones (Parveen and Clark 2002).  
The regulation of both calcium- and phosphate levels is closely linked together 
(Parveen and Clark 2002). The major hormones taking part in this process are 
PTH (parathyroid hormone) and Calcitonin. 1,25- dihydroxyvitamin D3 plays as 
well an important role in regulating calcium and phosphate homeostasis (Hope, 
Longmore et al. 1993).  
 
When levels of free calcium decrease, PTH is released. As a consequence 
osteoclastic activity, intestinal absorption of calcium, synthesis of 1,25- 
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dihydroxyvitamin D3, renal tubular reabsorption of calcium and excretion of 
phosphate will be increased (Parveen and Clark 2002). Vitamin D increases 
calcium absorption in the gut as well as PTH does. Calcitonin lowers the levels 
of calcium and phosphate (Hope, Longmore et al. 1993). This response shows 
clearly why, a sufficient dietary intake of calcium and vitamin D is necessary to 
keep human bones strong and healthy. A permanent decrease leads to 
permanent release of calcium of bones and the fracture risk rises.  
 
1.5 Influences on bone health 
 
During childhood and young adulthood the basis for healthy bones is built. At 
the age of 20-25 the bone growth is completed and peak bone mass is reached. 
Peak bone mass is the maximum of bone mass that can be achieved during 
live. The higher it is, the lower the risk of developing brittle bones in a later 
phase of life. The keys to developing strong bones in this period are balanced 
nutrition and regular exercise (Brown J.P and Fortier M. 2006) (International 
Osteoporosis Foundation 2008).  
 
With progressing age bone loss increases. The biggest reduction in bone 
density occurs during menopause due to decreasing oestrogen levels. Again it 
is very import during this period of life to exercise regularly and to ensure an 
adequate intake of calcium and vitamin D. However, lifestyle in general and 
environment have an impact on bone health as well. Certain factors can lead to 
a significant increase of fracture risk (Brown J.P and Fortier M. 2006).  
 
1.5.1 Risk factors for osteoporosis 
 
There are both modifiable and non-modifiable risk factors for osteoporosis 
(International Osteoporosis Foundation 2008).  
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1.5.1.1 Non-modifiable risk factors 
 
Those risk factors cannot be influenced by lifestyle changes but are 
nevertheless important for risk assessment and for targeting patient groups.  
 
 Age 
The risk of osteoporosis increases with ongoing age. In general women 
are likely to develop the disease earlier than men.  
 Gender 
Women are at greater risk of osteoporosis than men.  
 Ethnicity/ Race 
 Family history 
There is evidence for a genetic impact on peak bone mass. This could be 
the explanation for the fact that some families are more likely to develop 
osteoporosis than others. However, this is controversial as it could also be 
due to similar lifestyle attitudes. Nevertheless someone who has one or 
more relatives suffering from osteoporosis is surely also at higher risk.  
 Previous fracture 
Trials have shown that there is a significant link between sustaining a 
fracture during childhood and developing osteoporosis later on. As well it 
is clear that patients who already had a fracture are more likely to suffer 
from osteoporosis than others.  
 Secondary causes of osteoporosis 
There is a large list of secondary causes for osteoporosis. Some of them 
are modifiable, e.g. by pharmacological intervention. 
 
1.5.1.2 Modifiable risk factors  
 
Knowledge about modifiable risk factors is very important as they can be used 
to give specific advice to patients in order to reduce the possibility of developing 
osteoporosis or to stem the progress of the disease. Modifiable risk factors are: 
 
 Lack of physical activity 
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 Inadequate intake of calcium and vitamin D 
 Smoking 
 High intake of caffeine 
 Frequent falls 
 Low BMI 
 
1.6 Prevention 
 
Osteoporosis is a major burden on healthcare budgets and patients. Therefore, 
it is very important to healthcare providers to identify individuals at high risks 
and start preventative initiatives. The aim of course is to reduce osteoporosis 
incidence. However, osteoporosis prevention can also be seen in a different 
context- the prevention of fractures. Intervention should include 
pharmacological and non-pharmacological strategies (Gronholz 2008). Both 
strategies work only with the contribution of persons affected.  
 
1.6.1 Non-pharmacological interventions 
 
Non-pharmacological interventions are likely to be adequate for many 
individuals requiring primary prevention (before a fracture has occurred). The 
following possibilities are available: reducing falls risk, lifestyle modifications, 
nutritional counselling, physical exercise, osteopathic manipulative treatment 
and hip protectors (Gronholz 2008).  
 
1.6.1.1 Falls prevention 
 
Falls are a frequent problem among older people (Logan, Coupland et al. 
2010)- up to 35% of seniors aged 65 years or older fall at least once a year. 
Between 5 and 10% of them suffer a serious injury. Mulifactorial interventions 
reduce the risk of falls and subsequent health costs significantly (McClure, 
Hughes et al. 2010).   
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Patients should be encouraged to modify their environment appropriately 
(Gronholz 2008; Vondracek and Linnebur 2009) in order to reduce their risk of 
falling. Frequently recommended measures are listed in the box below: 
 
Table 1: How to prevent falls  
Add grab bars in the bathroom 
Increase lightning 
Remove loose floor coverage 
Install railings along stairways 
Safe foot wear 
 
(Mauck and Clarke 2006; Gronholz 2008; Vondracek and Linnebur 2009; Logan, Coupland et al. 2010) 
 
It is also necessary to assess vision and to treat visual impairments (Mauck and 
Clarke 2006; Gronholz 2008; Vondracek and Linnebur 2009). Visual function 
takes part in the balance system by helping to detect perturbations of   balance. 
Visual acuity and contrast sensitivity are moderately correlated to extent of 
sway, which is a risk factor for falls. It is a fact that older people, who are at 
higher risk for osteoporosis anyway, are more dependent on vision than 
younger. The fact that older people have longer reaction times and that the 
visual mechanism for correcting sway is relatively slow explains to some extent 
why it is harder for them to sufficiently correct loss of balance (Harwood 2001). 
Therefore, it is extremely important to correct visual impairments.  
  
Several other diseases, e.g. cardiovascular disease or musculoskeletal 
disorders, lead to an increased risk of falls (Mauck and Clarke 2006; Vondracek 
and Linnebur 2009). Therefore they should be regularly monitored and 
adequately treated. 
 
Pharmacists’ contribution in reducing the risk of falls could be a medication 
review. It is important to avoid medication that leads to hypotension or alters 
mental status or gait stability (Mauck and Clarke 2006). The following table lists 
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some medication groups which have a potential to higher the risk of falling: 
 
Table 2: Substances that higher the risk of falls 
Diuretics 
Antihypertensives 
Benzodiazepines 
Antipsychotics 
Antidepressants 
 
(Vondracek and Linnebur 2009) 
 
1.6.1.2 Physical Exercise 
 
Regular performance of physical exercise leads to an increased bone density 
and strengthens muscles and balance. Nevertheless not all kinds of sports are 
suitable for old people at risk of falls and/ or osteoporosis. It is best to 
recommend walking, mild forms of aerobic and resistance exercises as far as 
they are tolerated. It has been shown that it is possible to avoid up to 25% of 
falls, but there is no evidence that the risk of fractures decreases by exercise 
(Mauck and Clarke 2006).  
 
1.6.1.3 Life style adjustments 
 
Smoking decreased the BMD. Therefore, smoking cessation is recommended 
for the older senior as well as for the older patient. There is evidence that one 
year of cessation increases the BMD in the femoral trochanter and total hip 
(Vondracek and Linnebur 2009).  
In general a healthy lifestyle including regular activity and healthy nutrition helps 
to prevent osteoporosis or its progression (International Osteoporosis 
Foundation 2008).  
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1.6.1.4 Nutritional Counselling 
 
A healthy and balanced diet helps to keep our bones healthy and to prevent 
other chronic diseases like obesity, cardiovascular disease, cancer and 
diabetes. Calcium and vitamin D are especially important for the bone 
formation, but there is also a need for other substances like potassium, 
proteins, vitamin D, etc. (Weichselbaum and Dorner 2007).  
 
From a closer look at hip fracture patients it has been shown that up to 63% 
have a low nutritional status at the time of hospitalisation, which can negatively 
influence the healing process. Although there is a clear link between nutritional 
status and the risk of sustaining a hip fracture, there is still a lack of evidence 
concerning the benefit of various types of nutritional intervention. 
Supplementation of nutrients is the simplest intervention , but many  patients 
are non-compliant (Wyers, Breedveld-Peters et al. 2010).  
 
In 2006 Duncan et al. were able to show that the support of a dietetic assistant 
has a positive impact on the mortality of hip fracture patients. After four months 
of intervention this positive effect still lasted. The researchers were of the 
opinion that nutritional counselling should be introduced across the NHS 
because of its potential to improve quality of patient care (Duncan, Beck et al. 
2006).  
 
1.6.1.5 Hip protectors 
 
More than 90% of hip fractures are associated with falls. The highest incidence 
has been reported in nursing home residents who fell to the side. Therefore so 
called 'hip protectors' were designed in order to reduce the fracture risk (Kiel, 
Magizer et al. 2007). Whether they are really effective or not is still discussed 
controversially and seems to depend on multiple factors (Bulat, Applegarth et al. 
2008).  
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Several types of hip protectors are available: 
 hard shell (Kiel, Magizer et al. 2007; Bulat, Applegarth et al. 2008) 
 soft shell (= foam type) (Kiel, Magizer et al. 2007; Bulat, Applegarth et al. 
2008) 
 hybrid (Bulat, Applegarth et al. 2008) 
 
Hard shell hip protectors aim to divert the energy of fall into surrounding tissues, 
whereas, soft shell hip protectors absorb the energy of fall (Kiel, Magizer et al. 
2007; Bulat, Applegarth et al. 2008). Hybrids combine both principles (Bulat, 
Applegarth et al. 2008).  
 
Patients tend to low compliance concerning hip protectors, which might 
contribute to the fact that in many studies they were found to be ineffective in 
preventing fractures. A study by Bulat et al. showed that hip protectors do 
degrade with a rising number of impacts but most remain  effective in shielding 
patients from hip fractures (Bulat, Applegarth et al. 2008). 
 
1.6.1.6 Osteoporosis knowledge and preventative behaviour 
 
The knowledge about osteoporosis is an important contributor to preventative 
behaviour- meaning performing regular exercise and a sufficient calcium intake 
(Winzenberg, Oldenburg et al. 2003).  
 
1.6.2 Pharmacological interventions 
 
Neither the NICE guidelines nor the SIGN guidelines cover the treatment of 
osteopenia, but the Canadian guidelines state that the use of bisphosphonates 
can help to prevent fractures in women who have a diagnosis of osteopenia 
(Brown J.P and Fortier M. 2006). As osteopenia is the preliminary stage of 
osteoporosis it is suitable to conclude that an adequate treatment of osteopenia 
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can help to prevent osteoporosis.  
 
Administering bisphosphonates is also necessary if the long-term use of other 
substances leads to osteoporosis. The most popular example is the use of oral 
glucocorticoids (Scottish Intercollegiate Guideline Network 2003), but there are 
also a variety of other medications that increase  the fracture risk- e.g. 
antiepileptics or anastrozol.  
 
Knowledge about secondary causes for osteoporosis is necessary for 
pharmacists to identify patients at risk and to recommend starting  adequate 
pharmacological interventions (Mauck and Clarke 2006).  
 
1.7 Symptoms 
 
Osteoporosis often remains undiagnosed until the first fracture occurs (Mauck 
and Clarke 2006). The loss of bone though is progressive and silent 
(International Osteoporosis Foundation 2008).  
 
The most common sites for osteoporotic fractures are hip, spine and wrist. All 
injuries influence quality of life of the patients and are a burden on health care 
budgets, when both the  acute and chronic medical costs are taken into account 
(International Osteoporosis Foundation 2008).  
 
1.7.1 Hip fractures 
 
A majority of hip fractures that occur over the age of 50 are due to osteoporosis. 
(International Osteoporosis Foundation 2008). They are of notable concern as 
they are a major cause of mortality and morbidity (McColl, Roderick et al. 1998). 
After a year of sustaining the fracture up to 24% of patients die (Cooper, 
Atkinson et al. 1993). Of those who survive only 50% will walk again, but often 
not to the same degree before the fracture happened (International 
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Osteoporosis Foundation 2008).  
 
1.7.2 Vertebral fractures 
 
Although vertebral fractures cause pain and a loss of quality of life, they often 
remain undetected and undiagnosed - less than 10% lead to hospitalisation. 
The first vertebral fracture needs to be seen as a warning sign. After a year one 
in five women experiences another fracture - resulting potentially in a so called 
'fracture cascade' (Kanis, Johnell et al. 2004). 
 
The consequences of vertebral fractures are pain, physical changes and 
impairments and psychosocial declines (Hallberg, Ek et al. 2010) well as 
enormous costs that mostly arise from outpatient care (International 
Osteoporosis Foundation 2008). 
 
Patients describe two types of back pain - constant pain and activity related 
pain. Constant back pain is experienced as horrible and life-dominating, 
whereas activity-related pain eases when activity stops. Nevertheless, 
continuous movement stays impossible for a lot of patients (Hallberg, Ek et al. 
2010).  
 
Psychosocial decline often results in those constantly suffering pain. Many 
patients avoid coming together with friends and relatives as they are unable to 
sit down in an ordinary chair and feel like a burden to others (Hallberg, Ek et al. 
2010).  
 
1.8 Diagnosis 
 
The current gold standard for the diagnosis of osteoporosis is the measurement 
of bone mineral density by performing a DEXA scan. In clinical practice the 
disease is very often diagnosed in an already progressed state, when a low-
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trauma fracture or a fragility fracture occurs. A fragility fracture occurs without 
the presence of a trauma, that is spontaneously or due to coughing. A fracture is 
defined as 'low-traumatic' if it occurs after a fall from standing height or less 
(Mauck and Clarke 2006).   
 
Since 1994 DEXA scan opens the possibility to diagnose osteoporosis in an 
earlier stage - before the patient has sustained a fracture (Mauck and Clarke 
2006). Therefore it is necessary that healthcare professionals identify people at 
risk and refer them for a DEXA scan. According to the NICE and SIGN 
guidelines for osteoporosis, a DEXA scan should be performed at two specific 
sites - the hip and the spine (Scottish Intercollegiate Guideline Network 2003; 
National Institute of Health and Clinical Excellence 2008).  
 
The technique is non- invasive and available throughout all the member states 
of the European Union. In 2007 though many countries, including the UK, 
Bulgaria, Romania, Luxembourg, Spain and Sweden, did not reach the 
recommended number of scanners for their respective populations. This means 
that quite a lot of people could not be referred to a DEXA scan within recent  
years (International Osteoporosis Foundation 2008).   
 
The World Health Organisation (WHO) defines  that someone suffers from 
osteoporosis if the measured BMD is 2.5 standard deviations or more below the 
average value for young healthy women (WHO 2004).  
 
1.9 Treatment options 
 
Osteoporosis treatment involves acute care (treatment of fractures and acute 
pain), pharmacological and non-pharmacological interventions to increase bone 
density and decrease the risk of  sustaining future fractures (Mauck and Clarke 
2006). This section focuses mainly on pharmacological treatment as this 
knowledge is the basis for future understanding of MATosteo.    
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The universal basis for the management of   osteoporosis is an adequate 
calcium and vitamin supplementation. At the moment pharmacological 
treatment options, thereafter, fit into one of two categories: antiresorptive or 
osteoanabolic (Mauck and Clarke 2006).  
 
1.9.1 Antiresorptive agents 
 
Antiresorptive agents reduce bone resorption- bone loss decreases. 
Bisphosphonates, raloxifene, strontium ranelate, calcitonin and estrogen belong 
to this group (Mauck and Clarke 2006).  
 
1.9.1.1 Bisphosphonates 
 
Bisphosphonates alter the function of osteoclasts and thereby reduce bone 
resorption (National Institute of Health and Clinical Excellence 2008). Oral 
administration and intravenous application are possible.  Although NICE and 
SIGN guidelines only deal with oral ones, the intravenous administration can be 
seen as a good alternative for patients who cannot tolerate oral 
bisphosphonates (Sunyecz 2008). 
 
Oral bisphosphonates are poorly absorbed and should be taken with a glass of 
water in the morning after overnight fasting on an empty stomach. For the 30 
minutes after oral administration it is necessary for the patient to keep upright 
and to avoid food. All bisphosphonates have a potential to cause 
gastrointestinal side-effects. As the protocol for ingestion is quite complicated, 
oral bisphosphonates might not be the best option for patients who are 
confused and do not have help with coping with their medication (Scottish 
Intercollegiate Guideline Network 2003).  
 
When this project was started the national guidelines in the UK did not include 
i.v. bisphosphonates (zoledronic acid, ibandronic acid and pamidronate). 
Nevertheless those agents have some benefits, like an easy dose regimen or 
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the reduction of gastrointestinal side-effects compared to oral bisphosphonates. 
Zoledronic acid is administered once a year, ibandronic acid every three 
months. All i.v. bisphosphonates may cause minor flu symptoms for about one 
to three days,  but are otherwise generally tolerated well (Sunyecz 2008).  
 
The guidelines used for the development of MATosteo include alendronic acid, 
risedronate and etidronate.  
 
An American study by Tosteson et al showed that the use of bisphosphonates is 
cost-effective as women sustain fewer fractures and gain more QALYs from 
treatment compared with those untreated or who are treated with PTH. 
Treatment costs increased in the following order: no treatment, risedronate, 
alendronate, ibandronate and PTH. The high risk group was analysed for cost 
effectiveness and it included women aged 75 years who had a previous 
fracture. In this group the administration of any treatment offset additional costs 
of inpatient, outpatient and long-term care. The authors also stated that their 
results are comparable with those of studies in European countries, like the UK 
or Belgium (Tosteson, Burge et al. 2008).  
 
A common problem in osteoporosis therapy is non-compliance. Several studies 
show that only 40 to  50% of patients are compliant (obtain  their prescription 
refills and take their pills regularly) (Rackoff 2009).  
 
1.9.1.1.1 Alendronic acid 
 
Alendronate is authorised at the UK market as a once weekly preparation (70 
mg) and as well as a daily dose (10mg) (National Institute of Health and Clinical 
Excellence 2008). It is effective for the secondary prevention of vertebral and 
non-vertebral fractures by increasing bone mineral density and decreasing bone 
turnover. A retrospective study by Jun Iwamoto evaluated the outcome of 
Alendronate and showed that the increase of lumbar BMD after seven years is 
about 12.8%. Within this period no serious side-effects, like osteonecrosis of 
jaw or artrial fibriallation were observed. It was possible to prove changes in 
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bone metabolism by monitoring serum alkaline phosphatase and N-terminal 
telopeptides of type I collagen (Iwamotot, Sato et al. 2010).  
 
A cross-sectional Japanese study by Hisaya Kawate et al, showed that 
Alendronate significantly improves QOL in postmenopausal women after four 
months of treatment (Kawate, Ohnaka et al.).  
 
1.9.1.1.2 Risedronate 
 
Risedronate is authorised at the UK market as a once weekly preparation (35 
mg) and as well as a daily dose (5mg) for the treatment of postmenopausal 
osteoporosis (NICE). A study by Tahir Masud et al showed that orally 
administered risedronate reduces the risk of sustaining a hip fracture by 46% in 
elderly women with established osteoporosis compared to placebo (35). 
Risedronate is also effective in vertebral fractures and is beneficial in both 
women and men and also for glucocorticoid-induced osteoporosis. It has a good 
safety profile like all bisphosphonates – furthermore  atrial fibrillation was not 
shown (Rackoff 2009).  
 
1.9.1.1.3 Etidronate 
 
Etidronate is an oral bisphosphonate administered in 90 day cycles. The patient 
takes 400mg/day for 14 days and 1.25g calcium carbonate for the last 76 days 
(National Institute of Health and Clinical Excellence 2008). 
 
1.9.1.2 Raloxifene 
 
Raloxifene is a selective estrogen receptor modulator. It increases BMD and 
decreases cholesterol but does not increase the risk of breast cancer. 
Raloxifene is licensed for the prevention and treatment of postmenopausal 
osteoporosis. There is evidence for the reduction in  the risk of  vertebral 
fractures by about 50%, but currently there is no evidence to be found 
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concerning hip fractures. It is contraindicated for women with a history of 
venous thromboembolism and is not recommended in women on HRT (Mauck 
and Clarke 2006). Raloxifene is authorised for the UK market with a 
recommended dose of 60mg/day (National Institute of Health and Clinical 
Excellence 2008).  
 
1.9.1.3 Strontium ranelate 
 
Strontium ranelate has a UK market authorisation for the treatment of 
postmenopausal osteoporosis and prevents both vertebral and non-vertebral 
fractures. The recommended dose is 2g/day. The patient needs to swallow the 
product as a suspension with water. As food and milk products reduce the 
resorption of the agent, it should be administered 2 hours after eating and 
preferably at bedtime (National Institute of Health and Clinical Excellence 2008).   
 
1.9.1.4 Calcitonin 
 
Calcitonin cannot be recommended as first-line therapy for osteoporosis. It 
prevents vertebral fractures and may reduce pain in vertebral fractures, but 
there is no evidence for non-vertebral fractures. Calcitonin is licensed as an 
intranasal preparation (200 IU/day) (Scottish Intercollegiate Guideline Network 
2003). The only side effect known is rhinitis. Besides intolerance no 
contraindications are listed (Mauck and Clarke 2006).  
 
1.9.1.5 Oestrogen 
 
The decrease in oestrogen levels after the menopause leads to an increased 
bone loss. Though still controversially discussed, one treatment option is 
hormone replacement therapy (HRT) in which estrogen is administered alone or 
in combination. Possible adverse effects if oestrogen alone is used are stroke 
and venous thromboembolism (Mauck and Clarke 2006). When this project was 
started, neither the national nor the local guidelines recommended HRT for the 
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prevention or therapy of osteoporosis. 
 
1.9.2 Osteoanabolic agents 
 
Osteoanabolic agents stimulate bone formation (Mauck and Clarke 2006). 
When this project was started guidelines included only one preparation- 
Forsteo® (Teriparatide). 
 
1.9.2.1 Teriparatide 
 
Teripartide is a fragment of the human parathyroid hormone, which is 
recombinant produced and consists of the first 34 amino acids of the natural 
hormone. It is authorised for the UK market as an injectable preparation. The 
recommended dose is 20 micrograms/day for 18 months. After this period there 
is a need for treatment pause. Teriparatide is recommended for women with 
established osteoporosis only and rather expensive compared to the other 
treatment options on the market (National Institute of Health and Clinical 
Excellence 2008).  Known side-effects are dizziness, leg cramps, arthralgia and 
post-injection hypercalcaemia (Mauck and Clarke 2006).  
 
1.10  Frequent challenges in osteoporosis treatment 
 
As evidence shows mostly people aged 50 years or older suffer from 
osteoporosis. The majority of patients are female and postmenopausal. As the 
disease is silent until the first fractures occur, it is very often diagnosed in a 
quite progressed stage.  
 
Thinking about these facts already makes clear that within this patient sample 
pharmacological therapy might become quite complicated.  
 
Inappropriate prescribing is quite common in people aged 65 years or older. 
Possible reasons are a higher prevalence for chronic diseases, disability and 
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dependency. Additionally about 29% of older people are polymedicate - 
meaning they take five or more medication prescriptions and many take at least 
one over-the counter medication and supplements.  
 
Using medication starts with prescribing and continues with dispensing, drug 
administration and monitoring. The patient needs to be instructed about the 
drugs used. Each step is potentially tricky and may present health risks. 
Medication use problems may often be preventable and so need to be 
addressed by the principles of pharmaceutical care (Page, Linnebur et al. 
2010). 
 
Literature review identified some possible challenges, which might occur if 
osteoporosis patients are treated (renal impairment, non-compliance, 
inappropriate prescribing and adverse drug reactions). Knowledge about these 
challenges is necessary for the purposes of this project. Lack of such factual 
knowledge by the investigator may lead to wrong judgements concerning 
justifications of observed non-adherence to guidelines. 
  
1.10.1.1 Renal impairment 
 
The prevalence for both osteoporosis and chronic kidney disease (CKD) 
increases with age and always renal diseases increase the risk for skeletal 
abnormalities. The treatment for such patients is necessary but challenging, 
because there is a lack of data and evidence concerning the administration of 
antiresorptive agents. The safety and appropriateness of bisphosphonates in 
CKD patients is uncertain.  
 
The majority of manufacturers recommend not to prescribe bisphosphonates in 
patients with a creatinine clearance less than 30 ml/min. Courtney et al 
recommend to avoid alendronic acid if creatinine clearance is less than 35 
ml/min and to avoid ibandronic acid and risedronate acid if creatinine clearance 
is less than 30 ml/min. For those with a creatinine clearance betwenn 10 and 30 
ml/min it is suitable to administer 50% of the usual dose of sodium clodronate. 
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They stated that it was safe to use bisphosphonates under these conditions 
(Courtney, Leonard et al. 2009).  
 
1.10.1.2 Non-compliance 
 
The risk of non-compliance is high in patients with asymptomatic chronic 
diseases, like osteoporosis. It depends on several factors like tolerability or the 
scheme of administration (Stevenson, Jones et al. 2005). There is conflicting 
evidence concerning the link between osteoporosis knowledge or beliefs and 
the osteoporosis preventative behaviour of patients. Some studies show that an 
increased knowledge about the disease significantly increases preventative 
behaviour, some state that the increase of knowledge does not necessarily lead 
to changes in preventative behaviour (Winzenberg, Oldenburg et al. 2003).  
 
1.10.1.3 Inappropriate prescribing 
 
Inappropriate prescribing encompasses the following fields:  
 use of drugs that have a higher risk of adverse effects than alternative 
ones which are equal or more effective but less risky according to 
evidence 
 over- use of medication  
 longer duration than clinically indicated 
 higher frequency of administration 
 under-use of medication 
 use of multiple medication although there is evidence of drug-drug 
interactions 
 use of drugs that negatively interact with the disease 
 
However, inappropriate medication is associated with an increase in adverse 
drug events, morbidity and mortality (Page, Linnebur et al. 2010). 
 
Osteoporosis patients are at risk of inappropriate prescribing due to their age. In 
addition natural changes in the constitution of the human body increases the 
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risk of adverse drug events mostly due to changes in pharmacokinetics. 
 
1.10.1.4 Adverse drug events 
 
An adverse drug event (Yood, Mazor et al.) is an injury that results from a 
medical intervention related to a drug. It can be preventable or non preventable 
and due to loss of control of a disease or due to underuse (Bates, Miller et al. 
1999; Bates, Cullen et al. 2005).   Most of the preventable ADEs occur because 
drugs are used incorrectly. Most of these errors occur in the prescribing stage, 
the second highest risk for mistakes was found in the administration stage. 
ADEs potentially bring harm to the patients and are costly (Bates, Cullen et al. 
2005).   
 
Risk factors for ADEs are high age, high number of drugs received and factors 
that alter drug distribution or metabolism (Bates, Miller et al. 1999). The typical 
patient suffering from osteoporosis is elderly and therefore at higher risk of an 
ADE. They are important causes for morbidity and hospitalisations in this age 
group (Malhotra, Karan et al. 2001) and it is worthwhile to develop strategies to 
avoid such events. Therefore a pharmacist should be aware of drugs and 
situations with a high potential for ADEs. 
 
Moreover, Mahotra et al found that 7.6 % of ADEs were related to non-
compliance- mostly due to underuse, followed by overuse and misuse. Women 
were more likely to be non-compliant than men. Complicated treatment 
regimens, inability to properly recall one's medication increased the risk of non-
compliance (Malhotra, Karan et al. 2001).  
 
1.11  Pharmaceutical care 
 
Pharmaceutical care is the quality of medication use. It is a discipline to do with 
the quality assurance of medication use and it seeks to improve health-
outcomes of patients by, among other things, reducing adverse drug events, 
including side-effects and interactions. Pharmaceutical care can be provided by 
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the development of documentation (such as protocols and care plans) for 
patients or patient groups with special needs. Therefore, to help improve 
pharmaceutical care, the pharmacist unites the knowledge about pharmacology, 
medicinal chemistry, physiology, pathophysiology and technology for the benefit 
of the patient. Pharmacist’s actions involve the prevention, identification and 
resolution of  drug-related problems (Hepler and Strand 1990). Pharmacists can 
achieve those goals by working together with members of other medical 
professions in multidisciplinary team.  
 
MATosteo has the potential to identify patients who are not treated according to 
the guidelines to evaluate the use of pharmaceutical initiatives on quality of 
medication use.   
 
1.12  Clinical guidelines 
 
Guidelines are supposed to form a bridge between evidence-based medicine 
and clinical practice. Applying guidelines aims to improve quality of care, reduce 
inappropriate variations in practice and provide cost- effective care (Rogers 
2002).  
 
Adherence to guidelines impacts on how effective medicines are in healthcare. 
A study by J S Burgers et al suggests that guidelines are effective if the 
following characteristics are fulfilled:  
 
Table 3: Effectiveness of guidelines 
Evidence based recommendations 
Compatible with existing norms and values 
Easy to follow and not requiring new skills and knowledge 
(Burgers, Grol et al. 2003) 
 
Nevertheless, ethical considerations should be taken into account in order to 
realise the potential of guidelines to improve the health of both individuals and 
populations. Ethical issues arise as well during the development of guidelines 
as when guidelines are used in clinical practice (Rogers 2002). The following 
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
24 
 
ethical principles have to be implemented in healthcare and therefore as well in 
guidelines:  
 
Table 4: Ethical principles for guidelines 
To act for the good of the patients 
Non-maleficence 
Fairness in healthcare 
To respect patient's autonomy 
(Burgers, Grol et al. 2003) 
 
1.12.1 Guidelines used in MATosteo 
 
The 19 criteria of MATosteo are derived from three national (UK) guidelines 
provided by the 'National Institute for Health and Clinical Excellence' (NICE) and 
the 'Scottish Intercollegiate Guidelines Network' (SIGN). They where considered 
to be the most actual available standard and to be broadly accepted by 
healthcare professionals. All three include information which considerations 
where made when forming the recommendations and where thought to fulfil the 
ethical expects of healthcare. 
 
1.13 National Health Service Scotland (NHSScotland) 
 
In Scotland health services are delivered by the NHS through 14 health boards. 
The Scottish Government Health Directorate is responsible for the NHS and 
several other services.  
 
Each health board develops local health care strategies and is responsible for 
an effective and efficient performance of the services delivered. The field of 
duties includes the management of hospitals and General Practices in the area 
as well as all other health services. Glasgow belongs to the Greater Glasgow 
and Clyde Health Board (NHSScotland 2010).   
 
Most NHS services are free, but there are charges for some things like 
medicines.  Each patient gets a community health index number (CHI), which 
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aims to make it easier for NHS staff to find medical information and provide the 
best treatment possible. Whenever possible it is used for records the NHS 
keeps (NHS 2009).  
 
People in Scotland are asked to register in a GP surgery, health centre or 
medical practice as an NHS patient. The family doctor then helps them to look 
after their health and decides whether it is necessary or not to see another 
health care professional or not. The term general medical practitioner (GP) is 
equal to the term family doctor (NHS 2008). The GP is the contact point for the 
patient.  
 
Emergency care in a hospital, emergency transport in an ambulance, sexual 
health services and treatment for some infectious diseases and sexual 
transmitted diseases is free for everyone (NHS 2009).  
 
1.14  Important pharmacy services 
 
Pharmacies in Scotland offer several services to their costumers, which are co-
ordinated by the NHS. The services explained below seemed to be the most 
important in the understanding of the Scottish healthcare system.  
 
1.14.1 NHS minor ailment service (Masud, McClung et al.) 
 
In Scotland people who a registered with a GP surgery, and who do not live in a 
nursing home and do not pay for their prescriptions can register for the MAS. 
They register in a community pharmacy and can come and see a qualified 
pharmacist whenever it is suitable for them. The pharmacist can decide to give 
an over the counter or pharmacy only medicine or product to treat the 
symptoms or can decide to ask the patient to see a GP if the patient’s condition 
needs that (if it needs a medical assessment or a medicine that needs a 
prescription) (NHSScotland.).  
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1.14.2 NHS chronic medication service (CMS) 
 
The CMS is about to be made available in community pharmacies all over 
Scotland. Patients with long-term conditions will be able register in a pharmacy 
or via their GP. A qualified pharmacist will then review the use of medicines, 
discuss any problems that might occur with the patients and develop a care 
plan if necessary within a treatment period of 24-38 weeks during which their 
medicines are dispensed on a serial prescription (repeated dispensing). The 
patient won’t need to see his doctor or get a new prescription within this period. 
The GP however is allowed to decide whether the medication is suitable for this 
type of prescription or not (NHSScotland 2010).   
1.15  Role of pharmacists in the Scottish healthcare system 
 
In 2004 there were around 4000 pharmacists working in Scotland. They aim to 
work in partnerships with patients and other professionals to ensure the safest 
and best use of medicines - an approach called pharmaceutical care.  
 
Community pharmacists fulfil an important part in health improvement - they are 
ambassadors of public health. For quite a lot of patients they are the first and 
only contact with a healthcare professional. Pharmacies are an important link 
between the NHS and public.  
 
Hospital pharmacists specialise in clinical pharmacy, drug procurement, the safe 
preparation and dispensing of medicines, medicines information, 
radiopharmacy, manufacturing and quality assurance. Clinical pharmacists are 
specialised in certain therapeutic areas, which has been made possible 
because technicians and other staff were allowed to undertake some of 
pharmacists’ traditional duties.  
A small group of pharmacists works in academia or industry (Scottish Executive 
2004).  
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1.15.1.1 Non-Medical Prescribing and Prescribing by 
Pharmacists 
 
Pharmacists can become recognised as non-medical prescribers, a term which 
also applies to nurses recognised as such. This widening of prescribing was 
initiated by a supplementary prescribing role in the UK in 2003. The NHS 
defines supplementary prescribing as follows: “a voluntary partnership between 
an independent prescriber and a supplementary prescriber to implement an 
agreed patient specific Clinical Management Plan (CMP) with the patient's 
agreement”. The independent prescriber makes decisions about their clinical 
management including prescribing. The CMP includes guidelines to recognise 
or individually listed medicines and has to be accessible for the supplementary 
prescriber, who is allowed to administer doses, frequency of administration and 
products used. The early wave of supplementary prescribers has now been 
replaced by non-medical prescribers functioning as ‘independent prescribers’ 
who while now requiring a CMP do need to work within a guideline framework 
and to record their actions within the patients’ notes and within their own care 
plans to ensure they can defend their decisions when necessary. 
 
Non-medical prescribing aims to use the best of skills of healthcare 
professionals and encourages teamwork. Only pharmacists, who successfully 
completed an approved programme for supplementary prescribing, can be a 
supplementary prescriber (NHSScotland 2004).  
 
1.16  GPASS 
 
The General Practice Administrative System for Scotland (GPASS) is a 
computer software system that was developed in the 1980s by Dr. David 
Ferguson. It is used for registration, prescribing, patient recall and practice audit 
by GPs. Around 20 years ago some practitioners stored all data in the system 
but some only had selective data on their system (Taylor, Ritchie et al. 1990)- a 
fact that I could still observe in 2009. However each patient has his own patient 
key, which can be used instead of his/ her name to get the record on the 
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screen. Similar to Microsoft Access® GPASS® allows staff to run queries and 
thanks to the patient key it is possible to do this anonymously.  
 
For the purposes of this project three GPs were asked for permission to access 
their GPASS system in order to download medical histories and prescriptions of 
osteoporosis patients for analysing purposes.  
 
1.17  Osteoporosis management in Greater Glasgow and Clyde 
 
The health board of Greater Glasgow and Clyde offers several services for 
patients at high risk of sustaining a fracture, including primary (patients who did 
not yet sustain a fracture) and secondary prevention (patients who already 
sustained a fracture). The services are managed by the 'Osteoporosis and Falls' 
Strategy Group.  
 
1.17.1 Fracture liaison service (FLS) 
 
The FLS aims to re-assess people aged 50 years or older for their re-fracture 
risk, their need of treatment and prevention of secondary fractures.  
 
1.17.2 Direct Access DXA service (DADS) 
 
Some healthcare professional can refer patients to the DADS for assessing 
their fracture risk. Therefore at least one specific referral criterion has to be 
present. 
 
1.17.3 Secondary Care DXA service (SCDS) 
 
The SCDS offers an osteoporosis assessment for patients who are referred by 
a secondary care clinic and meet at least one specific referral criterion.  
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1.17.4 Bone/ Mineral Metabolism Clinics 
 
These clinics offer an assessment for patients who are not suitable for the 
services described above or present a very complex and severe form of 
osteoporosis. They also cover other metabolic bone diseases (NHS GGC 
2010).  
 
1.17.5 Community Falls Prevention Program (CFPP) 
 
Community pharmacies work together with pharmacist, who specialised on 
substances that might cause falls, and offer medication reviews for patients who 
have recently fallen and are on regular medication. If necessary suggestions for 
changes in the regular medication are made to the GP of the patient, who can 
accept or not (NHS GGC 2010).  
 
1.18  MAT 
 
A MAT is a 'Medication Assessment Tool' that focuses on the evidence base of 
treatment. It can be used as a clinical audit tool or as a research tool. When 
used as a clinical audit tool the intention is to examine prescribing. In research a 
MAT can be used to evaluate changes in prescribing associated to 
pharmaceutical care initiatives (McAnaw, Hudson et al. 2003).  
 
This project is about a MAT for osteoporosis (MATosteo). It consists of 19 
criteria measuring the quality of osteoporosis prescribing in Greater Glasgow 
and Clyde.    
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2 AIMS AND OBJECTIVES 
 
Aim 
This project aims to demonstrate the use of a Medication Assessment Tool for 
Osteoporosis (MATosteo) in the evaluation of adherence to Osteoporosis 
guidelines. As well inter-rater reliability has to be proved.  
 
Objectives  
1. To undertake a literature review of the management of osteoporosis and 
the role of specialists in the use of treatment alternatives 
2. To revise a MATosteo (designed by previous researchers) and redesign 
database protocols and evaluate inter-rater reliability 
3. Test the sensitivity of MATosteo in a comparison of patient samples 
drawn from two clinical settings and further revise the tool as necessary 
4. Test on a larger scale audit the revised MATosteo. Take one patient 
sample and compare with the result of another researcher 
5. Validate the revised MATosteo and critically review and critically review 
its potential value as a clinical and research tool 
 
A full version of the project protocol can be found in the appendices.  
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3 Methods 
3.1 Literature research and project planning 
 
For the purpose of this project background information was gathered by using 
PubMed®, MedlinePlus® and Clinicaltrials.gov®. The number of articles was 
narrowed down by using a combination of certain keywords. Useful articles 
were identified by reading abstracts.  
 
To learn about the local habits and Scotland’s healthcare system the official 
homepage of the health board “Greater Glasgow and Clyde” was searched. For 
information about local initiatives on osteoporosis leaflets were collected and 
the homepage of the “National Osteoporosis Society” was searched.  
 
As this project is based on projects of former researchers it was necessary to 
read the work of MSc pharmacist Johanna Schlais, Maga.pharm. Eva Past and 
the unpublished work of Anton Luf.  
 
After finishing collection of necessary information a project protocol was written, 
which was supposed to be the main-thread during the whole process of 
working. 
 
3.2 Study design 
 
The survey was designed as a retrospective study combined with an 
assessment for proofing interrater reliability and interviews for validating 
MATosteo.  
 
3.2.1 Inclusion criteria 
 
Patients alive who were registered with the participating general practice on 
date and had a diagnosis of osteoporosis or osteopenia were included in the 
study.  
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As the purpose of this project was to assess the actual adherence to guidelines 
only medication records meeting the following criteria were included: 
 
 Is Acute 0 and Is Active 1 or 
 Is Acute 1 and Is Active 1 and 
 Recorded within the last 6 months (time count starting at the day the data 
was downloaded from GPASS®) 
 
3.2.2 Exclusion criteria 
 
Patients with an unclear diagnosis for inclusion were excluded of the study as 
well as patients with Paget’s disease. If the download from the GPASS® system 
was incomplete inclusion was considered to be useless as well.  
 
3.3 Data collection  
 
To do the first round of applying MATosteo only data collected by previous 
researchers was used. It was already stored in Microsoft Access® data bases 
and partly pre-sorted.  
 
For enlarging the patient scale in a later phase of the project additional data 
was collected in a health centre (C). The backup file of GPASS® was accessed 
in order to guarantee privacy and keep patient records anonymous. As a first 
step the programme was linked to Microsoft Access® for filtering patients with a 
diagnosis of osteoporosis or osteopenia. The resulting patient keys were used 
for downloading medical history, medication records and patients’ 
characteristics by running queries. As a tribute to lack of time no data collection 
form was developed. Instead the final version of MATosteo was used to make 
sure all data needed was collected as far as possible. As access to paper 
records was not permitted and so collection of T-scores was not possible. 
Downloaded data however, were stored in Microsoft Excel® and saved on two 
flash sticks.  
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3.4 Revising MATosteo 
 
When first trying to apply MATosteoLuf several of its’ statements turned out to 
require further definition to render them more explicit. In order to clarify these 
questions the guidelines and BNF were reviewed. Suggestions for changes 
were discussed within the research group. Some criteria were deleted or 
summarised into one. For some of them a change in wording was necessary. 
Both MATosteLuf and the final version of the MAT (MAToste19), which was 
applied to all of the 3 patient samples as explained below, can be found in the 
appendix.  
 
3.5 Data analysis 
 
For analysing the data the Microsoft Access® form “Query Builder” developed by 
Tobias Dreischulte and Ian Thompson at the University of Strathclyde was used 
in combination with Microsoft Excel®. Although it is necessary to pre-sort the 
data carefully and design data items the advantage of this method is clear. It 
guarantees reliable and reproducible results even when large patient samples 
are audited. MATosteo was applied criterion by criterion by using the form. 
Results were transferred to Microsoft Excel® for final calculation.  
 
3.5.1 First step: pre-sorting data  
 
Before beginning with the analysis certain decisions had to be made. Data 
collected in practice A or B by a previous researcher was checked to make sure 
that none of the patients would meet exclusion criteria. This was done by 
running queries in the existing databases. Decision making about inclusion or 
exclusion of patients collected in health centre C was more time consuming. 
Collected patient keys and general information had to be imported into Microsoft 
Access® and searched for exclusion criteria. Finally a list containing patient keys 
of included patients was made for each practice.  
 
In order to be able to apply the “Query Builder” later on for each GP further pre-
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sorting was necessary. Therefore three databases were created- one for each 
practice- containing tables for diagnosis, general information, BMI and DEXA 
scans.  
 
3.5.2 Second step: creating data items and main tables for the 
Query Builder” 
 
Each field of the “Query Builder” depends on either a table and a query or two 
tables. For the purpose of this audit only the “Read code” field and the “Drugs” 
field were use. Therefore only the information for three tables had to be 
searched and stored in Microsoft Excel® files which were finally imported in the 
main tables of the “Query Builder”.  
 
It is best to create main tables in Microsoft Excel® before importing them into the 
form.  
 
The “Read Code” field accesses to the table “Patients: NHS Read codes_QOF 
and MAT data items_tbl” and the query “qry_MAT”. “qry_MAT” is already 
predesigned – so no further attention has to be paid to it in this phase.  The 
table “Patients: NHS Read codes_QOF and MAT data items-tbl” has to be filled 
with information. The first thing needing to be decided is what data items will be 
needed for applying the MAT later on. The purpose of a data item is to 
summarise slightly different terms, e.g.: 
 
Term to summarise 
 
Data item 
Glucocorticoid induced osteoporosis 
 
Osteoporosis 
Osteoporosis in spine Osteoporosis 
 
 
After creating a list of data items based on MATosteo the table can be filled with 
information. Therefore the orginal “Query Builder” was copied, the old data 
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
35 
 
deleted and the tables exported to Microsoft Excel®. Data to assess was copied 
in the columns “Patient key”, “Read Code” and “Date recorded”.  Then the 
matching data items were added. As a last step the data had to be imported 
again in Microsoft Access ®. After saving the table and running the query 
“qry_mat” the field “Read Code” was ready for use.  
 
The “Drugs” field accesses to two tables- “Patients: Drug History_tbl” and 
“Master: Drug list_tbl”.  
 
In “Patients: Drug History_tbl” the following columns were filled with original 
data: “patient key”, “drug name”, “preparation”, “dose” and “frequency”. The 
column “drug_category” was filled with invented names fulfilling the same sense 
as the data_items.  
 
In “Master: Drug list_tbl” the column ‘drug’ has to contain the same data, which 
is stored in the column ‘drug_name’ in, the ‘Patient: Drug History_tbl’. The 
column ‘drug_catagory’ has to contain the same data, which is stored in the 
column ‘drug_category’ in, the ‘Patient: Drug History_tbl’.  “Brand name” and 
“Drug group” can be invented, the rest of the columns do not necessarily need 
to conatain information.  
 
It is important not to change the name of columns and to fill relevant information 
by copying or running queries.  
 
3.5.3 Third step: Importing main tables into the query builder 
 
As mentioned above the main tables had to be imported into the “query builder” 
after creating them in Microsoft Excel®. This was done by copying the original 
“Query Builder”, deleting all old data in the main tables of the copy and 
importing the Microsoft Excel® files by using the “Import into an existing table” 
function.  
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3.5.4 Applying MATosteo 
 
For developing a reliable method of applying the form the smallest patient 
sample was analysed first. Each criterion was done manually and by using the 
query builder. The method was accepted when the agreement between the two 
methods was 100%. Then a database protocol was written for enabling other 
researchers to apply MATosteo by using the Query Builder.  
 
When writing the database protocol high effort was made to make the use of the 
form as easy as possible. This was done by structuring the protocol and paying 
attention to a clear layout. Finally the database protocol was shown to other 
students and lecturers for testing it in terms of validating its meaningfulness 
(clinical rationale). Where necessary further adaptation was done. The database 
protocol was finally used for applying MATosteo for all patient samples. 
 
MATosteo was applied criterion by criterion by using the “Read Code” field of 
the “Query Builder” alone or in combination with the “Drugs” field.   
 
3.5.4.1 Using the “Read Code” field only 
 
For very simple criteria it was feasible to use the Read Code field only. 
Therefore only the matching data items had to be selected. After pressing the 
“view” button a result table containing 1 and 0 appeared. 1 always stands for 
“yes”, 0 always stands for “no”. For further analysis of the results different 
methods were used.  
 
To filter patients meeting a certain combination of 1 and 0 the easiest way was 
to run a further query using the temporary table resulting for the form.  
 
Another possibility was to use the sort function and delete unneeded results 
directly in the result table.  
 
Finally all results were exported to Microsoft Excel® and used for calculation. 
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For some criteria it was also necessary to export partial steps- either for the 
purpose of final calculation or for being able to list the results on a per patient 
base.  
A full version of the data base protocol can be found in the appendix.  
 
3.5.4.2 Using the “Read Code” field in combination with the “Drugs” field 
For some criteria it was necessary to combine information of the Read Code 
field and the Drugs field. When this was necessary the first query had to be built 
and exported to Microsoft Excel®, as it is not possible to safe the temporary 
table. After exporting the results of the first query, they were imported and saved 
as a new table. Then it was possible to use the other field of the “Query Builder” 
without missing the results of the first run. In an additional step the results 
stored in the imported table could be combined with the results of the temporary 
table.  
 
Again all necessary information for calculation was exported to Microsoft 
Excel®. 
 
3.5.5 Calculation of Adherence and Applicabiltiy 
 
For calculating of applicability and adherence on a per patient base, on a per 
criterion base and overall Microsoft Excel® was used. The following formulas 
were applied: 
 
 
 
 
 
 
n … Total number 
of patients 
 
 
 
Applicability
n
IDSUNoYes ),(, *100 
 
 
 
 
Adherence 

IDSUNoYes
Yes
),(, *100 
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Resulting percentages of adherence were categorised arbitrarily as follows: 
 
≥ 70 %  High level of Adherence 
50- 69.9%  Intermediate level of Adherence 
< 50%  Low level of Adherence 
 
3.6 Demonstration of inter-rater reliability 
 
For Clydebank and Paisley another student also applied the MATosteo[21] by 
using the “Query Builder”. Results were compared by calculating the standard 
deviation and the percentage of discrepancy. For calculating the standard 
deviation the following formula was used: 
 
 
 
 
 
 
Adaptation to local needs 
 
 
3.7 Adaptation to local needs and validation of MATosteo[19] 
 
Local guidelines were collected and experts on osteoporosis were interviewed 
in order to validate MATosteo[19]. Only specialist nurses on osteoporosis, 
rheumatologist or doctors working in an osteoporosis unit were considered to be 
experts and were contacted.  
 
3.7.1 Invitation to interviews 
 
For getting easier access to such experts where possible a contact pharmacist 
was asked to help with organising appointments. Whenever this was not 
 
 
Standard deviation
n
xxi )( 
  
 
 
Xi Actual value 
 
X  Mean 
 
n  Total number  
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possible an email containing major information about the project and the 
purpose of the interview was sent directly to the expert. Once interest in 
participating in the interview was expressed the interview questions were sent in 
advance in order to give the interviewee the possibility to get familiar with the 
subject and to save time in performing the interview. 
 
3.7.2 Interview technique and follow up 
 
The semi-structured interview technique was chosen in order to being able to 
validate MATosteo[19] criterion by criterion. When using this technique the 
interviewer has a framework to stick to but nevertheless the possibility to come 
up with additional questions to clarify statements. 
 
At the beginning of the interview a short overview over the project was given 
and the purpose of the interview was explained. To warm- up a view general 
questions were asked before assessing the MAT criterion by criterion. 
Interviewees were asked to give their permittance to tape-recording. If tape 
recording was not possible for some reason, a second investigator was used for 
note taking. Some interviewees asked to restrict the interview time to 30 
minutes. In this case only the most important questions were asked.  
 
Interviews were summarised. The most important were highlighted and can be 
used to adapt MATosteo in the future.  
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4 Results 
 
4.1 Revised MATosteo 
 
Reviewing of MATosteoLuf resulted in some changes. Criteria 1- 5 remained the 
same. Several criteria were reworded and for better practicability of the 
electronic data analysis the order of criteria was changed. Whereas 
MATosteoLuf contained 21 criteria, the new version of MATostoe contains only 
19 criteria. The table compares the two MATs.  
 
Table 5: Changes in MATosteo 
 
MatosteLuf 
 
Matosteo[19] 
 
Action/ Comment 
 
Criterion 6 
A patient with osteoporosis and 
NOT prescribed  any of the 
following: bisphosphonates, 
raloxifene, strontium ranelate,  
calcitonin or teriparatide 
has a recorded contra-indication to 
each agent (see below) 
 
Contraindications to bisphosphonates 
are: 
 oesophageal strictures or 
achalasia 
 inability to remain upright for 
> 30 min after ingestion  
 hypocalcaemia 
 osteomalacia (etidronate)  
 moderate renal impairment 
(CrCl <  35 mL/min)  
 pregnancy and breast 
feeding]  
Contraindications to raloxifene are: 
 past/present venous 
thromboembolic events 
 hepatic impairment 
 cholestasis  
 severe renal impairment 
(CrCl < 10 mL/min)  
 endometrial cancer 
 uterine bleeding 
 pregnancy and breast 
feeding
 
 
 
 
Criterion 10 
A patient with osteoporosis and 
NOT prescribed  any of the 
following: bisphosphonates, 
raloxifene, strontium ranelate,  
calcitonin or teriparatide 
has a recorded contra-indication to 
each agent (see below) 
 
 
Contraindications to bisphosphonates 
are: 
 oesophageal strictures or 
achalasia 
 inability to remain upright for 
> 30 min after ingestion  
 hypocalcaemia 
 osteomalacia (etidronate)  
 moderate renal impairment 
(CrCl <  35 mL/min)  
 pregnancy and breast 
feeding]  
Contraindications to raloxifene are: 
 past/present venous 
thromboembolic events 
 hepatic impairment 
 cholestasis  
 severe renal impairment 
(CrCl < 10 mL/min)  
 endometrial cancer 
 uterine bleeding 
 pregnancy and breast 
feeding
 
 
Change of order 
Criterion 6 of 
MATosteoLuf is criterion 
10 in MATosteo [19]. The 
research group aimed to 
simplify the process of 
electronic data analysis. 
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Table 5: Changes in MATosteo 
 
MatosteLuf 
 
Matosteo[19] 
 
Action/ Comment 
 
Contraindications to strontium ranelate 
are: 
 pregnancy and breast 
feeding 
 hypersensitivity
Contraindications to calcitonin are: 
 hypocalcaemia 
 hypersensitivity
Contraindications to teriparatide are: 
 pre-existing hypercalcaemia 
 skeletal malignancies or 
bone metastases 
 metabolic bone diseases 
 including Paget’s disease 
and hyperparathyroidism 
 unexplained raised alkaline 
phosphatase 
previous radiation therapy to the 
skeleton 
 
 
Contraindications to strontium ranelate 
are: 
 pregnancy and breast 
feeding 
 hypersensitivity
Contraindications to calcitonin are: 
 hypocalcaemia 
 hypersensitivity
Contraindications to teriparatide are: 
 pre-existing hypercalcaemia 
 skeletal malignancies or 
bone metastases 
 metabolic bone diseases 
 including Paget’s disease 
and hyperparathyroidism 
 unexplained raised alkaline 
phosphatase 
previous radiation therapy to the 
skeleton 
 
 
 
Criterion 7  
  
A patient prescribed 
supplementary calcium  
is prescribed a daily dose of 500 – 
1500 mg calcium.  
 
Criterion 6  
  
A patient prescribed 
supplementary calcium  
is prescribed a daily dose of 500 – 
1500 mg calcium.  
 
Change of order 
Criterion 7 of 
MATosteoLuf is criterion 6 
in MATosteo[19]. The 
research group aimed to 
simplify the process of 
electronic data analysis. 
The topic ‘calcium and 
vitamin D’ should be 
analysed as a whole. 
 
Criterion 8 
A patient prescribed vitamin D  
is prescribed a daily dose of 10 – 20 
µg (400 - 800 IU) vitamin D.  
 
 
Criterion 7 
A patient prescribed vitamin D  
is prescribed a daily dose of 10 – 20 
µg (400 - 800 IU) vitamin D.  
 
 
Change of order 
Criterion 8 of 
MATosteoLuf is criterion 7 
in MATosteo[19]. The 
research group aimed to 
simplify the process of 
electronic data analysis. 
The topic ‘calcium and 
vitamin D’ should be 
analysed as a whole. 
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Table 5: Changes in MATosteo 
 
MatosteLuf 
 
Matosteo[19] 
 
Action/ Comment 
 
Criterion 9 
A patient with osteoporosis and 
NOT prescribed  any of the 
following: bisphosphonates, 
raloxifene, strontium ranelate or 
calcitonin  
is prescribed ≥1000mg calcium plus 
800 IU vitamin D per day 
 
 
 
Criterion 11 
A patient with osteoporosis and 
NOT prescribed  any of the 
following: bisphosphonates, 
raloxifene, strontium ranelate or 
calcitonin  
is prescribed ≥1000mg calcium plus 
800 IU vitamin D per day 
 
 
 
Change of order 
Criterion 9 of 
MATosteoLuf is criterion 
11 in MATosteo[19]. The 
research group aimed to 
simplify the process of 
electronic data analysis. 
 
Criterion 10 
A patient with a recorded 
diagnosis of osteoporosis 
is prescribed an oral bisphosphonate 
as first-line therapy. 
 
Recorded reasons for non-
conformance (justification): 
 
Criterion 10 
A patient with a recorded 
diagnosis of osteoporosis 
is prescribed an oral bisphosphonate 
as first-line therapy. 
 
Recorded reasons for non-
conformance (justification): 
 
Change of order 
Criterion 10 of 
MATosteoLuf is criterion 8 
in MATosteo[19]. The 
research group aimed to 
simplify the process of 
electronic data analysis. 
 
Criterion 14, 15, 16 
A postmenopausal woman when 
started on bisphosphonate 
therapy  
was initiated on alendronate. 
  
A postmenopausal woman 
diagnosed with 
osteoporosis/osteopenia and not 
treated with alendronate 
is prescribed risedronate.  
 
A postmenopausal woman with > 
2 vertebral fractures and NOT 
treated with alendronate or 
risedronate 
is prescribed intermittent cyclical 
etidronate. 
 
Criterion 14 
A patient with osteoporosis on 
bisphosphonate therapy  
is on the preferred choice* 
* 1- Alendronate, 2-risedronate, 3-
intermittent cyclical etidronate 
         [Preferred order as shown in 
the drug history] 
 
Rewording 
Criterion 14,15, 16 of 
MATosteoLuf were 
summarised in criterion 
14 of MATosteo[19]. The 
term ‘a postmenopausal 
woman’ was changed to 
‘a patient’.  The auditor is 
advised to look the order 
of choice up in the drug 
history 
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Table 5: Changes in MATosteo 
 
MatosteLuf 
 
Matosteo[19] 
 
Action/ Comment 
 
Criterion 11 
A patient with a recorded 
diagnosis of osteoPENIA  
is prescribed an oral bisphosphonate 
as first-line therapy.  
 
Recorded reasons for non-
conformance (justification): 
___________________________ 
 
 
Criterion 9 
A patient with a recorded 
diagnosis of osteoPENIA  
is prescribed an oral bisphosphonate 
as first-line therapy.  
 
Recorded reasons for non-
conformance (justification): 
_________________________ 
 
 
Change of order 
Criterion 11 of 
MATosteoLuf is criterion 
9 in MATosteo[19]. The 
research group aimed to 
simplify the process of 
electronic data analysis. 
 
Criterion 17 
 
A patient who is on long-term 
glucocorticoid therapy 
(> 7.5 mg prednisolone or 
equivalents for > 3 months) 
is prescribed a bisphosphonate.  
 
 
 
Criterion 15 
 
A patient who is on long-term 
glucocorticoid therapy 
(> 7.5 mg prednisolone or 
equivalents for > 3 months) 
is prescribed a bisphosphonate.  
 
 
 
Change of order 
Criterion 17 of 
MATosteoLuf is criterion 
15 in MATosteo[19]. The 
research group aimed to 
simplify the process of 
electronic data analysis. 
 
Criterion 18 
A postmenopausal woman with a 
diagnosis of osteoporosis, who 
has an identifiable reason for not 
being prescribed a 
bisphosphonate 
is prescribed strontium ranelate. 
 
[Reasons for non-use of 
bisphosphonates are 
Contraindications to bisphosphonates 
 contraindication to 
bisphosphonates (see 12) 
 inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
 intolerance to 
bisphosphonates (see12)] 
 
 
Criterion 16 
A postmenopausal woman 
prescribed strontium ranelate has 
an identifiable reason for not being 
prescribed a bisphosphonate 
  
Reasons for non-use of 
bisphosphonates are 
 contraindication to 
bisphosphonates (see 12) 
 inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
 intolerance to 
bisphosphonates (see12)] 
 
 
Rewording, Change of 
order 
The criterion was 
reworded in order to 
simplify the process of 
electronic data analysis. 
The research group 
chose a phrasing that did 
not change the meaning 
of the criterion. 
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Table 5: Changes in MATosteo 
 
MatosteLuf 
 
Matosteo[19] 
 
Action/ Comment 
 
Criterion 19 
A postmenopausal woman 
diagnosed with osteoporosis with 
at least one osteoporotic fracture 
who has an identifiable reason for 
not being prescribed a 
bisphosphonate  
is prescribed strontium ranelate or 
raloxifene. 
 
[Reasons for non-use of 
bisphosphonates are 
Contraindications to bisphosphonates 
 contraindication to 
bisphosphonates (see 12) 
 inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
 intolerance to 
bisphosphonates (see 12)] 
 
 
Criterion 17 
A postmenopausal woman 
prescribed raloxifene  
is receiving it for secondary 
prevention and has an identifiable 
reason for not being prescribed a 
bisphosphonate  
 
[Reasons for non-use of 
bisphosphonates are 
 contraindication to 
bisphosphonates (see 12) 
 inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
 intolerance to 
bisphosphonates (see 12)] 
 
 
Rewording, Change of 
order 
The criterion was 
reworded in order to 
simplify the process of 
electronic data analysis. 
The research group 
chose a phrasing that did 
not change the meaning 
of the criterion 
 
Criterion 20 
A postmenopausal woman 
diagnosed with osteoporosis and 
at least one osteoporotic fracture 
who has either 
 
 a reason to avoid 
bisphosphonates (See 12) 
 an intolerance to 
strontium ranelate 
o persistent nausea 
o persistent 
diarrhoea 
and who is either 
 aged ≥ 65 years with a T-
Score ≤ -4 SD 
 aged ≥ 65 years with a T-
Score ≤ -3.5 SD and 
has more than two 
fractures 
 aged 55-64 years with a T-
Score ≤ -4 and has 
more than two fractures 
is prescribed teriparatide. 
 
Criterion 18 
A patient prescribed teriparatide is 
prescribed it for secondary 
prevention and meets at least one 
of the following 2 criteria 
 has a reason to avoid 
bisphosphonates (See 12) 
 has an intolerance to 
strontium ranelate 
o persistent nausea 
o persistent 
diarrhoea 
And has DEXA scan assessment that 
puts them in one the following groups 
 
 aged ≥ 65 years with a T-
Score ≤ -4 SD 
 aged ≥ 65 years with a T-
Score ≤ -3.5 SD and 
has more than two 
fractures 
 aged 55-64 years with a T-
Score ≤ -4 and has 
more than two fractures 
 
Rewording, Change o 
order 
The criterion was 
reworded in order to 
simplify the process of 
electronic data analysis. 
The research group 
chose a phrasing that did 
not change the meaning 
of the criterion. 
 
 
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
45 
 
Table 5: Changes in MATosteo 
 
MatosteLuf 
 
Matosteo[19] 
 
Action/ Comment 
 
Criterion 21 
A postmenopausal woman 
diagnosed with osteoporosis with 
at least one vertebral fracture and 
NOT treated with a 
bisphosphonate, raloxifene or 
strontium ranelate  
is prescribed calcitonin.  
 
 
Criterion 19 
A patient prescribed calcitonin is 
prescribed it for secondary prevention 
after bisphosphonate, raloxifene or 
strontium ranelate have been tried or 
have reasons for excluding from 
consideration 
 
[Reasons for non-use of 
bisphosphonates are 
 contraindication to 
bisphosphonates (see 12) 
 inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
 intolerance to 
bisphosphonates (see 12)] 
 
[Reasons for non-use of strontium 
ranelate  are: 
 Contraindication to 
strontium ranelate (see 10)] 
 
[Reasons for non-use of raloxifene 
are: 
 Contraindication to 
raloxifene] 
 
 
Rewording, Change of 
order 
The criterion was 
reworded in order to 
simplify the process of 
electronic data analysis. 
The research group 
chose a phrasing that did 
not change the meaning 
of the criterion. 
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4.2 Revised database protocol 
 
The original database protocol was completely redesigned for the use of the 
query builder. For each criterion a work instruction can be found. The work 
instruction presents as a table. Each row explains a single working step. The 
very left column names the step of the procedure; the second column tells the 
auditor what to do and the third one how to process. 
 
Example of a work instruction:  
 
CRITERION 7 
 
Step What? How? 
 
Step 1 
 
Identify patients 
prescribed 
supplementary 
calcium  
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
 ‘supplement’ for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1, d1[not like “0”], c2, d2, c3 
Run query 1 
 
 
Step 2 
 
Identify number of 
Yes, No(J), No(U), 
IDS 
 
 
Export results of ‘step 1’ to Microsoft Excel® 
Inspect on the results 
 Patient prescribed a daily dose of 500-
1500 mg calcium= Yes 
 Patient not prescribed a daily dose of 500-
1500 mg calcium= No(U) 
 documentation concerning dose, 
preparation and frequency not clear= IDS  
 
 
 A full version of the new data base protocol can be found in Appendix 4.  
 
 
Patient prescribed supplementary calcium  
Is prescribed a daily dose of 500-1500 mg calcium 
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4.3 Demonstration of inter-rater reliability 
 
The inter-rater testing of MATosteo by two independent students (X, Y) showed 
99.1% agreement for applicability. Highest percentage of discrepancy was 
10.4%, but for 16/21 (76.2%) criteria 100.0% agreement was shown. For 
Adherence the mean agreement was 99.6%. Discrepancy was minimal and only 
shown for 3/21 (14.3%) criteria. The following table shows the results of the 
assessment for criterion 1 to 21, as the test was done in an early phase of the 
project.  
 
Table 6: Demonstration of the interrater reliability 
Criterion  ApplicabilityX ApplicabilityY 
 
Agreement 
(%) 
AdherenceX AdherenceY 
 
Agreement (%) 
1 40.2 40.2 100.0 78 78 100.0 
2 30.8 27.6 89.6 32 32 100.0 
3 50.0 50.0 100.0 100 100 100.0 
4 56.3 56.3 100.0 9 9 100.0 
5 59.1 58.8 99.5 101 100 99.0 
6 0.0 0.0 100.0 0 0 100.0 
7 99.2 99.2 100.0 118 118 100.0 
8 98.2 97.3 99.1 109 109 100.0 
9 22.6 23.5 96.2 19 20 95.0 
10 56.0 56.0 100.0 112 112 100.0 
11 56.3 56.3 100.0 9 9 100.0 
12 85.9 85.9 100.0 116 116 100.0 
13 82.1 84.1 97.6 119 122 97.5 
14 86.1 86.1 100.0 105 105 100.0 
15 12.4 12.4 100.0 12 12 100.0 
16 nr nr 100.0 0 0 100.0 
17 nr nr  100.0 0 0 100.0 
18 0.0 0.0 100.0 0 0 100.0 
19 0.0 0.0 100.0 0 0 100.0 
20 nr nr 100.0 0 0 100.0 
21 0.0 0.0 100.0 0 0 100.0 
Mean (%) 
SD 
  99.1 (2.4)   99.6 (1.2) 
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4.4 Total 
 
The results presented in the following section are a summary of test population 
A, B and C. Larger amount of patients make them more representative.  
 
4.4.1 Demographics 
 
90.3% of the patients with a diagnosis of osteoporosis or osteopenia are 
female. 97.9% of female patients are postmenopausal. 81.5% of the assessed 
population are diagnosed with osteoporosis. Age range is quite broad, but when 
calculating the mean age it turns out that only a few patients are less than 50 
years old. % of all patients have a low BMI, which is a risk factor for 
osteoporosis.  
 
Table 7: Characteristics of test population GP A+B+C 
Patient sample n =319 
 
Gender 
Female 
Male 
 
 
288/319 (90.3%) 
31/319 (9.7%) 
 
 
Diagnosis 
Osteoporosis 
 Female 
 Postmenopausal 
 Male 
 
Osteopenia 
 Female 
 Postmenopausal  
 Male 
 
 
 
260 
232 
227 
28 
 
59 
56 
55 
3 
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Table 7: Characteristics of test population GP A+B+C 
Patient sample n =319 
 
Age 
Age range (years) 
 
Age range osteoporotic patients (years) 
 Female 
 Male 
 
Mean age osteoporotic patients (years) 
 Female 
 Male 
 
 
24-96 
 
 
24-96 
24-96 
36-91 
 
74.0 (13.1) 
74.4 (12.9) 
70.8 (14.5) 
 
Age range osteopenic patients (years) 
 Female 
 Male 
 
Mean age osteopenic patients (years) 
 Female 
 Male 
 
39-92 
43-92 
39-72 
 
66.8 (13.1) 
67.2 (12.9) 
59.7 (18.0) 
 
 
BMI range (kg/ m2) 
Osteoporosis 
 Female 
 Male 
 
Osteopenia 
 Female 
 Male 
 
BMI <22 
 
14.1-40.8 
14.1-40.8 
14.1-40.8 
16.7-32.5 
 
16.2-39.0 
16.2-39.0 
26.1-31.7 
 
6/49 (12.2%) 
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4.4.2 Adherence per criterion  
 
For 3/19 criteria no result can be presented as they were not applicable to any 
patient. Overall adherence calculated on a per criterion base is 61.7 98% CI 
(59.8- 63.6), which is an intermediate level of adherence. The following table 
shows applicability and percentage of adherence for each criterion and overall 
in total for GP A, B and C.  
 
Table 8: Adherence and applicability per criterion GP A, B and C 
Criterion  
n= 2926 
 
N/A 
(%) 
 
Yes 
 
No 
(J) 
 
No 
(U) 
 
IDS 
 
IDQ 
 
Applicable 
(%) 
 
Adherence 
(CI 95%) 
1 Patient with a 
diagnosis  of OS  has 
a recorded DEXA scan 
66/115 
20.7% 
115 7 126 12 0 253/319 
79.3% 
115/253 
45.5% 
(44.3-46.7) 
2 Patient with 
measured BMD by 
DEXA scan has 
measures taken at 
spine and hip 
178/319 
20.7% 
36 0 89 16 44 141/319 
44.2% 
36/141 
25.5% 
(23.6-27.4) 
3 Patient with OS is 
prescribed 
supplementary calcium 
59/319 
81.5% 
138 0 122 0 0 260/319 
81.5% 
138/260 
53.1% 
(47-59.2) 
4 Osteopenic patient 
is prescribed 
supplementary calcium 
260/319 
81.5% 
22 0 37 0 0 59/319 
18.5% 
22/59 
37.3% 
(25-59.6) 
5 Patient with 
confirmed vitamin D 
deficiency or age ≥ 
65years is prescribed 
vitamin D 
79/319 
24.8% 
142 0 98 0 0 240/319 
75.2% 
142/240 
59.2% 
(53-65.4) 
6 Patient with 
osteoporosis is 
treated with 
antiresorptive/ 
osteoanabolic agent  
64/319 
20.1% 
153 5 97 5 0 255/319 
79.6% 
153/255 
60.0% 
(54.0-66.0) 
7 Patient prescribed 
calcium is prescribed 
500-1500 mg 
149/319 
46.7% 
169 0 1 0 0 170/319 
55.3% 
169/170 
99.4% 
(98.2-100.0) 
8 Patient prescribed 
vitamin D is prescribed 
400-800 IU 
157/319 
49.2% 
159 0 3 0 0 162/319 
50.8% 
159/162 
98.1% 
(96.0-100.0) 
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Table 8: Adherence and applicability per criterion GP A, B and C 
Criterion  
n= 2926 
 
N/A 
(%) 
 
Yes 
 
No(J) 
 
No(U) 
 
IDS 
 
IDQ 
 
Applicable 
(%) 
 
Adherence 
(CI 95%) 
9 Patient with 
osteoporosis 
untreated by 
antiresorptive/ 
anabolic agent  is 
prescribed >=1000mg 
calcium plus 800 IU 
vitamin D 
212/3
19 
66.5
% 
32 0 74 1 0 107/319 
33.5% 
32/107 
29.9% 
(27.2-32.6) 
10 Patient with OS  is 
prescribed an oral BP 
as first-line therapy 
65/31
9 
20.4
% 
149 6 100 5 0 254/319 
79.6% 
149/254 
58.6% 
(52.5-64.7) 
11 Osteopenic patient 
is prescribed an oral 
BP as first-line therapy  
260/3
19 
81.5
% 
19 0 40 0 0 59/319 
18.5% 
19/59 
32.2% 
(20.3-44.1) 
12 Patient treated 
with antiresorptive/ 
osteoanabolic agent 
has no contra-
indication on record 
146/3
19 
45.8
% 
144 0 23 36 0 173/319 
54.2% 
114/173 
65.9% 
(58.8-73.0) 
13 Patient  receiving 
treatment for 
osteopenia/osteoporo
sis is prescribed a 
standard dose regimen 
126/3
19 
39.5
% 
150 0 30 13 0 193/319 
60.5% 
150/319 
77.7% 
(71.0-84.4) 
14 A patient with 
osteoporosis on 
bisphosphonate 
therapy  
is on the preferred 
choice* 
* 1- Alendronate, 2-
risedronate, 3-
intermittent cyclical 
etidronate 
169/3
19 
53.0
% 
130 0 20 0 0 150/319 
47.0% 
130/150 
86.7% 
(81.3-92.1) 
15 A patient who is on 
long-term 
glucocorticoid 
therapy 
(> 7.5 mg 
prednisolone or 
equivalents for > 3 
months) 
is prescribed a 
bisphosphonate.  
 
318/3
19 
99.7
% 
1 0 0 0 0 1/319 
0.3% 
1/1 
100.0% 
16 A postmenopausal 
woman prescribed 
strontium ranelate 
has an identifiable 
reason for not being 
prescribed a 
bisphosphonate 
 
316/3
19 
99.1
% 
 
3 0 0 0 0 3/319 
0.9% 
3/3 
100.0% 
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Table 8: Adherence and applicability per criterion GP A, B and C 
Criterion  
n= 2926 
 
N/A 
(%) 
 
Yes 
 
No(J) 
 
No(U) 
 
IDS 
 
IDQ 
 
Applicable 
(%) 
 
Adherence 
(CI 95%) 
17 A postmenopausal 
woman prescribed 
raloxifene  
is receiving it for 
secondary prevention  
319/3
19 
100.0
% 
0 0 0 0 0 0/319 
0.0% 
nr 
18 A patient 
prescribed 
teriparatide is 
prescribed it for 
secondary prevention 
and meets specific 
criteria 
319/3
19 
100.0
% 
0 0 0 0 0 0/319 
0.0% 
nr 
19 A patient 
prescribed calcitonin 
is prescribed it for 
secondary prevention 
after bisphosphonate, 
raloxifene or strontium 
ranelate have been 
tried or have reasons 
for excluding from 
consideration 
 
319/3
19 
100.0
% 
0 0 0 0 0 0/319 
0.0% 
nr 
Overall 3581/6
061 
59.1% 
1532 18 860 88 44 2480/6061 
40.9% 
 
1532/2480 
61.7% 
(59.8-63.6) 
 
N/A: not applicable; No(J): justified non-adherence to the guideline; No(U): unjustified non-adherence to 
the guideline; IDS: insufficient data on the standard; IDQ: insufficient data on the qualifier; CI: confidence 
interval; OS: Osteoporosis 
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4.4.3 Levels of Adherence 
 
Levels of adherence was ranked as low for 5/19 criteria, intermediate for 5/19 criteria 
and high for 6/19 criteria. The following table shows level of adherence ranked from 
lowest to highest percentage.  
 
Table 9: Level of adherence  GP A, B and C 
 
Level 
 
Criterion  
 
Adherence 
(%) 
 
    
2  
Patient with measured BMD by DEXA scan has measures taken at spine 
and hip 
25.5 
9  
Patient with osteoporosis untreated by antiresorptive/ anabolic agent  
is prescribed >=1000mg calcium plus 800 IE vitamin D 
29.9 
11  
Osteopenic patient is prescribed an oral BP as first-line therapy 
32.2 
4  
Osteopenic patient is prescribed supplementary calcium 
37.3 
 
Low 
 
1  
Patient with a diagnosis  of OS  has a recorded DEXA scan 
45.5 
3  
Patient with OS is prescribed supplementary calcium 
53.1 
10  
Patient with OS  is prescribed an oral BP as first-line therapy 
58.2 
5  
Patient with confirmed vitamin D deficiency or age ≥ 65years is 
prescribed vitamin D 
59.2 
6  
Patient with osteoporosis is treated with antiresorptive/ osteoanabolic 
agent 
60.0 
Intermediate 
12  
Patient treated with antiresorptive/ osteoanabolic agent has no contra-
indication on record 
65.9 
13  
Patient  receiving treatment for osteopenia/osteoporosis is prescribed a 
standard dose regimen 
77.7 
14  
A patient with osteoporosis on bisphosphonate therapy  
is on the preferred choice* 
* 1- Alendronate, 2-risedronate, 3-intermittent cyclical etidronate 
86.7 
7  
Patient prescribed calcium is prescribed 500-1500 mg 
99.4 
8  
Patient prescribed vitamin D is prescribed 400-800 IU 
98.1 
15 A patient who is on long-term glucocorticoid therapy 
(> 7.5 mg prednisolone or equivalents for > 3 months) 
is prescribed a bisphosphonate.  
 
100.0 
 
16 A postmenopausal woman prescribed strontium ranelate has an 
identifiable reason for not being prescribed a bisphosphonate 
 
100.0 
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4.4.4 Main findings 
 
4.4.4.1 Patients with osteoporosis 
 
152/260 (58.5 %) of patients with osteoporosis received an antiresorptive 
treatment. 149/260 (57.3%%) patients were treated with a bisphosphonate.  
Mainly alendronic acid was prescribed. Only 3/85 (3.5%) of the patients 
received an alternative treatment (strontium ranelate). Standard dose was 
mainly used.  
 
108/260 (41.5%) patients did not receive an osteoanabolic or an antiresorptive 
treatment. 32/260 (12.3%) were only prescribed calcium and vitamin D. 29.2% 
of all osteoporotic patients neither received a treatment nor a supplement.  
 
Calitonin, raloxifene and teriparatide were not prescribed at all.  
 
4.4.4.2 Patients with osteopenia 
 
19/59 (32.2%) of patients with osteopenia received an antiresorptive treatment. 
13 of  them were prescribed alendronic acid and 6 received risedronate sodium. 
Both substances were prescribed in the dose licensed for osteoporosis but not 
for the indication osteopenia.   
 
40/59 (67.8%) patients did not receive an antiresorptive treatment. Only 8/40 
(20.0%) of those patients were prescribed calcium and vitamin D. Respectively, 
33/59 (55.9%) of all osteoporotic patients neither received a treatment nor a 
supplement.  
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4.5 Practice A  
 
Data were downloaded from the GPASS® system of a practice in Glasgow.  
 
4.5.1 Demographics 
 
92% of the patients with a diagnosis of osteoporosis or osteopenia are female. 
97% of female patients are postmenopausal. 90% of the assessed population 
are diagnosed with osteoporosis. Age range is quite broad, but when calculating 
the mean age it turns out that only a few patients are less than 50 years old. 
32% of all patients have a low BMI, which is a risk factor for osteoporosis.  
 
The following table shows the demographic characteristics of test population A.  
 
Table 10: Characteristics of test population GP A 
Patient sample n =154 
 
Gender 
Female 
Male 
 
 
141/ 154 (91.6%) 
13/ 154 (8.4%) 
 
 
Diagnosis 
Osteoporosis 
 Female 
 Postmenopausal 
 Male 
 
Osteopenia 
 Female 
 Postmenopausal  
 Male 
 
 
 
138 
126 
122 
12 
 
16 
15 
15 
1 
Age  
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Age range (years) 
 
Age range osteoporotic patients (years) 
 Female 
 Male 
24-96 
 
24-96 
24-96 
48-84 
Table 10: Characteristics of test population GP A 
Patient sample n =154 
 
Mean age osteoporotic patients (years) 
 Female 
 Male 
 
 
74 
75 
67 
 
Age range osteopenic patients (years) 
 Female 
 Male 
Mean age osteopenic patients (years) 
 Female 
 Male 
 
48-92 
48-92 
72-72 
 
73 
72 
 
 
BMI range (kg/ m2) 
Osteoporosis 
 Female 
 Male 
 
Osteopenia 
 Female 
 Male 
 
BMI <22 
 
 
17.3-39.1 
17.3-39.1 
17.8-32.0 
 
25.9-31.2 
25.9-31.2 
No record 
 
22/68 (32%) 
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4.5.2 Adherence per Criterion  
 
For 7/19 criteria no result can be presented as no patient was applicable. 
Overall adherence calculated on a per criterion base is 52.1 ± 3.5%, which is an 
intermediate level of adherence. The following table shows applicability and 
percentage of adherence for each criterion and overall for GP B.  
 
Table 11: Adherence and applicability per criterion GP A 
Criterion  
n= 2926 
 
N/A 
(%) 
 
Yes 
 
No(J) 
 
No(U) 
 
IDS 
 
IDQ 
 
Applicable 
(%) 
 
Adherence 
(CI 95%) 
1 Patient with a 
diagnosis  of OS  has 
a recorded DEXA scan 
22/154 
14.3% 
 
 
77 6 55 0 0 132/154 
85.7% 
77/132 
58.3% 
(57.2-59.4) 
2 Patient with 
measured BMD by 
DEXA scan has 
measures taken at 
spine and hip 
61/154 
39.6% 
32 0 55 6 0 93/154 
60.4% 
32/93 
34.4% 
(32.9-35.9) 
3 Patient with OS is 
prescribed 
supplementary calcium 
16/154 
10.4% 
76 0 62 0 0 138/154 
89.6% 
76/138 
55.1% 
(54.0-56.2) 
4 Osteopenic patient 
is prescribed 
supplementary calcium 
138/216 
89.6% 
9 0 7 0 0 16/154 
10.4% 
9/16 
56.3% 
(50.0-65.6) 
5 Patient with 
confirmed vitamin D 
deficiency or age ≥ 
65years is prescribed 
vitamin D 
30/154 
19.5% 
73 0 51 0 0 124/154 
80.5% 
73/124 
58.9% 
(57.7-60.1) 
6 Patient with 
osteoporosis is 
treated with 
antiresorptive/ 
osteoanabolic agent  
16/154 
10.4% 
84 0 54 0 0 138/154 
89.6% 
84/138 
60.8% 
(59.7-61.9) 
7 Patient prescribed 
calcium is prescribed 
500-1500 mg 
69/154 
44.8% 
84 0 1 0 0 85/154 
55.2% 
84/85 
98.8% 
(98.4-99.1) 
8 Patient prescribed 
vitamin D is prescribed 
400-800 IU 
76/154 
49.4% 
77 0 1 0 0 78/154 
50.6% 
77/78 
98.7% 
(98.3-99.1) 
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Table 11: Adherence and applicability per criterion GP A 
Criterion  
n= 2926 
 
N/A 
(%) 
 
Yes 
 
No(J) 
 
No(U) 
 
IDS 
 
IDQ 
 
Applicable 
(%) 
 
Adherence 
(CI 95%) 
9 Patient with 
osteoporosis 
untreated by 
antiresorptive/ 
anabolic agent  is 
prescribed >=1000mg 
calcium plus 800 IE 
vitamin D 
100/154 
64.9% 
11 0 42 1 0 54/154 
35.1% 
11/54 
20.4% 
(18.1-22,6) 
10 Patient with OS  is 
prescribed an oral BP 
as first-line therapy 
16/154 
10.4% 
81 0 57 0 0 138/154 
89.6% 
81/138 
58.7% 
(57.6-59.8) 
 
 
11 Osteopenic patient 
is prescribed an oral 
BP as first-line therapy  
138/154 
89.6% 
9 0 7 0 0 16/154 
10.4% 
9/16 
56.3% 
(47.0-65.6) 
12 Patient treated 
with antiresorptive/ 
osteoanabolic agent 
has no contra-
indication on record 
60/154 
39% 
78 0 16 0 0 94/154 
61% 
78/94 
83% 
(81.8-84.2) 
13 Patient  receiving 
treatment for 
osteopenia/osteoporo
sis is prescribed a 
standard dose regimen 
60/154 
39% 
81 0 10 3 0 94/154 
61% 
81/94 
86.2% 
(85.1-87.3) 
14 A patient with 
osteoporosis on 
bisphosphonate 
therapy  
is on the preferred 
choice* 
* 1- Alendronate, 2-
risedronate, 3-
intermittent cyclical 
etidronate 
72/154 
46.8% 
72 0 10 0 0 82/154 
53.2% 
72/82 
87.8% 
(86.6-89.0) 
15 A patient who is 
on long-term 
glucocorticoid 
therapy 
(> 7.5 mg 
prednisolone or 
equivalents for > 3 
months) 
is prescribed a 
bisphosphonate.  
154/154 
100% 
0 0 0 0 0 0/154 
0% 
nr 
16 A postmenopausal 
woman prescribed 
strontium ranelate 
has an identifiable 
reason for not being 
prescribed a 
bisphosphonate 
 
152/154 
98.7% 
2 0 0 0 0 2/154 
1.3% 
2/2 
100% 
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Table 11: Adherence and applicability per criterion GP A 
Criterion  
n= 2926 
 
N/A 
(%) 
 
Yes 
 
No(J) 
 
No(U) 
 
IDS 
 
IDQ 
 
Applicable 
(%) 
 
Adherence 
(CI 95%) 
17 A postmenopausal 
woman prescribed 
raloxifene  
is receiving it for 
secondary prevention  
154/154 
100% 
0 0 0 0 0 0/154 
0% 
nr 
18 A patient 
prescribed 
teriparatide is 
prescribed it for 
secondary prevention 
and meets specific 
criteria 
154/154 
100% 
0 0 0 0 0 0/154 
0% 
nr 
19 A patient 
prescribed calcitonin 
is prescribed it for 
secondary prevention 
after bisphosphonate, 
raloxifene or strontium 
ranelate have been 
tried or have reasons 
for excluding from 
consideration 
 
154/154 
100% 
0 0 0 0 0 0/154 
0% 
nr 
Overall 1642 846 6 428 10 0 1284 846/1284 
65.8% 
(62.3-69.3) 
 
N/A: not applicable; No(J): justified non-adherence to the guideline; No(U): unjustified non-adherence to 
the guideline; IDS: insufficient data on the standard; IDQ: insufficient data on the qualifier; CI: confidence 
interval; OS: Osteoporosis 
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4.5.3 Level of Adherence 
 
Level of adherence was ranked as low for 2/19 criteria, intermediate for 7/19 
criteria and high for 6/19 criteria. The following table shows level of adherence 
ranked from lowest to highest percentage.  
 
Table 12: Level of adherence for GP A 
 
Level 
 
Criterion  
Adherence 
(%) 
 
9  
Patient with osteoporosis untreated by antiresorptive/ anabolic agent  is 
prescribed >=1000mg calcium plus 800 IE vitamin D 
20.4  
Low 
 
2  
Patient with measured BMD by DEXA scan has measures taken at spine and 
hip 
34.4 
3  
Patient with OS is prescribed supplementary calcium 
55.1 
4  
Osteopenic patient is prescribed supplementary calcium 
56.3 
11  
Osteopenic patient is prescribed an oral BP as first-line therapy 
56.3 
1  
Patient with a diagnosis  of OS  has a recorded DEXA scan 
58.3 
10  
Patient with OS  is prescribed an oral BP as first-line therapy 
58.7 
5  
Patient with confirmed vitamin D deficiency or age ≥ 65years is prescribed 
vitamin D 
58.9 
Intermedia
te 
6  
Patient with osteoporosis is treated with antiresorptive/ osteoanabolic agent 
60.8 
12 
Patient treated with antiresorptive/ osteoanabolic agent has no contra-
indication on record 
83.0 
13  
Patient  receiving treatment for osteopenia/osteoporosis is prescribed a 
standard dose regimen 
86.2 
14  
A patient with osteoporosis on bisphosphonate therapy  
is on the preferred choice: 1- Alendronate, 2-risedronate, 3-intermittent cyclical 
etidronate 
87.8 
8  
Patient prescribed vitamin D is prescribed 400-800 IU 
98.7 
7  
Patient prescribed calcium is prescribed 500-1500 mg 
98.8 
High 
16  
A postmenopausal woman prescribed strontium ranelate has an identifiable 
reason for not being prescribed a bisphosphonate 
 
100.0 
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4.5.4 Adherence per patient 
 
80/154 (52.0%) patients treated showed a high level of adherence. Those 
patients are marked green in the table below. Some 16 (23.0%) of patients 
(25/154) showed an intermediate level of adherence. For 49/154 (31.8%) 
patients less than 49.9% guideline adherence was calculated. Intermediate 
levels were marked yellow and low levels are red.  
 
Table 13: Adherence per patient GP A 
Pat YES NO(U) NO(J) IDS 
APPLICABILITY 
% 
ADHERENCE 
% 
CI 
min 
CI 
max 
1 3 4 0 0 36.84 42.9 41.3 44.5 
2 10 1 0 0 57.89 90.9 90.2 91.7 
3 5 2 1 0 36.84 71.4 70.0 72.9 
4 9 1 0 0 52.63 90.0 89.2 90.8 
5 9 0 1 0 47.37 100.0 100.0 100.0 
6 2 5 0 0 36.84 28.6 27.1 30.0 
7 9 1 0 0 52.63 90.0 89.2 90.8 
8 6 3 0 0 47.37 66.7 65.3 68.0 
9 7 2 0 0 47.37 77.8 76.6 79.0 
10 10 1 0 0 57.89 90.9 90.2 91.7 
11 8 2 0 0 52.63 80.0 78.9 81.1 
12 5 4 0 0 47.37 55.6 54.1 57.0 
13 0 6 0 0 31.58 0.0 0.0 0.0 
14 1 6 0 0 36.84 14.3 13.2 15.4 
15 7 3 0 0 52.63 70.0 68.8 71.2 
16 8 3 0 0 57.89 72.7 71.6 73.9 
17 3 6 0 0 47.37 33.3 32.0 34.7 
18 7 2 0 0 47.37 77.8 76.6 79.0 
19 8 1 0 0 47.37 88.9 88.0 89.8 
20 0 6 0 0 31.58 0.0 0.0 0.0 
21 0 6 0 0 31.58 0.0 0.0 0.0 
22 9 1 0 0 52.63 90.0 89.2 90.8 
23 9 1 0 0 52.63 90.0 89.2 90.8 
24 4 4 0 0 42.11 50.0 48.5 51.5 
25 5 4 0 0 47.37 55.6 54.1 57.0 
26 11 0 0 0 57.89 100.0 100.0 100.0 
27 6 3 0 0 47.37 66.7 65.3 68.0 
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Table 13: Adherence per patient GP A 
Pat YES NO(U) NO(J) IDS APPLICABILITY ADHERENCE 
CI 
min 
CI 
max 
28 3 4 0 0 36.84 42.9 41.3 44.5 
29 9 1 0 0 52.63 90.0 89.2 90.8 
30 3 4 0 0 36.84 42.9 41.3 44.5 
31 5 3 0 0 42.11 62.5 61.0 64.0 
32 10 1 0 0 57.89 90.9 90.2 91.7 
33 9 1 0 0 52.63 90.0 89.2 90.8 
34 0 6 0 0 31.58 0.0 0.00 0.0 
35 0 6 0 0 31.58 0.0 0.00 0.0 
36 0 5 0 0 26.32 0.0 0.00 0.0 
37 6 3 0 0 47.37 66.7 65.3 68.0 
38 8 1 0 0 47.37 88.9 88.0 89.8 
39 10 1 0 0 57.89 90.9 90.2 91.7 
40 5 4 0 0 47.37 55.6 54.1 57.0 
41 6 3 0 0 47.37 66.7 65.3 68.0 
42 7 2 0 0 47.37 77.8 76.59 79.0 
43 0 6 0 0 31.58 0.0 0.0 0.0 
44 9 1 0 0 52.63 90.0 89.2 90.8 
45 0 6 0 0 31.58 0.0 0.0 0.0 
46 10 1 0 0 57.89 90.9 90.2 91.7 
47 8 1 0 1 52.63 80.0 78.9 81.1 
48 1 6 0 0 36.84 14.3 13.2 15.4 
49 0 6 0 0 31.58 0.0 0.0 0.0 
50 5 2 0 0 36.84 71.4 70.0 72.9 
51 0 6 0 0 31.58 0.0 0.0 0.0 
52 1 5 0 0 31.58 16.7 15.4 18.0 
53 2 4 0 0 31.58 33.3 31.7 35.0 
54 0 5 1 0 26.32 0.0 0.0 0.0 
55 5 3 0 0 42.11 62.5 61.0 64.0 
56 9 1 0 0 52.63 90.0 89.2 90.8 
57 0 6 0 0 31.58 0.0 0.0 0.0 
58 6 3 0 0 47.47 66.7 65.3 68.0 
59 9 1 0 0 52.63 90.0 89.2 90.8 
60 5 3 0 0 42.11 62.5 61.0 64.0 
61 5 3 0 0 42.11 62.5 61.0 64.0 
62 5 4 0 0 47.37 55.6 54.1 57.0 
63 1 6 0 0 36.84 14.3 13.2 15.4 
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Table 13: Adherence per patient GP A 
Pat YES NO(U) NO(J) IDS APPLICABILITY ADHERENCE 
CI 
min 
CI 
max 
64 7 2 0 0 47.37 77.8 76.6 79.0 
65 8 2 0 0 52.63 80.0 78.9 81.1 
66 0 6 0 0 31.58 0.0 0.00 0.0 
67 7 2 0 0 47.37 77.8 76.6 79.0 
68 7 2 0 0 47.37 77.8 76.6 79.0 
69 0 5 1 0 26.32 0.0 0.0 0.0 
70 10 1 0 0 57.89 90.9 90.2 91.7 
71 9 1 0 0 52.63 90.0 89.2 90.8 
72 6 3 0 0 47.37 66.7 65.3 68.0 
73 10 1 0 0 57.89 90.9 90.2 91.7 
74 0 6 0 0 31.58 0.0 0.00 0.0 
75 10 1 0 0 57.89 90.9 90.2 91.7 
76 10 1 0 0 57.89 90.9 90.2 91.7 
77 10 1 0 0 57.89 90.9 90.2 91.7 
78 9 0 1 0 47.37 100.0 100.0 100.0 
79 8 2 0 0 52.63 80.0 78.9 81.1 
80 4 3 0 1 42.11 50.0 48.5 51.5 
81 0 5 0 0 26.32   0.0 0.0 0.0 
82 10 1 0 0 57.89 90.9 90.2 91.7 
83 6 2 0 0 42.11 75.0 73.7 76.3 
84 10 1 0 0 57.89 90.9 90.2 91.7 
85 8 2 0 0 52.63 80.0 78.9 81.1 
86 10 1 0 0 57.89 90.9 90.2 91.7 
87 5 3 0 0 42.11 62.5 61.0 64.0 
88 1 5 0 0 31.58 16.7 15.4 18.0 
89 11 0 0 0 57.89 100.0 100.0 100.0 
90 0 6 0 0 31.58 0.0 0.0 0.0 
91 11 0 0 0 57.89 100.0 100.0 100.0 
92 10 1 0 0 57.89 90.9 90.2 91.7 
93 6 3 0 0 47.37 66.7 65.3 68.0 
94 9 1 0 0 52.63 90.0 89.2 90.8 
95 5 3 0 0 42.11 62.5 61.0 64.0 
96 10 1 0 0 57.89 90.9 90.2 91.7 
97 10 1 0 0 57.89 90.9 90.2 91.7 
98 0 6 0 0 31.58 0.0 0.0 0.0 
99 1 6 0 0 36.84 14.3 13.2 15.4 
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Table 13: Adherence per patient GP A 
Pat YES NO(U) NO(J) IDS APPLICABILITY ADHERENCE 
CI 
min 
CI 
max 
100 10 0 0 1 57.89 90.9 90.17 91.7 
101 9 2 0 0 57.89 81.8 80.82 82.8 
102 6 3 0 0 47.37 66.7 65.3 68.0 
103 0 6 0 0 31.58 0.0 0.00 0.0 
104 10 1 0 0 57.89 90.9 90.2 91.7 
105 9 2 0 0 57.89 81.8 80.8 82.8 
106 11 0 0 0 57.98 100.0 100.0 100.0 
107 0 6 0 0 31.58 0.0 0.0 0.0 
108 10 0 0 1 57.89 90.9 90.2 91.7 
109 10 1 0 0 57.89 90.9 90.2 91.7 
110 0 6 0 0 31.58 0.0 0.00 0.0 
111 9 2 0 0 57.89 81.8 80.8 82.8 
112 10 0 0 0 52.63 100.0 100.0 100.0 
113 4 4 0 0 42.11 50.0 48.5 51.5 
114 4 4 0 0 42.11 50.0 48.5 51.5 
115 2 0 0 0 42.11 75.0 73.7 76.3 
116 5 3 0 0 42.11 62.5 61.0 63.4 
117 0 5 0 0 23.32 0.0 0.0 0.0 
118 10 1 0 0 57.89 90.9 90.2 91.7 
119 6 2 0 0 42.11 75.0 73.7 76.3 
120 0 5 0 0 26.32 0.0 0.0 0.0 
121 8 1 1 1 47.37 88.9 88.0 89.8 
122 5 4 0 0 47.37 55.6 54.1 57.0 
123 0 6 0 0 31.58 0.0 0.0 0.0 
124 1 5 0 0 31.58 16.7 15.4 18.0 
125 9 1 0 0 52.63 90.0 89.2 90.8 
126 10 1 0 0 57.89 90.9 90.2 91.7 
127 7 2 0 0 47.37 77.8 76.6 79.0 
128 4 4 0 0 42.11 50.0 48.5 51.5 
129 10 1 0 0 57.89 90.9 90.2 91.7 
130 6 2 0 0 42.11 75.0 73.7 76.3 
131 0 5 0 0 26.32 0.0 0.0 0.0 
132 11 0 0 0 57.98 100.0 100.0 100.0 
133 7 2 0 0 47.37 77.8 76.6 79.0 
134 5 3 0 0 42.11 62.5 61.0 64.0 
135 9 2 0 0 57.89 81.8 80.8 82.8 
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Table 13: Adherence per patient GP A 
Pat YES NO(U) NO(J) IDS APPLICABILITY ADHERENCE 
CI 
min 
CI 
max 
136 0 6 0 0 31.58 0.0 0.0 0.0 
137 0 5 0 0 26.32 0.0 0.0 0.0 
138 5 4 0 0 47.37 55.6 54.1 57.0 
139 7 0 0 0 36.84 100.0 100.0 100.0 
140 0 2 0 1 15.79 0.0 0.0 0.0 
141 7 0 0 1 42.11 87.5 86.5 88.5 
142 5 1 0 0 31.58 83.3 82.0 84.6 
143 7 0 0 1 42.11 87.5 86.5 88.5 
144 2 4 0 0 31.58 33.3 31.7 35.0 
145 2 4 0 0 31.58 33.3 31.7 35.0 
146 4 1 0 1 31.58 66.7 65.0 68.3 
147 6 2 0 0 42.11 75.0 73.7 76.3 
148 0 3 0 1 21.05 0.0 0.0 0.0 
149 0 3 0 1 21.05 0.0 0.0 0.0 
150 7 1 0 0 42.11 87.5 86.5 88.5 
151 3 2 0 0 26.32 60.0 58.1 61.9 
152 3 3 0 0 31,58 50.0 48.3 51.7 
153 1 0 0 0 36.84 85. 84.6 86.8 
154 0 3 0 0 15.79 0.0 0.0 0.0 
Total 
846 428 6 10 43.9  
% 
89.7 
% 
88.8 90.6 
 
 
4.5.5 Main findings 
 
4.5.5.1 Patients with osteoporosis 
 
85/138 (61.6 %) of patients with osteoporosis received an antiresorptive 
treatment. 1 of those patients received ibandronic acid, which is not covered by 
the guidelines but a legal treatment option. Osteoanabolic substances were not 
prescribed at all. 82/85 (96.5%) patients who received a treatment were treated 
with a bisphosphonate.  Mainly alendronic acid was prescribed. Only 3/85 
(3.5%) of the patients received an alternative treatment (strontium ranelate). 
Standard dose was mainly used.  
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53/138 (38.4%) patients did not receive an osteoanabolic or an antiresorptive 
treatment. Only 20.8% of those patients were prescribed calcium and vitamin d. 
Respectively, 30.4% of all osteoporotic patients neither received a treatment nor 
a supplement.  
 
Calitonin, raloxifene and teriparatide were not prescribed at all.  
 
4.5.5.2 Patients with osteopenia 
 
9/16 ( 56.25%) of patients with osteopenia received an antiresorptive treatment. 
7 of were prescribed alendronic acid and 2 received risedronate sodium. Both 
substances were prescribed in the dose licensed for osteoporosis but not for the 
indication osteopenia.   
 
7/16 (43.8%) patients did not receive an antiresorptive treatment. Only 42.9% of 
those patients were prescribed calcium and vitamin D. Respectively, 25% of all 
osteoporotic patients neither received a treatment nor a supplement.  
 
4.6 Practice B  
 
4.6.1 Demographics 
 
89% of the patients with a diagnosis of osteoporosis or osteopenia are female. 
98% of female patients are postmenopausal.  100% of the assessed population 
are diagnosed with osteoporosis. Age range is quite broad, but when calculating 
the mean age it turns out that only a few patients are less than 50 years old.  
 
The following table shows the demographic characteristics of test population B.  
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Table 14: Characteristics of test population GP B 
Patient sample n =62 
 
Gender 
Female 
Male 
 
 
55/62 (88.7%) 
7/62 (11.3%) 
 
 
Diagnosis 
Osteoporosis 
 Female 
 Postmenopausal 
 Male 
 
 
62 
55 
54 
7 
 
 
Age 
 
Age range osteoporotic patients (years) 
 Female 
 Male 
 
Mean age osteoporotic patients (years) 
 Female 
 Male 
 
 
 
 
29-92 
29-92 
36-88 
 
72.4 (13.2) 
73.5 (12.0) 
63 (19.3) 
 
 
 
BMI range (kg/ m2) 
Osteoporosis 
 Female 
 Male 
 
 
BMI <22 
 
 
14.8-39.6 
24-34.6 
14.7-23.7 
 
 
3/15 (20%) 
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4.6.2 Adherence per Criterion 
 
For 4/19 criteria no result can be presented as no patient was applicable. Overall 
adherence calculated on a per criterion base is 65.8 ± 3.5%, which is an intermediate 
level of adherence. The following table shows applicability and percentage of 
adherence for each criterion and overall for GP A.  
 
Table 15: Adherence and applicability per criterion GP B 
 
Criterion  
n=  1178 
 
N/A 
(%) 
 
Yes 
 
No(J) 
 
No(U) 
 
IDS 
 
IDQ 
Applicable 
(%) 
Adherence 
(CI 95%) 
1 Patient with a 
diagnosis  of OS  has 
a recorded DEXA scan 
0/62 
0.0% 
1 0 54 7 0 62/62 
100.0% 
1/62 
1.6% 
(0-4.7) 
2 Patient with 
measured BMD by 
DEXA scan has 
measures taken at 
spine and hip 
51/62 
82.3% 
0 0 1 10 39 11/62 
17.7% 
0/11 
0.0% 
3 Patient with OS is 
prescribed 
supplementary calcium 
0/62 
0.0% 
24 0 38 0 0 62/62 
100.0% 
24/62 
38.7% 
(26.5-50.9) 
4 Osteopenic patient 
is prescribed 
supplementary calcium 
62/62 
100.0% 
0 0 0 0 0 0/62 
0.0% 
nr 
5 Patient with 
confirmed vitamin D 
deficiency or age ≥ 
65years is prescribed 
vitamin D 
15/62 
24.2% 
28 0 19 0 0 47/62 
75.8% 
28/47 
59.6% 
(45.5-73.7) 
6 Patient with 
osteoporosis is 
treated with 
antiresorptive/ 
osteoanabolic agent  
0/62 
0.0% 
31 0 31 0 0 62/62 
100.0% 
31/62 
50.0% 
(37.6-62.4) 
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Table 15: Adherence and applicability per criterion GP B 
 
Criterion  
n=  1178 
 
N/A 
(%) 
 
Yes 
 
No(J) 
 
No(U) 
 
IDS 
 
IDQ 
Applicable 
(%) 
Adherence 
(CI 95%) 
7 Patient prescribed 
calcium is prescribed 
500-1500 mg 
28/62 
45.2% 
34 0 0 0 0 34/62 
54.8% 
34/34 
100.0% 
 
8 Patient prescribed 
vitamin D is prescribed 
400-800 IU 
28/62 
45.2% 
32 0 2 0 0 34/62 
54.8% 
32/34 
94.1% 
(86.2-100.0) 
9 Patient with 
osteoporosis 
untreated by 
antiresorptive/ 
anabolic agent  is 
prescribed >=1000mg 
calcium plus 800 IE 
vitamin D 
31/62 
50.0% 
 
12 0 19 0 0 31/62 
50.0% 
12/31 
38.7% 
(21.6-55.8) 
10 Patient with OS  is 
prescribed an oral BP 
as first-line therapy 
0/62 
0.0% 
31 0 31 0 0 62/62 
100.0% 
31/62 
50.0% 
(37.6-62.4) 
11 Osteopenic patient 
is prescribed an oral 
BP as first-line therapy  
62/62 
100.0% 
0 0 0 0 0 0/62 
0.0% 
nr 
12 Patient treated 
with antiresorptive/ 
osteoanabolic agent 
has no contra-
indication on record 
31/62 
50.0% 
13 0 5 13 0 31/62 
50.0% 
13/31 
41.9% 
(24.5-59.3) 
13 Patient  receiving 
treatment for 
osteopenia/osteoporo
sis is prescribed a 
standard dose regimen 
11/62 
17.7% 
38 0 5 8 0 51/62 
82.3% 
38/51 
74.5% 
(62.5-86.5) 
14 A patient with 
osteoporosis on 
bisphosphonate 
therapy  
is on the preferred 
choice* 
* 1- Alendronate, 2-
risedronate, 3-
intermittent cyclical 
etidronate 
31/62 
50.0% 
26 0 5 0 0 31/62 
50.0% 
26/31 
83.9% 
(71-96.8) 
15 A patient who is 
on long-term 
glucocorticoid 
therapy 
(> 7.5 mg 
prednisolone or 
equivalents for > 3 
months) 
is prescribed a 
bisphosphonate.  
 
62/62 
100.0% 
0 0 0 0 0 0/62 
0.0% 
nr 
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Table 15: Adherence and applicability per criterion GP B 
 
Criterion  
n=  1178 
 
N/A 
(%) 
 
Yes 
 
No(J) 
 
No(U) 
 
IDS 
 
IDQ 
 
Applicable 
(%) 
Adherence 
(CI 95%) 
16 A postmenopausal 
woman prescribed 
strontium ranelate 
has an identifiable 
reason for not being 
prescribed a 
bisphosphonate 
 
62/62 
100.0% 
0 0 0 0 0 0/62 
0.0% 
nr 
17 A postmenopausal 
woman prescribed 
raloxifene  
is receiving it for 
secondary prevention  
62/62 
100.0% 
0 0 0 0 0 0/62 
0.0% 
nr 
18 A patient 
prescribed 
teriparatide is 
prescribed it for 
secondary prevention 
and meets specific 
criteria 
62/62 
100.0% 
0 0 0 0 0 0/62 
0.0% 
nr 
19 A patient 
prescribed calcitonin 
is prescribed it for 
secondary prevention 
after bisphosphonate, 
raloxifene or strontium 
ranelate have been 
tried or have reasons 
for excluding from 
consideration 
 
62/62 
100.0% 
0 0 0 0 0 0/62 
0.0% 
nr 
Overall 
 
660/1178 
56.1% 
270 0 210 38 39 518/1178 
43.9% 
270/518 
52.1% 
(47.8-56.4) 
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4.6.3 Level of Adherence 
 
Level of adherence was ranked as low for 5/19 criteria, intermediate for 3/19 
criteria and high for 4/19 criteria. The following table shows level of adherence 
ranked from lowest to highest percentage.  
 
 
Table 16: Level of adherence GP B 
 
Level 
 
Criterion  
Adherence  
(%) 
2  
Patient with measured BMD by DEXA scan has measures taken at spine 
and hip 
0.0 
1  
Patient with a diagnosis  of OS  has a recorded DEXA scan 
1.6 
3  
Patient with OS is prescribed supplementary calcium 
38.7 
Low 
9  
Patient with osteoporosis untreated by antiresorptive/ anabolic agent  
is prescribed >=1000mg calcium plus 800 IE vitamin D 
41.9 
12 
Patient treated with antiresorptive/ osteoanabolic agent has no contra-
indication on record 
50.0 
6  
Patient with osteoporosis is treated with antiresorptive/ osteoanabolic 
agent 
50.0 
Intermediate 
5 
Patient with confirmed vitamin D deficiency or age ≥ 65years is 
prescribed vitamin D 
59.6 
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Table 16: Level of adherence GP B 
10  
Patient with OS  is prescribed an oral BP as first-line therapy 
100.0 
13  
Patient  receiving treatment for osteopenia/osteoporosis is prescribed a 
standard dose regimen 
74.5 
14  
A patient with osteoporosis on bisphosphonate therapy  
is on the preferred choice: 1- Alendronate, 2-risedronate, 3-intermittent 
cyclical etidronate 
83.9 
8  
Patient prescribed vitamin D is prescribed 400-800 IU 
100.0 
High 
7  
Patient prescribed calcium is prescribed 500-1500 mg 
94.1 
 
4.6.4 Adherence per patient 
 
21/62 (33.87%) patients treated showed a high level of adherence. Those 
patients are marked green in the table below. 29.03% of patients (18/62) 
showed an intermediate level of adherence. For 23/62 (37.10%) patients less 
than 49.9% guideline adherence was calculated. Intermediate levels were 
marked yellow and low levels are red.  
 
Table 17: Adherence per patient GP B 
Pat YES NO(U) NO(J) IDS IDQ APPLICABILITY ADHERENCE 
CI  
min 
CI 
max 
1 4 2 0 1 0 36.84 57.1 55.5 58.7 
2 8 1 0 1 0 52.63 80.0 78.9 81.1 
3 0 6 0 0 0 31.58 0.0 0.0 0.0 
4 0 6 0 0 0 31.58 0.0 0.0 0.0 
5 7 1 0 2 1 52.63 70.0 68.8 71.2 
6 0 6 0 0 0 31.58 0.0 0.0 0.0 
7 7 2 0 1 0 52.63 70.0 68.8 71.2 
8 7 2 0 1 0 52.63 70.0 68.8 71.2 
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Table 17: Adherence per patient GP B 
Pat YES NO(U) NO(J) 
ID
S 
IDQ APPLICABILITY ADHERENCE 
CI  
min 
CI max 
9 5 3 0 0 0 42.11 62.5 61.0 64.0 
10 8 0 0 2 1 52.63 80.0 78.9 81.1 
11 3 4 0 1 0 42.11 37.5 36.0 39.0 
12 0 6 0 0 0 31.58 0.0 0.0 0.0 
13 7 2 0 1 0 52.63 70.0 68.8 71.2 
14 8 1 0 1 0 52.63 80.0 78.9 81.1 
15 4 3 0 1 0 42.11 50.0 48.5 51.5 
16 3 3 0 1 0 36.84 42.9 41.3 44.5 
17 5 3 0 1 0 55.56 55.6 54.1 57.0 
18 0 4 0 1 1 26.32 0.0 0.0 0.0 
19 3 4 0 1 0 42.11 37.5 36.0 39.0 
20 8 2 0 0 0 52.63 80.0 78.9 81.1 
21 0 6 0 0 0 31.58 0.0 0.0 0.0 
22 5 3 0 0 0 42.11 62.5 61.0 64.0 
23 5 3 0 0 0 42.11 62.5 61.0 64.0 
24 0 5 0 0 0 26.32 0.0 0.0 0.0 
25 9 0 0 1 1 52.63 90.0 89.2 90.8 
26 2 5 0 1 0 42.11 25.0 24.0 26.3 
27 0 6 0 0 0 31.58 0.0 0.0 0.0 
28 8 2 0 0 0 52.63 80.0 78.9 81.1 
29 8 2 0 0 0 52.63 80.0 78.9 81.1 
30 8 0 0 2 1 52.63 80.0 78.9 81.1 
31 4 3 0 0 0 36.84 57.1 55.5 58.7 
32 9 1 0 0 0 52.63 90.0 89.2 90.8 
33 5 3 0 0 0 42.11 62.5 61.0 64.0 
34 5 3 0 0 0 42.11 62.5 61.0 64.0 
35 5 3 0 0 0 42.11 62.5 61.0 64.0 
36 0 6 0 0 0 31.58 0.0 0.0 0.0 
37 0 6 0 0 0 31.58 0.0 0.0 0.0 
38 4 2 0 1 1 36.84 57.1 55.5 58.7 
39 4 2 0 1 0 36.84 57.1 55.5 58.7 
40 7 1 0 2 0 52.63 70.0 68.8 71.2 
41 0 6 0 0 0 31.58 0.0 0.0 0.0 
42 4 3 0 0 0 36.84 57.1 55.5 58.7 
43 7 1 0 2 0 52.63 70.0 68.8 71.2 
44 0 6 0 0 0 31.58 0.0 0.0 0.0 
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Table 17: Adherence per patient GP B 
Pat YES NO(U) NO(J) IDS IDQ APPLICABILITY ADHERENCE 
CI  
min 
CI  
max 
45 0 6 0 0 0 31.6 0.0 0.0 0.0 
46 9 1 0 0 0 52.6 90.0 89.2 90.8 
47 5 3 0 0 0 42.1 62.5 61.0 64.0 
48 7 3 0 0 0 52.6 70.0 68.8 71.2 
49 0 5 0 0 0 26.3 0.0 0.0 0.0 
50 0 5 0 0 0 26.3 0.0 0.0 0.0 
51 8 2 0 0 0 52.6 80.0 78.9 81.1 
52 1 5 0 0 0 31.6 16.7 15.4 18.0 
53 8 2 0 0 0 52.6 80.0 78.9 81.1 
54 4 3 0 0 0 36.8 57.1 55.5 58.7 
55 1 4 0 0 0 26.3 20.0 18.5 21.5 
56 7 1 0 1 0 47.4 77.8 76.6 79.0 
57 8 1 0 0 0 47.4 89.0 88.0 89.8 
58 5 3 0 0 0 42.1 62.5 61.0 64.0 
59 4 4 0 0 0 42.1 50.0 48.5 51.5 
60 4 4 0 0 0 42.1 50.0 48.5 51.5 
61 0 5 0 0 0 26.3 0.0 0.0 0.0 
62 3 4 0 1 1 42.1 37.5 36.0 39.0 
Tot
al 
260 200 
 
0 28 7 41.7% 53.3% 51.8 55.0 
 
4.6.5 Main findings 
 
31/62 (50.0 %) of patients with osteoporosis received an antiresorptive 
treatment. All patients received an oral bisphosphonate. 87.1% were on 
alendronic acid.  Although a legal treatment option, ibandronic acid, zoledronic 
acid, strontium ranelate, raloxifene, teriparatde and calcitonin were not used at 
all.     
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
75 
 
 
31/62(50%) patients did not receive an osteoanabolic or an antiresorptive 
treatment. Only 38.7% of those patients were prescribed calcium and vitamin D. 
Respectively 19/ 61 (31.1%) patients were neither received an osteoanabolic or 
antiresorptive treatment nor supplementary calcium and vitamin D.  
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4.7 Practice C  
 
Data were downloaded from the GPASS® system in a practice of a general 
practitioner in Springburn 
 
4.7.1 Demographics 
 
89.3% of the patients with a diagnosis of osteoporosis or osteopenia are 
female. 98.9% of female patients are postmenopausal.  58.3% of the assessed 
population are diagnosed with osteoporosis. Age range is quite broad, but when 
calculating the mean age it turns out that only a few patients are less than 50 
years old.  
 
The following table shows the demographic characteristics of test population C. 
 
Table 18: Characteristics of test population GP C 
Patient sample n =103 
 
Gender 
Female 
Male 
 
 
92/103 (89.3%) 
11/103 (10.7%) 
 
 
Diagnosis 
Osteoporosis 
 Female 
 Postmenopausal 
 Male 
 
 
 
60/103 (58.3%) 
51/60 (85.0%) 
51/60 (85.0%) 
9/60 (15.0%) 
Osteopenia 
 Female 
 Postmenopausal 
 Male 
43/103 (41.7%) 
41/43 (95.3%) 
40/43 (93.0%) 
2/43 (4.7%) 
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Table 18: Characteristics of test population GP C 
Patient sample n =103 
 
Age 
Age range (years) 
 
Age range osteoporotic patients (years) 
 Female 
 Male 
 
Mean age osteoporotic patients (years) 
 Female 
 Male 
 
Age range osteopenic patients (years) 
 Female 
 Male 
 
 
 
39-92 
 
43-93 
43-93 
67-91 
 
75.9 (10.6) 
75.0 (10.9) 
80.8 (7.6) 
 
39-92 
43-92 
39-68 
 
 
Mean age osteopenic patients (years) 
 Female 
 Male 
 
64.5 (12.5) 
65.0 (12.10) 
53.5 (20.5) 
 
 
BMI range (kg/ m2) 
Osteoporosis 
 Female 
 Male 
 
14-41 
14-41 
14-41 
17-33 
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Table 18: Characteristics of test population GP C 
 
BMI range (kg/ m2) 
Osteopenia 
 Female 
 Male 
 
 
16-40 
16-40 
26-32 
 
4.7.2 Adherence per Criterion 
 
For 3/19 criteria no result can be presented as no patient was applicable. 
Overall adherence calculated on a per criterion base is 61.4 ± 3.7%, which is an 
intermediate level of adherence. The following table shows applicability and 
percentage of adherence for each criterion and overall for GP C. 
 
Table 19: Adherence and applicability GP C 
 
Criterion  
n=  1178 
 
N/A 
(%) 
 
Yes 
 
No(J) 
 
No(U) 
 
IDS 
 
IDQ 
 
Applicable 
(%) 
Adherence 
(CI 95%) 
 
1 Patient with a 
diagnosis  of OS  has 
a recorded DEXA scan 
44/103 
42.7% 
37 1 17 5 0 59/103 
57.3% 
37/59 
62.7% 
(50.4-75.0) 
2 Patient with 
measured BMD by 
DEXA scan has 
measures taken at 
spine and hip 
66/103 
64.1% 
4 0 33 0 5 37/103 
35.9% 
4/37 
10.8% 
(0.8-20.8) 
3 Patient with OS is 
prescribed 
supplementary calcium 
43/103 
41.7% 
38 0 22 0 0 60/103 
58.3% 
38/60 
63.3% 
(51.1-75.5) 
4 Osteopenic patient 
is prescribed 
supplementary calcium 
60/103 
58.3% 
13 0 30 0 0 43/103 
41.7% 
13/43 
30.2% 
(16.5-43.9) 
5 Patient with 
confirmed vitamin D 
deficiency or age ≥ 
65years is prescribed 
vitamin D 
34/103 
33% 
41 0 28 0 0 69/103 
67% 
41/69 
59.4% 
(47.8-70.8) 
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Table 19: Adherence and applicability GP C 
 
Criterion  
n=  1178 
 
N/A 
(%) 
 
Yes 
 
No(J) 
 
No(U) 
 
IDS 
 
IDQ 
 
Applicable 
(%) 
Adherence  
(CI 95%) 
 
         
6 Patient with 
osteoporosis is 
treated with 
antiresorptive/ 
osteoanabolic agent  
48/103 
46.6% 
38 5 12 5 0 55/103 
53.4% 
38/55 
69.1% 
(56.9-81.3) 
7 Patient prescribed 
calcium is prescribed 
500-1500 mg 
52/103 
50.5% 
51 0 0 0 0 51/103 
49.5% 
51/51 
100.0% 
8 Patient prescribed 
vitamin D is 
prescribed 400-800 IU 
53/103 
51.5% 
50 0 0 0 0 50/103 
48.5% 
50/50 
100.0% 
9 Patient with 
osteoporosis 
untreated by 
antiresorptive/ 
anabolic agent  is 
prescribed >=1000mg 
calcium plus 800 IE 
vitamin D 
81/103 
78.6% 
9 0 13 0 0 22/103 
21.4% 
9/22 
40.9% 
(20.4-61.4) 
10 Patient with OS  is 
prescribed an oral BP 
as first-line therapy 
49/103 
47.6% 
37 6 12 5 0 54/103 
52.4% 
37/54 
68.5% 
(56.1-80.9) 
11 Osteopenic patient 
is prescribed an oral 
BP as first-line therapy  
60/103 
58.3% 
10 0 33 0 0 43/103 
41.7% 
10/43 
23.3% 
(10.7-35.9) 
12 Patient treated 
with antiresorptive/ 
osteoanabolic agent 
has no contra-
indication on record 
55/103 
53.4% 
23 0 2 23 0 48/103 
46.6% 
23/48 
47.9% 
(33.8-62.0) 
13 Patient  receiving 
treatment for 
osteopenia/osteoporo
sis is prescribed a 
standard dose regimen 
55/103 
53.4% 
31 0 15 2 0 48/103 
46.7% 
31/48 
64.6% 
(51.1-78.1) 
14 A patient with 
osteoporosis on 
bisphosphonate 
therapy  
is on the preferred 
choice* 
* 1- Alendronate, 2-
risedronate, 3-
intermittent cyclical 
etidronate 
66/103 
64.1% 
32 0 5 0 0 37/103 
35.9% 
23/37 
86.5% 
(75.5-97.5) 
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Table 19: Adherence and applicability GP C 
 
Criterion  
n=  1178 
 
N/A 
(%) 
 
Yes 
 
No(J) 
 
No(U) 
 
IDS 
 
IDQ 
 
Applicable 
(%) 
 
Adherence  
(CI 95%) 
15 A patient who is on 
long-term 
glucocorticoid 
therapy 
(> 7.5 mg 
prednisolone or 
equivalents for > 3 
months) 
is prescribed a 
bisphosphonate.  
 
102/103 
99.0% 
1 0 0 0 0 1/103 
1.0% 
1/1 
100.0% 
16 A postmenopausal 
woman prescribed 
strontium ranelate 
has an identifiable 
reason for not being 
prescribed a 
bisphosphonate 
 
102/103 
99.0% 
1 0 0 0 0 1/103 
1.0% 
1/1 
100.0% 
17 A postmenopausal 
woman prescribed 
raloxifene  
is receiving it for 
secondary prevention  
103/103 
100.0% 
0 0 0 0 0 0/103 
0.0% 
nr 
18 A patient 
prescribed 
teriparatide is 
prescribed it for 
secondary prevention 
and meets specific 
criteria 
103/103 
100.0% 
0 0 0 0 0 0/103 
0.0% 
nr 
19 A patient 
prescribed calcitonin 
is prescribed it for 
secondary prevention 
after bisphosphonate, 
raloxifene or strontium 
ranelate have been 
tried or have reasons 
for excluding from 
consideration 
 
103/103 
100.0% 
0 0 0 0 0 0/103 
0.0% 
nr 
Overall 
 
1279/ 
1957 
65.4% 
416 12 222 40 5 678/1957 
34.6% 
416/678 
61.4% 
(57.7-65.1) 
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4.7.3 Level of Adherence 
 
Level of adherence was ranked as low for 5/19 criteria, intermediate for 6/19 
criteria and high for 5/19 criteria. The following table shows level of adherence 
ranked from lowest to highest percentage.  
 
 
TableI 20: Level of adherence GP C 
 
Level 
 
Criterion  
 
Adherence  
(%) 
 
2  
Patient with measured BMD by DEXA scan has measures taken at 
spine and hip 
10.8 
11  
Osteopenic patient is prescribed an oral BP as first-line therapy 
23.3 
4  
Osteopenic patient is prescribed supplementary calcium 
30.2 
9  
Patient with osteoporosis untreated by antiresorptive/ anabolic 
agent  is prescribed >=1000mg calcium plus 800 IE vitamin D 
40.9 
 
Low 
 
12 
Patient treated with antiresorptive/ osteoanabolic agent has no 
contra-indication on record 
47.9 
5  
Patient with confirmed vitamin D deficiency or age ≥ 65years is 
prescribed vitamin D 
 
59.4  
1  
Patient with a diagnosis  of OS  has a recorded DEXA scan 
62.7 
3  
Patient with OS is prescribed supplementary calcium 
63.3 
13  
Patient  receiving treatment for osteopenia/osteoporosis is 
prescribed a standard dose regimen 
64.6 
10  
Patient with OS  is prescribed an oral BP as first-line therapy 
68.5 
Intermediate 
6  
Patient with osteoporosis is treated with antiresorptive/ 
osteoanabolic agent 
69.1 
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TableI 20: Level of Adherence GP C 
7 
Patient prescribed calcium is prescribed 500-1500 mg 
100.0 
8  
Patient prescribed vitamin D is prescribed 400-800 IU 
100.0 
15  
A patient who is on long-term glucocorticoid therapy 
(> 7.5 mg prednisolone or equivalents for > 3 months) 
is prescribed a bisphosphonate.  
 
100.0 
16  
A postmenopausal woman prescribed strontium ranelate has an 
identifiable reason for not being prescribed a bisphosphonate 
 
100.0 
High 
14  
A patient with osteoporosis on bisphosphonate therapy  
is on the preferred choice* 
* 1- Alendronate, 2-risedronate, 3-intermittent cyclical etidronate 
86.5 
 
 
4.7.4 Adherence per patient 
 
42/103 (40.78%) patients treated showed a high level of adherence. Those 
patients are marked green in the table below. 17.48% of patients (18/103) 
showed an intermediate level of adherence. For 43/103 (41.75%) patients less 
than 49.9% guideline adherence was calculated. Intermediate levels were 
marked yellow and low levels are red. 
 
Table 21: Adherence per patient GP C   
P
at 
YES NO(U) NO(J) 
ID
S 
ID
Q 
APPLICABILITY ADHERENCE 
CI 
min 
CI 
max 
 
1 5 3 0 0 0 42.11 62.5 61.0 64.0 
2 5 3 0 0 0 42.11 62.5 61.0 64.0 
3 3 4 0 1 0 42.11 37.5 36.0 39.0 
4 9 1 0 1 0 57.89 81.8 80.8 81.8 
5 8 1 0 1 0 52.63 80.0 78.9 81.1 
6 7 1 1 1 0 47.37 77.9 76.6 78.6 
7 9 0 0 1 0 52.63 90.0 89.2 90.8 
8 5 4 1 0 0 47.37 55.6 54.1 56.9 
9 7 0 0 2 0 47.37 77.9 75.6 78.6 
10 6 3 0 0 0 47.37 66.7 65.3 68.0 
11 0 4 2 0 0 21.05 0.0 0.0 0.0 
12 1 5 0 0 0 31.58 16.7 15.4 18.0 
13 10 1 0 0 0 57.89 90.9 90.2 91.7 
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Table 21: Adherence per patient GP C   
 
P
at 
YES NO(U) NO(J) 
ID
S 
ID
Q 
APPLICABILITY ADHERENCE 
CI 
min 
CI 
max 
14 1 6 0 0 0 36.84 14.3 13.2 15.4 
15 8 1 0 1 0 52.63 80.0 78.9 81.1 
16 4 2 0 2 0 42.11 50.0 48.5 50.5 
17 9 1 0 0 0 52.63 90.0 89.2 90.8 
18 1 5 0 0 0 31.58 16.7 15.4 17.9 
19 6 3 0 0 0 47.37 66.7 65.3 68.0 
20 9 2 0 0 0 57.89 81.8 80.8 82.8 
21 1 4 2 0 0 26.32 20.0 18.5 21.5 
22 10 0 0 1 0 47.89 90.9 90.2 91.7 
23 4 3 0 1 0 42.11 50.0 48.5 51.5 
24 4 2 0 2 0 42.11 50.0 48.5 51.5 
25 10 0 0 1 0 57.89 90.9 90.2 91.7 
26 2 4 2 0 0 31.58 33.3 31.7 35.0 
27 8 2 0 1 0 57.39 72.7 71.6 74.0 
28 5 1 2 0 0 31.58 83.3 82.0 84.6 
29 5 2 0 1 1 42.11 62.5 61.0 64.0 
30 6 2 0 2 1 52.63 60.0 58.7 61.3 
31 9 1 0 1 0 57.89 81.8 80.8 82.8 
32 6 1 2 0 0 36.84 85.7 84.6 86.8 
33 0 4 0 2 0 31.58 0.0 0.0 0.0 
34 0 5 0 0 0 26.32 0.0 0.0 0.0 
35 5 3 0 1 0 47.37 55.6 54.1 57.0 
36 0 3 0 2 0 26.32 0.0 0.0 0.0 
37 9 1 0 1 0 57.89 81.8 80.8 82.8 
38 5 3 0 1 0 55.56 55.6 54.1 57.0 
39 10 1 0 0 0 57.89 90.9 90.2 91.6 
40 8 1 0 1 0 52.63 80.0 78.9 81.1 
41 8 2 0 0 0 52.63 80.0 78.9 81.1 
42 7 2 0 1 0 52.63 70.0 68.8 71.2 
43 6 2 0 1 0 47.37 66.7 65.3 68.0 
44 9 2 0 0 0 57.89 81.8 80.8 82.8 
45 8 3 0 0 0 57.89 72.7 71.6 73.9 
46 8 0 0 1 1 47.37 88.9 88.0 89.8 
47 4 3 0 1 0 42.11 50.0 48.5 51.5 
48 9 1 0 1 0 57.89 81.8 80.8 82.8 
49 10 1 0 0 0 57.89 90.9 90.2 91.6 
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Table 21: Adherence per patient GP C  
P
at 
YES NO(U) NO(J) 
ID
S 
ID
Q 
APPLICABILITY ADHERENCE 
CI 
min 
CI 
max 
50 10 1 0 0 0 57.9 90.9 90.2 91.6 
51 10 1 0 0 0 57.9 90.9 90.2 91.6 
52 1 6 0 0 0 36.8 14.3 13.2 15.4 
53 1 6 0 0 0 36.8 14.3 13.2 15.4 
54 9 1 0 0 0 52.6 90.0 89.2 90.8 
55 5 3 0 0 0 42.1 62.5 61.0 64.0 
56 1 5 0 0 0 31.6 16.7 15.4 18.0 
57 5 0 0 2 0 36.8 71.4 69.7 72.9 
58 9 0 0 1 0 52.6 90.0 89.2 90.8 
59 8 1 0 0 0 47.4 88.9 88.0 89.8 
60 9 1 0 0 0 52.6 90.0 89.2 90.8 
61 0 3 0 0 0 15.8 0.0 0.0 0.0 
62 0 2 0 0 0 10.5 0.0 0.0 0.0 
63 0 2 0 0 0 10.5 0.0 0.0 0.0 
64 5 1 0 0 0 31.6 83.3 82.0 84.6 
65 0 3 0 0 0 15.8 0.0 0.0 0.0 
66 5 1 0 0 0 31.6 83.3 82.0 84.6 
67 0 3 0 0 0 15.8 0.0 0.0 0.0 
68 5 1 0 1 0 36.8 71.4 70.0 72.9 
69 5 1 0 1 0 36.8 71.4 70.0 72.9 
70 0 2 0 0 0 10.5 0.0 0.0 0.0 
71 4 1 0 0 0 26.3 80.0 78.5 81.5 
72 0 3 0 0 0 15.8 0.0 0.0 0.0 
73 5 1 0 0 0 31.6 83.3 82.0 84.6 
74 0 2 0 0 0 10.5 0.0 0.0 0.0 
75 0 2 0 0 0 15.8 0.0 0.0 0.0 
76 0 2 0 0 0 10.5 0.0 0.0 0.0 
77 3 1 0 0 0 21.1 75.0 73.2 76.9 
78 4 1 0 0 0 26.3 80.0 78.5 81.5 
79 0 2 0 0 0 10.5 0.0 0.0 0.0 
80 2 3 0 0 0 26.3 40.0 38.1 41.9 
81 5 1 0 1 0 36.8 71.4 70.0 72.9 
82 6 1 0 0 0 36.8 85.7 84.6 86.8 
83 0 2 0 0 0 10.5 0.0 0.0 0.0 
84 0 2 0 0 0 10.5 0.0 0.0 0.0 
85 0 2 0 0 0 10.5 0.0 0.0 0.0 
86 0 2 0 0 0 10.5 0.0 0.0 0.0 
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Table 21: Adherence per patient GP C  
 
P
at 
YES NO(U) NO(J) 
ID
S 
ID
Q 
APPLICABILITY ADHERENCE 
CI 
min 
CI 
max 
87 0 3 0 0 0 15.8 0.0 0.0 0.0 
88 5 1 0 0 0 31.6 83.3 82.0 84.6 
89 0 3 0 0 0 15.79 0.0 0.0 0.0 
90 0 2 0 0 0 10.53 0.0 0.0 0.0 
91 0 2 0 0 0 10.53 0.0 0.0 0.0 
92 0 3 0 0 0 1579 0.0 0.0 0.0 
93 0 2 0 0 0 10.53 0.0 0.0 0.0 
94 1 1 0 0 0 10.53 50.0 47.0 53.0 
95 2 3 0 0 0 26.32 40.0 38.2 41.9 
96 0 2 0 0 0 10.53 0.0 0.0 0.0 
97 0 2 0 0 0 10.53 0.0 0.0 0.0 
98 3 1 0 1 0 26.32 60.0 58.1 61.9 
99 1 2 0 0 0 15.79 33.3 31.0 35.7 
100 0 2 0 0 0 10.53 0.0 0.0 0.0 
101 1 1 0 0 0 10.53 50.0 47.0 53.0 
102 2 3 0 0 0 1579 0.0 0.0 0.0 
103 0 2 0 0 0 10.53 0.0 0.0 0.0 
Total 
41
6 
218 12 40 5 35.73 61.7 60.1 63.3 
 
4.7.5 Main findings 
 
4.7.5.1 Patients with osteoporosis 
 
38/60 (63.3%) of patients with osteoporosis received an antiresorptive 
treatment. 37/38 (97.4%) patients received an oral bisphosphonate. 29/37 
(78.4%) were on alendronic acid.  Although a legal treatment option, ibandronic 
acid, zoledronic acid, raloxifene, teriparatde and calcitonin were not used at all. 
Only one patient was treated with an alternative to bisphosphonates (strontium 
ranelate). 
 
22/60(36.7%) patients did not receive an osteoanabolic or an antiresorptive 
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
86 
 
treatment. Only 40.9% of those patients were prescribed calcium and vitamin D. 
Respectively 13/22 (59.1%) patients were neither received an osteoanabolic or 
antiresorptive treatment nor supplementary calcium and vitamin D.  
4.7.5.2 Patients with osteopenia 
 
10/43 (23.3%) of patients with osteopenia received an antiresorptive treatment. 
6 of were prescribed alendronic acid and 4 received risedronate sodium. Both 
substances were prescribed in the dose licensed for osteoporosis but not for the 
indication osteopenia.   
 
33/43 (76.7%) patients did not receive an antiresorptive treatment. Only 4/33 
(12.1%) of those patients were prescribed calcium and vitamin D. Respectively, 
67.4% of all osteoporotic patients neither received a treatment nor a 
supplement.  
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4.8 Comparison between practices 
 
4.8.1 Applicability to each criterion per practice 
The chart below shows that applicability to criteria varies strongly between the 
three GP practices. Criteria 17,18 and 19 were not applicable to any patients . 
Criterion 15 was applicable to only one patient. Criteria 4 and 11 deal with 
osteopenia- therefore were applicable to no patients in Practice B.  
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Figure 1: Applicability to each criterion 
 
4.8.2 Clinical guideline adherence to each criterion per practice 
 
The chart above shows the adherence to each criterion for each GP Practice. 
Major differences of the level of adherence between practice A, B and C are 
recorded for criteria 1, 2, 3, 4, 6, 9, 10, 11 and 12. The highest agreement was 
assessed for the use of standard dose regimen of supplements.  For criterion 
15 comparison between practices was not possible as only in one GP Practice 
were applicable patients found.  
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Figure 2: Adherence per criterion for practice A, B and C 
 
Applying Fisher’s exact test showed that prescribing and diagnostic behaviour differed 
between the three GP Practices. This of course also means that MATosteo is able to 
detect such differences.  The following table shows the results of Fisher’s exact test 
overall and per criterion. The higher the p-Value the less significant is the link in 
“behaviour” between the compared GPs. Non significant results are marked red.  
 
Table 22:: Comparison between A, B and  C; Fisher’s exact test 
Overall 
adherence 
GP A 
(%) 
(95% CI) 
GP B 
(%) 
(95% CI 
GP C 
(%) 
(95% CI 
p (A, B) p (A, C) p (B, C) 
Applicability 1284/2926 43.8% 
518/1178 
44.0% 
678/1957 
34.6% 
Adherence 
846/1284 
65.8% 
(62.3-69.3) 
270/518 
52.1% 
(47.8-56.4) 
416/678 
61.4% 
(57.7-65.1) 
 
< 0.0001 
 
0.0298 
 
 
< 0.0001 
 
1  
Applicability 
132/154 
85.7% 
62/62 
100% 
 
59/103 
57.3% 
Adherence  
77/132 
58.3% 
(49.9-66.7) 
1/62 
1.6% 
(-1.5.-4.7) 
37/59 
62.7% 
(50.4-75.0) 
 
<0.0001 0.6333 <0.0001 
2  
Applicability 93/154 60.4% 
11/62 
17.7% 
37/103 
35.9% 
Adherence  
32/93 
34.4% 
(24.7-44.1) 
0/11 
0.0% 
4/37 
10.8% 
(0.8-20.8) 
<0.0001 0.0028 0.0401 
Adherence  
76/138 
55.1% 
(46.8-63.4) 
24/62 
38.7% 
(26.5-50.9) 
41/69 
59.4% 
(47.8-70.8) 
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Table 22: Comparison between A, B and  C; Fisher’s exact test 
3  
Applicability 138/154 89.6% 
62/62 
100.0% 
60/103 
58.3% 
Adherence  
76/138 
55.1% 
(46.8-63.4) 
24/62 
38.7% 
(26.5-50.9) 
41/69 
59.4% 
(47.8-70.8) 
 
0.0464 
 
0.3480 
 
0.0072 
4  
Applicability 16/154 10.4% 
0/62 
0.0% 
43/103 
41.7% 
Adherence 
9/16 
56.3% 
(32-80.6) 
nr 
13/43 
30.2% 
(16.5-43.9) 
nr 0.0785 nr 
5  
Applicability 124/154 80.5% 
47/62 
75.8% 
69/103 
67.0% 
Adherence 
73/124 
58.9% 
(50.2-67.6) 
28/47 
59.6% 
(45.5-73.7) 
41/69 
59.4% 
(47.8-70.8) 
0.99 0.99 0.99 
6  
Applicability 138/154 89.6% 
62/62 
100.0% 
55/103 
53.4% 
Adherence 
84/138 
60.8% 
(52.7-68.9) 
31/62 
50.0% 
(37.6-62.4) 
38/55 
69.1% 
(56.9-81.3) 
0.1660 0.3236 0.0404 
7  
Applicability 85/154 55.2% 
34/62 
54.8% 
51/103 
49.5% 
Adherence 
84/85 
98.8% 
(96.5-
101.1) 
34/34 
100.0% 
51/51 
100.0% 
 
0.99 0.99 0.99 
8  
Applicability 78/154 50.6% 
34/62 
54.8% 
50/103 
48.5% 
Adherence 
77/78 
98.7% 
(96.2-
101.2) 
32/34 
94.1% 
(86.2-100.2) 
50/50 
100.0% 
 
0.2182 0.99 0.1609 
9  
Applicability 54/154 35.1% 
31/62 
50% 
22/103 
21.4% 
Adherence 
11/54 
20.4% 
(9.7-31.1) 
12/31 
38.7% 
(21.6-55.8) 
9/22 
40.9% 
(20.4-61.4) 
0.0800 0.0866 1.0000 
10  
Applicability 138/154 89.6% 
62/62 
100% 
54/103 
52.4% 
Adherence 
11/54 
20.4% 
(9.7-31.1) 
12/31 
38.7% 
(21.6-55.8) 
9/22 
40.9% 
(20.4-61.4) 
0.2826 0.2494 0.0587 
11  
Applicability 16/154 10.4% 
0/62 
0.0% 
43/103 
41.7% 
Adherence 
9/16 
56.3% 
(32-80.6) 
nr 
10/43 
23.3% 
(10.7-35.9) 
 
nr 
 
0.0270 
 
nr 
12  
Applicability 94/154 61% 
31/62 
50% 
48/103 
46.6% 
Adherence 
78/94 
83.0% 
(75.4-90.6) 
13/31 
41.9% 
(24.5-59.3) 
23/48 
47.9% 
(33.8-62.0) 
 
< 0.0001 
 
< 0.0001 
 
0.6491 
13  
Applicability 94/154 61% 
51/62 
82.3% 
48/103 
46.7% 
Adherence 
81/94 
86.2% 
(79.2-93.2) 
38/51 
74.5% 
(62.5-86.5) 
31/48 
64.6% 
(51.1-78.1) 
 
0.1116 
 
0.0044 
 
0.3818 
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Table 22: Comparison between A, B and  C; Fisher’s exact test 
14  
Applicability 82/154 53.2% 
31/62 
50% 
37/103 
35.9% 
Adherence 
72/82 
87.8% 
(80.8-94.8) 
26/31 
83.9% 
(71-96.8) 
32/37 
86.5% 
(75.5-97.5) 
 
0.5508 
 
0.99 
 
0.99 
16  
Applicability 2/154 1.3% 
0/62 
0.0% 
1/103 
1.0%    
Adherence 
2/2 
100.0% 
 
nr 1/1 
100.0% 
 
nr 0.99 nr 
 
4.9 Validation of MATosteo and adaptation to local needs 
 
4.9.1 Summary Interview I  
 
Interviewee: head of an osteoporosis unit 
 
General statements 
 
Value of MATosteo 
The interviewee thought that MATosteo could be valuable but probably more for 
pharmacy because from the doctor's point of view the decision-making was 
completely different. In Glasgow there are other criteria for referring to DEXA 
scans and for risk assessment mostly FRAX is used. However there is a 
controversy going on whether FRAX leads to an over- or under-estimation of 
fracture risk or not.  
 
Possible benefits/ obstacles 
The interviewer thought that it might be difficult to perform such an audit. He 
thought that the standard used is already a bit behind, which might lower the 
adherence although people are treated correctly if newest evidence considered. 
In addition he thought that the guidelines do not really cover the needs of 
people with certain co-morbidities (like CKD), which might make things 
complicated.  
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Auditor 
The audit should definitely be performed by somebody with a medical 
background- probably a specialist nurse.  
 
Inclusion of relevant issues 
All in all the tool covers the relevant issues of osteoporosis care. Maybe a 
criterion about HRT in men could be added.  
 
Handling of results 
The interviewer was not a hundred percent sure how to handle the results of 
such an audit.  
 
Comments on criteria 
 
Criteria 1/ 2 (DEXA scans): 
Referring to DEXA is handled totally different in Glasgow. There is a service 
called DADS that suggests the use of other criteria may be necessary. What 
NICE suggests is not incorrect but probably there is need for adaptation if this 
tool is going to be used in Glasgow.  
 
Criteria 3 and 4 (Calcium and vitamin D supplementation): 
Before prescribing calcium it is important to know about the baseline calcium. 
One reason for the finding of low adherence to this criterion could be that 
usually doctors do not document in the system if they discover hyperglycaemia 
and therefore do not prescribe calcium. In most cases patients are simply non-
compliant to the supplementation of calcium and vitamin D. Nevertheless it 
should be part of the standard treatment. The criteria were thought to be straight 
forward. 
 
Criteria 6/7 (dosing of calcium and vitamin D): 
The interviewee agreed with the criteria and mentioned that there is no need of 
dose adaptation in case of very low or very high BMI. 
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Criterion 9 (contraindications to agents): 
It is possible that some patients have contraindications to all agents. Mostly they 
suffer from GI problems (malabsorption or ulcers).  
 
Criteron 10/11 (bisphosphonates as first-line therapy):  
The interviewee agreed with the content but suggested to reword as follows: “... 
prescribed an oral bisphosphonate most likely alendronic acid”. He did not think 
it would be feasible to add i.v. BPs. 
 
Criterion 13 (standard dose regimen for pharmacological treatment): 
There is no reason for prescribing alendronic acid or risedronate sodium as a 
daily dose. Ibandronic acid is not used at all in Glasgow. Preoctat should be 
added. Zoledronic acid i.v. and teriparatide are for secondary care only. Dose 
adaptation is not common practice in Glasgow. There is only one exception- 
impaired renal function. Unfortunately - there is no rule how to do that.  
 
Criterion 15 (use of BPs in patients on long-term glucocorticoids): 
The interviewee asked to reword to “... > 5 mg prednisolone ...”. 
 
To the other criteria of MATosteo no suggestions for changing or important 
comments were made in this interview. 
 
4.9.2 Summary Interview II  
 
Interviewee: specialist nurse 
 
General statements 
 
Value of MATosteo 
The interviewee thought that the tool was valuable but probably more 
community based.  
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Possible benefits/ obstacles 
The interviewee would be concerned about maybe upsetting the prescribers, 
but could not think of any other obstacles.  
 
Auditor 
In the interviewees opinion this audit could be done by anybody. 
Inclusion of relevant issues 
All in all the tool covers the relevant issues of osteoporosis care. Maybe a 
criterion measuring compliance should be added.  
Handling of results 
The interviewer was not sure how to handle the results of such an audit.  
 
Comments on criteria 
 
Criteria 1/ 2 (DEXA scans): 
The interviewee stated that she agreed with both criteria and mentioned some 
differences to the handling in Glasgow. In Glasgow people are referred either by 
GPs or by a physician working in a hospital. The service is called 'direct access 
to DEXA scan' (DADS). Patients are not targeted on the basis of risk factors- a 
DEXA scan is preferred. The nurse thought that it was possible to diagnose 
somebody over 60 with two or more vertebral fractures without a DEXA scan 
but would not do this with a postmenopausal woman over 75. 
 
Criteria 3 and 4 (Calcium and vitamin D supplementation): 
It is not necessary to prescribe calcium, if the dietary intake is very good. There 
is as well no need for prescribing vitamin D, if the levels measured are high 
enough. This is not common though.  
The interviewee did not fully agree with criterion 4. She stated that the need for 
calcium and vitamin D supplementation depends on whether the dietary intake 
is sufficient or not and on the measured T-score.  
 
Criteria 6/7 (dosing of calcium and vitamin D): 
The interviewee agreed with the criteria and mentioned that there is only a need 
for dose adaptation in case of renal impairment. This is done by renal 
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physicians and nurses do not routinely get involved with that.  
 
Criterion 12 (reasons to avoid bisphosphonates): 
The interviewee was not sure if the wording 'another fracture occurs' should be 
kept. In clinical practice the substance would not necessarily be changed if the 
patient sustained a fracture when recently started on a bisphosphonate. 
 
Criterion 14 (preferred choice of oral bisphosphonates):  
The interviewee thought that the wording was probably not totally correct. If 
somebody could not tolerate alendronic acid or risedronate sodium, then 
strontium would be the next oral option. If somebody suffers from problems with 
the GI, one might want to go straight to i.v. BPs- preferably zoledronic acid.  
 
Criterion 15 (use of BPs in patients on long-term glucocorticoids): 
In Glasgow there is another way of dealing with such patients. If they are less 
than 55 years old a DEXA scan is arranged and whether BPs are administer or 
not depends on the result. If the patients are older than 55 it works the other 
way round.  
 
To the other criteria of MATosteo no suggestions for changing or important 
comments were made in this interview. 
 
4.9.3 Summary Interview III 
 
Interviewee: specialist nurse  
 
General statements 
 
Possible benefits/ obstacles 
The interviewee thought that the tool could be beneficial for patients. She 
considered it to be feasible for the use in a professional environment. She 
underlined the importance of using an actual standard when applying such an 
audit and stated that the performance might be too time consuming for using it 
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routinely. 
 
Auditor 
The audit should not be done by doctors or pharmacists as they are far to 
expensive. Students or technicians would be a good choice.  
Inclusion of relevant issues 
All in all the tool covers the relevant issues of osteoporosis care. Maybe a 
criterion measuring compliance should be added. 
 
Handling of results 
As time is limited it was suggested to discuss only the worst cases with the 
prescribers.  
 
Suggestions 
If MATosteo is used as a clinical audit tool it is necessary to adapt it to local 
guidelines.  
 
Comments on criteria 
 
Criterion 1 (DEXA scans)  
Agrees. Also about the fact that we included age in the criterion. Issue is not too 
common. Wording is ok. DEXAs are age-dependent.  
 
Criterion 2 (DEXA scans) 
Does not fully agree. There are also other sites for performing a DEXA scan. 
Also thinks that we should include things like: 
Always use the same machine for performing the scan 
Always go to the same hospital 
Perform a scan regularly (according to local guidelines- they use the guidelines 
of Greater Glasgow and Clyde. In general she thinks that most health boards 
have their own guideline. They are more or less about the same. SIGN 
guidelines are a bit old hat.) 
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Criterion 3 (calcium and vitamin D supplementation) 
Thinks it is important to think about the fact that it might be necessary for some 
patients to measure calcium and vitamin D levels first. Thinks like vitamin D 
deficiency or sufficient intake of calcium and vitamin D would not be 
documented in the system of her hospital.  
 
Criterion 11 (treatment of osteopenia) 
Does not agree. An osteopenic patient does not necessarily need a treatment. 
Dependent on age, fractures, etc.  
 
Criterion 13 (correct dosing): 
Concerning osteopenia: see 11 
Osteoporosis: Disodium etidronate is not used at all. To complicated. Bad for 
compliance. Ibandronic acid is sometimes prescribed by general practitioners, 
but rarely considered by her ward.  
Calcitonin rarely and more additional.  
Teriparatide is very rare but effecitive.  
Dose is ok in general 
 
14 (prefered choice of BPs) 
Does not agree with the preferred choice. 
Thinks it would rather be Alendronic acid, risedronate sodium, i.v. 
bisphosphonates. Exclude etidronate 
 
15 (patients on long-term glucocorticoids) 
There are guidelines they use. It is age dependent. Would like to change 7.5mg 
to 5mg prednisolone. Thinks we should think about this criterion again.  
Inhaled steroids: grey zone. No evidence. Hard to say.  
 
To the other criteria of MATosteo no suggestions for changing or important 
comments were made in this interview. 
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4.9.4 Summary Interview IV 
 
Interviewee: specialist nurse  
 
General statements 
 
Possible benefits/ obstacles 
The interviewee thought that the tool could be beneficial it the standard used is 
not old hat and adapted to local needs. She thought it might be most useful for 
specialised clinics. 
 
Auditor 
The audit should someone with a medical background.  
 
Inclusion of relevant issues 
All in all the tool covers the relevant issues of osteoporosis care.  
 
Handling of results 
As time is limited it is not possible to discuss every case with the prescriber.  
 
Suggestions 
If MATosteo is used as a clinical audit tool it is necessary to adapt it to local 
guidelines.  
 
Criterion 1/2 (DEXA scans)  
DEXA scans are age dependent. 
 
Criterion 3/4 (calcium and vitamin D supplementation) 
Does not fully agree with that. Also not with 4. Thinks in certain cases 
measurement of calcium levels is necessary, e.g. if the patient shows signs of 
hypercalcemia. 
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Criterion 10 (oral BPs as first-line therapy):  
Does not fully agree-  i.v. BPs should be added.  
 
Criterion 11 (treatment of osteopenia) 
An osteopenic patient should be treated like an osteoporotic patient.  
 
Criterion 13 (correct dosing): 
Agrees although there are substances included that are not really used in 
Glasgow- e.g. raloxifene. 
 
15 (patients on long-term glucocorticoids) 
Change prednisolone dose to 5 mg. 
 
To the other criteria of MATosteo no suggestions for changing or important 
comments were made in this interview. 
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4.9.5 Main findings 
 
General statements 
All interviewees thought that MATosteo was valuable or beneficial for the 
patients.  
 
3/4 stated that the tool covers the most important issues of osteoporosis care. 
2/4 suggested to add a criterion measuring compliance. 1/4 asked for a criterion 
covering HRT.  
Content of MATosteo
3
2
1
0 1 2 3 4
Covers most important issues
Add criterion measuring
compliance
Add criterion covering HRT
Interviewees
 
Figure 3 Content of MATosteo 
 
2/4 stated that the standard used is old hat- although it is consistent with the 
most actual guidelines. 
3/4 thought it was necessary to adapt the tool to local guidelines if used as a 
clinical audit tool.  
Other possible problems mentioned were:  
 Upsetting the prescriber 
 Too time-consuming for implementation in daily routine 
 Guidelines do not cover needs of people with co-morbidities 
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Problems associated
0 1 2 3 4
Guidelines do not cover needs of
patients with comorbidities
Not adapted to guidelines used in
Glasgow
Standard not actual
Time-consuming
Upsetting prescriber
Interviewees
 
Figure 4: Problems that might occur when performing the audit 
 
 
3/4 thought the auditor should have a medical education. 1 stated anybody 
could perform MATosteo.   
 
Qualification of auditor
0 0,5 1 1,5 2 2,5
Medical
background
Anybody
Interviewees
 
Figure 5: Qualification of the auditor 
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2/4 interviewees were not sure how to handle the results of such an audit. 2/4 
suggested to discuss only the worst cases with the prescribers.  
 
Handling of Results 
0 0,5 1 1,5 2 2,5
Not sure how
to handle
results
Discuss only
worst cases
with prescriber
Interviewees
 
Figure 6: Handling of results 
 
4.10  Guidance for the prescriber- summary of the guidelines 
 
The following figures can be used by prescribers ‘quick guide’ for supporting 
their prescribing decision. They do not replace basic knowledge about 
substances and safe use of drug, but summarise the guidelines used for the 
development of MATosteo.  
 
4.10.1 Osteopenia 
 
 
 
 
 
 
 
 
 
                                                                              Figure: 7 Treatment of osteopenia 
OSTEOPENIA 
Alendronic acid (10mg daily or 70 mg 
weekly) 
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The treatment of osteopenia is only covered by the Summary of the 2002 
Canadian Guidelines for the Diagnosis and Management of Osteoporosis (2005 
Update).
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4.10.2 Osteoporosis primary prevention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Treatment of osteoporosis primary prevention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 PRIMARY PREVENTION 
Postmenopausal 2 
 
 
Men  
 
Glucocorticoid-
induced 
Alendronate 
 
Risedronate3 
 
 
Strontium ranelate4 
 
Alendronate  
 Alendronate 
Risedronate3 
Etidronate4 Etidronate  
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4.10.3 Osteoporosis secondary prevention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Treatment of osteoporosis secondary prevention 
 
SECONDARY PREVENTION 
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Teriparatide5 
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raloxifene4 
 
Calcitonin6 
 
 
Alendronate 
 
Risedronate3 
 
 
Teripatide5 
 
 
Calcitonin
6
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5 DISCUSSION 
 
5.1 General observations 
 
As mentioned at the beginning of this thesis osteoporosis is an age-associated 
disease and a big burden on healthcare budgets and on patient's quality of life. 
Therefore introducing an evidenced based standard for screening, diagnosis 
and therapy is enormously important. To reach this goal healthcare 
professionals should work together as a multi professional team.  
 
As there is always room for mistakes and improvement in life, each system,  
method, tool etc. should regularly be undertaken a review, control or 
assessment in order to keep standards high or to even improve them. This is 
also valid for medical processes like diagnosing or prescribing and ideally leads 
to benefits for the patient and our healthcare budgets. At University of 
Strathclyde Professor Stephen Hudson and John McAnaw had an idea of how 
pharmacists could contribute in the process of assessing quality of prescribing- 
the so called Medication Assessment Tool (MAT) was born. The method was 
adapted for many diseases- as well for osteoporosis.  
 
This thesis aimed to demonstrate the use of a Medication Assessment Tool for 
osteoporosis (MATosteo) in the evaluation of adherence to the osteoporosis 
guidelines. Scientifically, I was able to demonstrate that the tool is systematic 
and reliable, by analysing GPASS® records of 319 patients and performing an 
inter-rater test. Clinical experts on osteoporosis agreed in interviews that 
MATosteo is valid as a clinical audit tool as well.  
 
Before working on this thesis it seemed enormously important to me to be 
familiar with the current literature and guidelines about osteoporosis and with 
the Scottish healthcare system. As a foreign student I had to learn about the 
National Health Care System (NHS), local guidelines and of course- maybe the 
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most important thing- local initiatives on Osteoporosis. I also tried to get familiar 
with the work of previous researchers, which was planned to be the base for my 
future work.  
 
5.2 Reviewing MATosteo 
 
After finishing the first step of gathering as many information as possible, I was 
finally able to start of with my project. A very time consuming but necessary part 
was to review MATosteo. For this purpose the actuality of the applied standard, 
the practicability for electronic data analysis and a clear wording were taken into 
consideration. The standard applied- meaning the 19 criteria of MATosteo, each 
representing a guideline recommendation- had to be perfectly up to date. It is 
senseless to measure quality of prescribing by using an incorrect standard. It 
will draw a wrong picture and probably present things worse than they are. 
Another thing is to use the correct standard for the correct period of time. Four 
the purposes of MATosteo it does not make sense to apply the most actual 
standard for 20 year old data.  
 
The wording of MATosteo had to be clear and unequivocal. Therefore ideas 
were collected and over and over revised again by the help of my collaborator 
and my supervisors, who were native speakers. The challenge of rewording 
criteria is not to loose the original sense of a guideline recommendation and to 
keep them simple for applying electronic data analysis. Electronic data analysis 
was thought to be necessary in order to be able to produce more representative 
results for Scotland's population by scaling up number of patients included in 
the survey.  
 
5.3 Data 
 
For the purpose of this study only electronic data was used. This seemed to be 
feasible as in Scotland an IT system called 'GPASS®' is used in more than 80% 
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of general medical practices for storing all relevant information about a patient, 
like medical history and prescriptions. It was also seen as chance to get away 
from the manual performance of MATosteo and speeding up the process of 
analysing.  
 
The problem with GPASS® data is, that it is sometimes confusing, as a lot of 
information is stored as a so called 'Read Code'. Read Codes replace technical 
terms like e.g. 'osteoporosis' and are quite complicated to understand- 
especially if you never worked with them before. Sometimes different codes are 
used for the same term.  
 
After data collection it is hardly possible to clarify unclear records, which highers 
the number of IDQs and IDS in the results. Some general practitioners use 
written records in combination with GPASS®- there was no access to them.  
 
Last but not least the results of an audit like MATosteo, can only be as good as 
the documentation evaluated. This means that if the prescriber does not 
document all his interventions in the system, the tool shows a low adherence 
although in reality the patient is treated correctly. Therefore, I would like to 
suggest to conduct this audit directly in the practice in the future. This offers the 
possibility to talk to the prescriber if lack of clarity appears and maybe improves 
access to data.  
 
5.3.1 Collection  
 
For the purpose of this study three electronic patient samples were drawn from 
the GPASS® system in three general medical practices in Glasgow. Two of 
them were put on my disposal by a previous researcher. The third one was 
collected with the support of Mr Ian Towle. In order to collect all information 
needed MATosteo was used as an aid to orientation for running queries in the 
system. To copy the full patient records would of course be more complete but 
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as well cost to much EDV storage space. Collecting the data of one GP the way 
we did takes about a working day, but runs the risk of missing data after 
 collection. To avoid this it would be good to carefully design a data collection 
form- because of a lack of time I was not able to do that. The form should 
contain a check-list of data needed for the audit and if possible a field to write 
down the most important details about the sample, like GP and collection date, 
number of patients. For the process of data collection it is necessary to be 
familiar with the software that is worked with. 
 
5.3.2 Creation of a database protocol 
 
The creation of a database protocol is the prerequisite to getting reliable results 
no matter who conducts the audit. The purpose of such a protocol is to guide 
the researcher threw the process of analysing. Therefore it has to be written in a 
way that lets no doubts how to process.  
 
In collaboration with my collaborator and our supervisors I tried to design the 
database protocol logical and clear. The protocol consists of 19 little guides- one 
for each criterion. On the top of those the criterion is placed in a little grey box. 
This helps knowing what is actually worked on and separating the 'headline' 
from the technical part of the guide. A full version of the database protocol can 
be found in the appendix. It is only of use in combination with the query builder.  
 
5.4 Analysis 
 
For data analysis several methods were tested. They are discussed below. 
 
5.4.1 Manually 
 
The manual way of analysing is time-consuming but very exact. It is perfect for 
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
109 
 
proving the correctness of other methods of auditing, for small patient samples 
or for screening the prescriptions of a single patient. Maybe it could be chosen 
for a public pharmacy service. The manual way of analysing is not the most 
economic one when it comes to audits on bigger patient samples, as it takes far 
to long. For scientific purposes or for a general prescribing audit, I would 
suggest to use at least Microsoft Access® in terms of building queries manually.  
5.4.2 Microsoft Access®- classical query building 
 
This way of data analysis presupposes basic knowledge about Microsoft 
Access®. It is for sure much quicker than the manual method, but not perfectly 
reliable. Little variations in creating a query- even in spelling single words- can 
make big differences in the results received. Therefore I would like to suggest to 
use the Microsoft Access® form 'Query builder'. It is discussed in the following 
section and the method that was finally used in this project for final data 
analysis.  
5.4.3 Query builder 
 
The 'Query builder' is a Microsoft Access® form developed by Tobias 
Dreischulte and collaborators. It can be used for the purposes of any MAT if 
correctly adapted, but it takes some time to get familiar with storing data for final 
analysis. To make this process easier for future researchers I wrote a guide that 
can be found in the appendix.  
 
Storing data, however is tricky and takes a bit of time. If it is not done correctly 
the form will constantly give you an error or you will reproduce the same 
mistake over and over again- most likely even without taking notice of that. It is 
recommendable to take some time to organise and store the data. Once this is 
done a quick method of analysing data is available.  
 
In combination with the database protocol I was able to prove that the audit is 
reliable. My personal experience is that it is possible to finish the process of 
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
110 
 
analysing within one third of the time compared to the methods prescribed 
above.  
The design of the tool also allows to ask your database a lot of additional 
questions in a very easy and understandable way. I used this function for 
rechecking the demographics of my survey.  
 
5.5 Results 
 
Results of the retrospective survey were expressed as the percentage of 
adherence to osteoporosis guidelines. They were ranked as low (<50%), 
intermediate (50.0-69.95%) or high (>70%). Before interpreting the results it 
might be useful to be aware of some general facts about guidelines.  
 
The use of guidelines for medical purposes is still discussed controversially. 
Mostly they are seen as a tool for providing consistent and efficient care and for 
closing the gap between science and clinical practice. Potential benefits of 
clinical guidelines are:  
 
 to improve patient's quality of life 
 to reduce morbidity and mortality 
 to educate patients about their diseases and therapies 
 calling attention to mostly unrecognised diseases, services, etc.  
 to free resources by providing efficient and economic care 
 to support healthcare providers in making clinical decisions 
 to highlight gaps in evidence 
 to raise new research questions 
 to safe money by providing health care in a sufficient and economic way 
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Nevertheless the value of guidelines is limited- they can even be harmful under 
certain circumstances. The probably most important limitation of clinical 
guidelines is that the standard recommended might be wrong or correct for 
most of the patients but harmful for individuals. Recommendations are often 
based on lacking evidence or influenced by personal opinions of experts.  
Additionally the motivation for giving a recommendation is not always 
necessarily providing best care for the individual patient- aims like cost 
reduction might turn the balance. A potential harm of guidelines is that they 
don't leave enough room to adapt care to patient's needs and circumstances. 
Guidelines providing a bad standard can lead to harmful practices and 
inefficient car and raise the deficit of health care budgets (BMJ Article, Use of 
guidelines).  
 
Adherence to guidelines can be seen as a marker for quality of prescribing. One 
should keep in mind that percentage of adherence is only meaningful if enough 
people are applicable to the criterion analysed. For instance, 100% adherence 
to a certain criterion is not representative if only 3/ 319 patients were applicable. 
For 3/19 criteria no results could be presented- nobody was applicable. This 
shows impressively that at least general practitioners in Glasgow apparently do 
not prescribe the treatment alternatives raloxifene, teriparatide and calcitonin.  
MATosteo can help to identify weak points in prescribing and to target high risk 
patient groups or patients who need special or individualised treatment.  
 
5.5.1 Demographics 
 
Demographics do not show any unexpected things to someone who is familiar 
with osteoporosis. The age range is very broad (24-96 years), but a mean age 
of 74.0 years (osteoporotic patients) and 66.8 years (osteopenic patients) 
makes clear that only a few very young patients already suffer from 
osteoporosis or osteopenia. 
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Osteopenia can be seen as the preliminary stage of osteoporosis- in this patient 
sample as well osteopenic patients are younger than osteoporotic ones on 
average.  
BMI was not recorded for all patients. Therefore, it is not possible to discuss 
BMI properly. Most of the patients, who had a BMI recorded, tended to have a 
slightly raised BMI or were obese. Only a few patients (6/49) were registered 
with very low BMI of <22. If this facts are representative for the whole patient 
sample or not, can not be stated.  
 
5.5.2 Weak points of osteoporosis care in Glasgow 
 
Criterions for DEXA scan show a low adherence. Surprisingly less than 50% of 
the patients diagnosed with osteoporosis have a recorded DEXA scan. I can 
think of two possible reasons for that: 
 
 not all DEXA scan are recorded in GPASS 
 different guidelines for referring to DEXA scans are used in Glasgow 
 
DEXA scan records also showed, that the scans are seldom performed 
according to guidelines. In only 25.5% they were performed at two specific 
sites. I was not able to find out the reason for that. 
 
Strikingly, osteopenic patients are hardly ever treated according to guidelines. 
During performing the interviews with experts on osteoporosis I got the feeling 
that this might have something to do with a lack of evidence and acceptance of 
the treatment guidelines for this patient group.  
 
Although the basic therapy of osteoporosis is calcium and vitamin D 
supplementation, only 53.1% of patients received those supplements. There 
were no possible justifications documented in the electronic system. 
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Interviewees conjectured the reason for this lack in treatment might be non- 
compliance, as patients have to take care of their refillings on their own.  
 
Only 60% of patients diagnosed with osteoporosis received an antiresorptive or 
an osteoanabolic agent. A possible reason for that might be that a lot of the 
untreated patients were patients with additional diseases and that it was hard to 
tailor the treatment standard to their circumstances. I got the impression that a 
lot of these patients suffered from renal impairment and that it might be useful to 
develop pharmaceutical care initiatives in order to support the prescribers in 
their treatment decision. As this is just a personal impression this question 
should be subject of further research.  
 
Only 65.9% of patients who received an antiresorptive or an osteoanabolic 
agent had no contraindication on record. Against the background that only 3/ 
319 patients received an alternative to bisphosphonates (strontium ranelate) 
this seems to be avoidable by bringing treatment options home to prescribers.  
 
5.5.3 Strengths of osteoporosis care in Glasgow 
 
All criteria dealing with dose regimens reached high level of adherence. For the 
masses of patients this is something very positive and helps in avoiding side 
effects. Nevertheless this is a good example for a field where the non-critical 
use of guidelines can lead to potential harm for patients. Firstly I was impressed 
by the high standard of dosing in Glasgow but after having a closer look on the 
results I recognised that the standard regimen is as well used for patients were 
dose adaptation is needed. Especially people with renal impairment and very 
low BMI should benefit from lowering doses. Because of basic pharmacokinetic 
principles one should also think of administering higher doses in patients, who 
are obese as long as their kidney and liver function is normal.  
 
Bisphosphonates are used as first-line therapy and mostly Alendronate is 
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prescribed. Only in two cases Risedronate is used. This goes along with current 
evidence and economic principles.  
5.5.4 Handling of results 
 
MATosteo can be used as a research tool or as a clinical audit tool. Depending 
on the purpose of the audit different handling of results will become necessary.  
 
Using MATosteo as a research tool only will probably make things easier after 
receiving the results. After making anonymous original data, general statements 
about patient groups or the whole patient sample can be made and used as a 
starting-point for the development of pharmaceutical care initiatives. There will 
be no direct or intermediate benefit for the patients included in the study but 
probably long-term benefits for future patients. 
 
Using MATosteo as a clinical research tool might become challenging  when it 
comes to presenting negative results to the prescriber. Nevertheless it offers the 
possibility to directly influence osteoporosis care of certain patients in certain 
practices. 
 
In my opinion prerequisite to the performance of a clinical audit is an accurate 
enlightenment of the prescriber. The best thing would be to decide together 
what exactly the audit aims for and how possible results of low or intermediate 
adherence will be handled. The prescriber should be asked how much time 
he/she can spend for this audit and if he/ she would prefer an informative 
discussion or a written presentation of the results. It should be clear that the aim 
of performing MATosteo is not to harm the prescriber and offers the chance to 
turn already good clinical practice into best clinical practice.  
 
I would like to suggest to train the communicational skills of the auditor before 
having the first talks with the prescribers.  
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5.6 Interviews 
 
Experts on osteoporosis were interviewed in order to evaluate MATosteo as a 
clinical audit tool. Unfortunately, it was not possible to perform more than four 
interviews within the remaining time, but nevertheless I was able to identify 
several points in which all interviewees agreed on as regards content.  
 
All participants worked within Greater Glasgow and Clyde and were specialised 
on osteoporosis care. General practitioners were excluded from the interviews 
as one of the aims of the interviews was to evaluate content and wording of the 
criteria of MATosteo and the research group decided that this should be done by 
experts.  
 
The most frequent reason given for denying the participation in the interviews 
was a lack of time. Some of the candidates invited who worked outside Greater 
Glasgow and Clyde asked to invite Glasgow' experts in order to save time for 
writing up my project.  
 
Interviews were carefully planned. The semi-structured technique was chosen, 
as it seems to potentially be the most beneficial one. It offers the possibility to 
immediately clarify unclear statements, but prevents the interviewer from losing 
the thread.  
 
Interviews were audio recorded with the permission of the interviewees and 
transcribed later on. This was important for me and made it easier to 
concentrate on the interview itself instead of writing down the comments. 
Furthermore, it helped me to remember exactly what was said during the 
interviews and to avoid mistakes in reproducing the content. Additionally, audio 
recording helps to make the situation more comfortable for all participants as 
the interviewer is able to face the interviewee while talking and to pay full 
attention to the opposite.  
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To make it easier to find out agreement of all interviews were summarised. Main 
outcomes were listed in a box and discussed within the research group.  
 
The interviewees thought that the wording and the content of the criteria were 
good, with the exception of the criteria for DEXA scans. All stated that within 
Glasgow other guidelines were used for referring. A copy of those can be found 
in the appendix. The decision if MATosteo will be adapted to those if used for 
further audits in Glasgow was not yet made, when I finished this thesis. One 
must take into consideration the fact that the local guidelines contradict the 
national ones in this point. Based on the assumption that the guidelines 
MATosteo is derived from are evidence based and actual, the sense of an 
adaptation to local needs in this case is questionable. On the other hand both 
DEXA scan criteria showed a low guideline adherence and therefore also 
reduce  the overall adherence to guidelines.  
 
5.7 Strengths of the project 
 
 MATosteo was updated according to the newest national osteoporosis 
guidelines. Therefore, the standard used for analysis can be seen as 
appropriate.  
 3/ 4 experts on osteoporosis totally agreed with the statement above. 1 
thought that most of the criteria were acceptable.  
 MATosteo covers both  diagnosis and therapy.  
 Embedding of MATosteo in a model of care developed by Anton Luf 
(unpublished work) offers the possibility of covering the field of risk 
assessment as well.  
 The wording of MATosteo's criteria was simplified for the purpose of data 
analysing, but kept the original sense of the guidelines. All experts 
agreed with the wording. 
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 Number of patients included was scaled up from previous work. The 
method chosen for electronic data analysis was shown to be reliable by 
an inter-rater test.  
 The study was thought to be of interest for the presentation at the ESCP 
conference in Geneva in 2010.  
5.8 Limitations of the project 
 
 Access to data was limited. Therefore more IDS or IDQ than necessary 
appeared. This might also have minor influence on the percentage of 
adherence resulting calculations.  
 Storing the data in the Microsoft Access® form 'Query builder' is time 
consuming and as well complicated for someone who is not yet familiar 
with the tool. Additionally, mistakes that happen during this process, are 
at high risk of remaining undiscovered and being reproduced over and 
over again.  
 The number of interviews conducted was too few. 
 The tool does not measure compliance or cover pain management of 
acute fractures.  
 A standard for handling results of such an audit is not yet developed.  
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6 PROPOSALS FOR THE FUTURE 
 
The method of analysing electronic data is systematic and reliable but not yet 
perfect enough. Storing data in the tool is still too time consuming. The process 
of analysing itself is valid. I would like to suggest to start a project in 
collaboration with the IT department to further improve this method of using a 
Microsoft Access® form for applying MATs. Another, maybe even better, 
possibility would be to try to get the permission to work directly in the GP in 
GPASS®. This could kill two birds with one stone, as it has also the potential to 
improve access to data.        
 
The number of patients included in the MATosteo audit should further be 
enlarged. The aim is to get representative results for Glasgow or even the whole 
of Scotland that can be presented to the NHS. It would be possible to 
impressively show weak points of osteoporosis care. In combination with a 
study showing the impact they have on healthcare budgets and patient's quality 
of life, it would be hard for politicians to refuse to free research money. 
 
Enlarging the patient sample would also enable researchers to conduct 
subgroup analyses in order to identify patient groups, which are at high risk of 
not being treated according to the guidelines. As well it would be possible to 
verify some hypothesises that appeared while performing this study. The most 
interesting patient group in this context is the 'renal impairment' one. I had the 
impression that patients suffering from renal diseases are at high risk of not 
being treated against osteoporosis at all or of not being treated the best way.  
 
Once patient groups with special needs or circumstances are identified it is time 
for the development of pharmaceutical care initiatives. Pharmacist can 
contribute in making prescriptions safer for those patients and support 
prescribers in their clinical decisions this way.  
 
I also think it is necessary to develop a standard for handling the results of 
clinical audits. The ethical responsibility is high. Ignoring negative outcomes of 
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such a study is no option, as they are, dramatically spoken, the connecting 
factor for reducing harm to patients and for reducing costs in the healthcare 
system. A good standard for handling the results of such an audit can also help 
to keep the good relationship between auditor and prescriber and to keep the 
possibility for further productive teamwork.  
 
Last but not least it would be good to implement such audits in real working life 
of healthcare providers. This process might be the trickiest one, as it is always 
hard to get acceptance for new things- especially if they somehow evaluate the 
quality of people's work, like MATosteo does in the end. I think this process is a 
whole project itself and probably the researcher will need the help of the 
psychology department for the development of a suitable strategy.  
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7  CONCLUSION 
 
Prerequisites to the performance of a systematic and reliable audit using 
MATosteo are full data access and sufficient medical and pharmaceutical 
knowledge of the auditor. Full data access is equal for the correct interpretation 
of treatment documentation and consequently for the correct calculation of the 
percentage of guideline adherence. For the decision whether the criteria of a 
guideline recommendation are fulfilled or not, medical and pharmaceutical 
knowledge is necessary- someone without an appropriate education won't even 
be able to understand most of the terms documented.  
 
For the analysis of larger patient samples, basic knowledge about software 
programs like Microsoft Access® and GPASS® is equally valuable. 
  
The Microsoft Access® form 'Query builder' is a promising method for analysing 
GPASS® data, that is already able to produce quickly reliable results, but still 
needs further development now and there. Especially the process of storing 
data is open to improvement.  
 
MATosteo can only produce reliable results, if the single parts of the audit are 
perfectly linked and co-ordinated. The data collected has to be total and 
accurate - free of input error - a feasible standard for this process can help to 
fulfil this criterion. The audit itself should be performed according to an explicitly 
defined procedure - a database protocol, which should be designed in a clear 
and understandable way. Different and independent raters will be able to 
produce correct results under this circumstances. Last but not least the auditors 
themselves have to be appropriately qualified for the work as discussed above. 
 
The results can only be as reliable as the doctor documents and the standard 
used for analysis. An old or bad standard will give a distorted impression about 
quality of prescribing as well as a poor performance of MATosteo.  
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Nevertheless the results of MATosteo can disclose lacks in osteoporosis care- 
depending on the patient sample- for single patients, GPs or even areas. The 
results are a first stage in addressing pharmaceutical care issues. How exactly 
the results of medication assessment should be handled should be topic of 
further research. The vision however is, to discuss results of low or intermediate 
adherence with the prescriber and then to develop methods to improve the 
integration of an evidence based standard in osteoporosis care. Pharmacists 
and prescribers should be in the same boat.   
 
Interviewing experts suggested that MATosteo is valuable as a clincial research 
tool.  
 
Mainly, the experts were of the opinion that the content of the criteria and the 
wording were good. Some suggestions were made for measuring additional 
parts of osteoporosis care. All in all they thought the tool was beneficial for the 
patients. The number of interviews conducted though was little. Therefore 
conducting further interviews might change this impression gained.
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9.1 Appendix 1  
Project Protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Pharmaceutical Care Model on Osteoporosis: 
Targeting Patient Groups 
 
Project Protocol  
 
 
Investigator Karin Doblhammer 
Supervisor Prof Steven Hudson  
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Proposed duration of the project  
The project should be completed within 6 months 
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1.  Introduction  
 
“Osteoporosis is a systemic skeletal disorder characterized by a low BMD and 
microarchitectural deterioration of bone tissue, leading to enhance bone fragility and a 
consequent increase of fracture risk.” (Brown J.P and Fortier M., 2006) 
 
As its prevalence increases with age and as it is particularly common in 
postmenopausal patients one could think, it is a disease of elderly women(Scottish 
Intercollegiate Guideline Network 2003).  Nevertheless, there are several secondary 
causes of osteoporosis and clinicians should be aware of the fact that it can also occur 
in younger people and men (National Osteoporosis Foundation, 2008).  
 
In the European Union, someone suffers an osteoporotic fracture every 30 
seconds(International Osteoporosis Foundation 2008). In Scotland around 240 000 
people are affected by the disease(Scottish Intercollegiate Guideline Network 2003).  
Osteoporosis-related fractures are a big burden on both healthcare-budgets and 
patients (International Osteoporosis Foundation 2008; National Osteoporosis 
Foundation, 2008).  These statistics and the fact that population ages show clearly, why 
osteoporosis should be declared a national healthcare priority (International 
Osteoporosis Foundation, 2008; National Osteoporosis Foundation, 2008).  
 
Healthcare professionals should work together in a multidisciplinary team and develop 
strategies in order to stop the progression of osteoporosis before fractures occur and 
provide optimised treatment and support to each individual. In the European Union, 
more than 36 billion euros are spent annually for the treatment of osteoporotic 
fractures(International Osteoporosis Foundation 2008). In the United Kingdom 
osteoporotic fractures cost the government and the NHS around 1.7 billion £ every 
year(Scottish Intercollegiate Guideline, Network 2003). Therefore, improving risk 
assessment strategies and quality of individual treatment and support would as well be 
a big benefit for the society as a hole in terms of saving thousands of pounds for 
treatment and social care (International Osteoporosis Foundation 2008). 
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2.  Research questions, Aims and Objectives 
 
Research questions 
 Can a medication assessment tool for osteoporosis (MATOsteo) reliably be 
administered to computerised medical records? 
 Is the MATOsteo a sensitive tool for comparing prescribing practices in 
different clinical settings? 
 Is the MATOsteo a clinically valid tool and what are its limitations? 
 
Aims 
To demonstrate the use of a medical assessment tool for osteoporosis 
(MATOsteo) in the evaluation of the level of adherence to osteoporosis guidelines. 
To demonstrate the inter-rater reliability of such a tool.  
 
Objectives: 
 To undertake a literature review of the management of osteoporosis and 
the role of specialists in the use of treatment alternatives 
 To revise a MATOsteo (originally designed by previous researchers)  and 
redesign database protocols. Test the protocols on a GPASS® database 
and evaluate  inter-rater reliability. 
 Test the sensitivity of the MATOsteo in a comparison of patient samples 
drawn from two clinical settings and further revise the tool as necessary. 
 Test on a larger scale audit the revised MATOsteo.  Take one patient 
sample and compare with the results of another researcher. 
 Validate a revised MATOsteo and critically review its potential value as a 
clinical and research tool. 
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3.  Study design, Subjects and Settings 
 
Study design 
Retrospective survey including the application of a tool designed for medication 
assessment in the field of osteoporosis 
 
Subjects 
 1 Patients from two practices in Clydebank and Paisley previously used in an 
earlier project to design the MATOsteo 
 2 Patients recruited from a third practice to be compared with those from a 
fourth  
 3 Interviewees (4-6) representing osteoporosis specialists in secondary care 
 
The inclusion criteria for patients for whom specific guideline criteria are 
applicable are: 
 Patients alive who are registered with the GP practice on date 
 Patients who are diagnosed with osteoporosis or osteopenia 
 
Settings 
 GP practices offering permission for the audit. The patients should be 
situated in general medical practice within Community Health 
Partnerships in Renfrewshire and/or Greater Glasgow. 
 Interviewees who have been nominated to participate and accepted the 
invitation. 
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4.  Methods 
 
To undertake a literature review of the management of osteoporosis and the 
role of specialists in the use of treatment alternatives 
 
For the purpose of this project background information will be gathered by using 
PubMed®, Medlineplus® and ClincialTrials.gov®. The number of articles 
presented will be narrowed down by using a combination of certain keywords. 
Useful articles will be identified by reading abstracts. MATOsteo, which will be 
tested concerning reliability, is based on SIGN and NICE guidelines and on the 
British National Formulary. 
 
To revise a MATOsteo (originally designed by previous researchers)  and redesign 
database protocols. Test the protocols on a GPASS® database and evaluate  
inter-rater reliability. 
 
A Microsoft Access® form, the ‘query maker’, will be applied to analyse 
electronic data.  Therefore, it will be necessary to decide which data to include 
and which not, which will be done by discussing within a research group. For 
each criterion of the MAT a strategy of analysing will be developed by 
manipulating the tool. Each strategy will be validated by analyzing the dataset 
manually. The database protocol will be  redesigned in Microsoft Word® in order 
to be understandably for everybody with basic knowledge of Microsoft Excel® 
and Microsoft Access®. It should lead through the analyzing process in a clear 
way.  Once the database protocol is finished it will be shown to supervisors and 
other students to validate it. The inter-rater reliability will be tested by calculating 
the percentage of discrepancy and the percentage of agreement.  
 
Test the sensitivity of the MATOsteo in a comparison of patient samples drawn 
from two clinical settings and further revise the tool as necessary 
 
Results will be interpreted, discussed and used to revise the MATOsteo . 
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Test on a larger scale audit the revised MATOsteo.  Take one patient sample and 
compare with results of another researcher.. 
 
The revised MATOsteo will be applied on another patient sample drawn from the 
GPASS® system. The results will be compared with the results of another 
student’s data analysis.   
 
Validate a revised MATOsteo and critically review its potential value as a clinical 
and research tool. 
 
Interviewees will be given a short overview about the project and asked if they 
give their permission to be recorded. The semi-structured interview technique 
was chosen in order to validate the MAT criterion by criterion. The interview will 
be started and ended by using open-ended questions. Closed-ended questions 
will be used to clarify the statements. In the main part of the interview, specific 
questions for each criterion will be asked. Once the MAT is modified it will be 
sent back to all interviewees and they will be asked for written comments.  
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9.2 Appendix 2 
MATosteoLuf 
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Medication Assessment Tool for use in osteoporosis/osteopenia (MATOsteo) – 
Draft 1 
 
 
 
Patient Code:                                                                                    
 
Date and setting:  
 
 
Key for the six answer categories: 
 
NA Not applicable 
Yes Standard is adhered to in eligible patients 
No(J) No, but justified 
No(U) No, unjustified 
IDQ Insufficient data to address the qualifying 
statement 
IDS Insufficient data to address the standard 
statement 
 
 
Definitions: 
Osteoporosis … is defined as a value of bone mineral density at least 2.5 standard 
deviations below the young adult mean (T-score < - 2.5). 
 
Osteopenia … is defined as a value of bone mineral density between 1 and 2.5 standard 
deviations below the young adult mean (T-score < - 1 and > - 2.5).  
 
DEXA scan Dual-energy X-ray absorptiometry is a method to assess the bone mineral 
density. The result is expressed in relation to the young adult mean (T-score) in 
standard deviation units.  
 
BMD Bone mineral density (g/cm2) = Bone mineral content (g/cm) / width at the 
scanned line (W)  
 
References:  
 1 Scottish Intercollegiate Guidelines Network (SIGN). Management of Osteoporosis 71 (April 2004 Update) 
 
 2 National Institute for Clinical Excellence (NICE). Alendronate, etidronate, risedronate, raloxifene, strontium ranelate for 
the primary prevention of osteoporotic fragility fractures in postmenopausal women Technology Appraisal TA160, 
October 2008 
 
 3 National Institute for Clinical Excellence (NICE). Alendronate, etidronate, risedronate, raloxifene, strontium ranelate 
and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Technology 
Appraisal TA161, October 2008 
 
 4 Summary of the 2002 Canadian Guidelines for the Diagnosis and Management of Osteoporosis (2005 Update) 
 
 5 British National Formulary (BNF) 56, September 2008 
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 NA  Yes No (J) No 
(U) 
IDQ IDs Ref 
 
 
Diagnosis of osteoporosis/osteopenia  
 
 1 A patient with a diagnosis of 
osteoporosis  
has a recorded DEXA Scan to confirm 
osteoporosis 
 
[Justification for not being assessed by DEXA 
scan to confirm osteoporosis 
Patient > 60 years and > 2 vertebral fractures imply a 
diagnosis of osteoporosis or  
a postmenopausal woman ≥ 75 years and two or 
more independent clinical risk factors for fracture or 
indicators of low BMD]  
 

           1,2,3 
 
 2 Measurement of the BMD by DEXA 
scan  
is performed at least at the two specific 
sites – namely, anteroposterior spine and 
hip. 
 
           1 
 
 
 Calcium and vitamin D supplementation  
 
 3 A patient with a recorded diagnosis of 
osteoporosis 
is prescribed supplementary calcium (  
vitamin D).  
 
[Justification for non-prescribing calcium and vitamin 
D: There is a record that the patient has an adequate 
dietary intake of calcium and no vitamin D deficiency.] 
 
           1 
 
 4 A patient with a recorded diagnosis of 
osteoPENIA  
is prescribed supplementary calcium (  
vitamin D) for the prevention of 
osteoporosis.  
 
[Justification for non-prescribing calcium and vitamin 
D: There is a record that the patient has an adequate 
dietary intake of calcium and no vitamin D deficiency.] 
          4 
 
Independent clinical 
risk factors  
Indicators for low 
BMD 
 low body mass 
index defined as 
less than 22 
kg/m² 
 parental history of 
hip fracture, 
 ankylosing 
spondylitis 
 alcohol intake of 4 
or more units/d 
 Crohn’s disease  rheumatoid 
arthritis  
 conditions that 
result in 
prolonged 
immobility 
 
 untreated 
premature 
 
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
139 
 
  
 NA  Yes No (J) No 
(U) 
IDQ IDs Ref 
 
 5 A patient with confirmed vitamin D 
deficiency or aged > 65  
is prescribed vitamin D.  
 
           1 
 
 6 A patient with osteoporosis and NOT 
prescribed  any of the following: 
bisphosphonates, raloxifene, strontium 
ranelate,  calcitonin or teriparatide 
has a recorded contra-indication to each 
agent (see below) 
[Contraindications to bisphosphonates are: 
 oesophageal strictures or achalasia 
 inability to remain upright for > 30 min 
after ingestion  
 hypocalcaemia 
 osteomalacia (etidronate)  
 moderate renal impairment (CrCl <  35 
mL/min)  
 pregnancy and breast feeding]  
 Contraindications to raloxifene are: 
 past/present venous thromboembolic 
events 
 hepatic impairment 
 cholestasis  
 severe renal impairment (CrCl < 10 
mL/min)  
 endometrial cancer 
 uterine bleeding 
 pregnancy and breast feeding 
 Contraindications to strontium ranelate are: 
 pregnancy and breast feeding 
 hypersensitivity 
 Contraindications to calcitonin are: 
 hypocalcaemia 
 hypersensitivity 
[Contraindications to teriparatide are: 
 pre-existing hypercalcaemia 
 skeletal malignancies or bone 
metastases 
 metabolic bone diseases 
 including Paget’s disease and 
hyperparathyroidism 
 unexplained raised alkaline phosphatase 
 previous radiation therapy to the 
skeleton] 
 
           1,2,5 
 
 7 A patient prescribed supplementary 
calcium  
is prescribed a daily dose of 500 – 1500 
mg calcium.  
 
 
           1,4 
 
 8 A patient prescribed vitamin D  
is prescribed a daily dose of 10 – 20 µg 
(400 - 800 IU) vitamin D.  
 
           1 
 
 9 A patient with osteoporosis and NOT 
prescribed  any of the following: 
bisphosphonates, raloxifene, strontium 
ranelate or calcitonin  
           1 
 
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
140 
 
is prescribed ≥1000mg calcium plus 800 
IU vitamin D per day 
 
  
 NA  Yes No (J) No 
(U) 
IDQ IDs Ref 
 
 10 A patient with a recorded diagnosis of 
osteoporosis 
is prescribed an oral bisphosphonate as 
first-line therapy. 
 
Recorded reasons for non-conformance 
(justification): 
__________________________________________ 
 
           1,4 
 
 11 A patient with a recorded diagnosis of 
osteoPENIA  
is prescribed an oral bisphosphonate as 
first-line therapy.  
 
Recorded reasons for non-conformance 
(justification): 
__________________________________________ 
 
           4 
 
 12 A patient who is prescribed a 
bisphosphonate 
has no reason on record  to avoid 
bisphosphonates.  
 
 Reasons to avoid bisphosphonates are: 
 contraindication to bisphosphonates  
o oesophageal strictures or 
achalasia 
o inability to remain upright for > 
30 min after ingestion 
o hypocalcaemia 
o osteomalacia (etidronate)  
o moderate renal impairment (CrCl 
<  35 mL/min)  
o pregnancy and breast feeding 
 
 inability to comply with the instructions for 
use of bisphosphonates  
o ingestion on an empty stomach 
o washing the medication down 
with 250 ml water 
o avoidance of food for 30 min 
o avoidance of lying flat within 30 
min of ingestion 
 
 unsatisfactory response to 
bisphosphonates  
o another fracture occurs  
o decrease in BMD despite 
adherence to treatment 
 
 intolerance to bisphosphonates 
o oesophageal ulceration 
o erosion or stricture 
o severe lower GI symptoms] 
 
 
 
 
 
 
           1,2,5 
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 NA  Yes No (J) No 
(U) 
IDQ IDs Ref 
 
13 A patient receiving treatment for 
osteoporosis/osteopenia 
is prescribed a standard dose regimen.    
              

           1,5 
 
14 A postmenopausal woman when 
started on bisphosphonate therapy  
was initiated on alendronate. 
 
           2,3 
 
 15 A postmenopausal woman diagnosed with 
osteoporosis/osteopenia and not treated with alendronate 
is prescribed risedronate.  
           1 
 
  
 NA  Yes No (J) No 
(U) 
IDQ IDs Ref 
 
16 A postmenopausal woman with > 2 
vertebral fractures and NOT treated 
with alendronate or risedronate 
           1 
 
 Prevention 
(in 
osteopenia) 
 Treatment 
(of 
osteoporosis
) 
Postmenopausal Osteoporosis 
 Alendronic acid 
  5 mg daily PO   10 mg daily or 70 mg  
once weekly PO 
 Disodium etidronate 
  400 mg for 14 days 
PO; 1,25 g calcium 
carbonate for 76 days 
PO 
  400 mg for 14 days 
PO, 1,25 g calcium 
carbonate for 76 days PO 
 Ibandronic acid (not in guidelines)  
   150 mg once a month 
PO  
or 3 mg every 3 months 
IV  
 Risedronate sodium  
  5 mg daily PO   5 mg daily PO  
or 35 mg weekly PO  
 Calcitonin  
   200 units daily 
intranasally 
 
 Raloxifene  
  60 mg daily PO   60 mg daily PO 
 Strontium ranelate 
   2 g daily PO 
 Teriparatide 
   20 micrograms daily, 
for a maximum duration 
of treatment of 18 months 
 
Osteoporosis in men 
 Alendronic acid 
   10 mg daily PO 
Glucocorticoid-induced Osteoporosis 
 Alendronic acid  
  5 mg daily PO    5 mg daily PO  
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is prescribed intermittent cyclical 
etidronate1.  
17 A patient who is on long-term 
glucocorticoid therapy 
(> 7.5 mg prednisolone or equivalents 
for > 3 months) 
is prescribed a bisphosphonate.  
 
 
           1 
 
18 A postmenopausal woman with a 
diagnosis of osteoporosis, who has 
an identifiable reason for not being 
prescribed a bisphosphonate 
is prescribed strontium ranelate. 
 
[Reasons for non-use of bisphosphonates are 
Contraindications to bisphosphonates 
 contraindication to bisphosphonates (see 
12) 
 inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
 intolerance to bisphosphonates (see12)] 
 
           2 
 
19 A postmenopausal woman diagnosed 
with osteoporosis with at least one 
osteoporotic fracture who has an 
identifiable reason for not being 
prescribed a bisphosphonate  
is prescribed strontium ranelate or 
raloxifene. 
 
[Reasons for non-use of bisphosphonates are 
Contraindications to bisphosphonates 
 contraindication to bisphosphonates (see 
12) 
 inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
 intolerance to bisphosphonates (see 12)] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           3 
 
20 A postmenopausal woman diagnosed 
with osteoporosis and at least one 
osteoporotic fracture 
who has either 
 
 a reason to avoid 
            3 
 
                                               
1  standard dose regimen see criterion 13 
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bisphosphonates (See 12) 
 an intolerance to strontium 
ranelate 
o persistent nausea 
o persistent diarrhoea 
and who is either 
 aged ≥ 65 years with a T-Score 
≤ -4 SD 
 aged ≥ 65 years with a T-Score 
≤ -3.5 SD and 
has more than two fractures 
 aged 55-64 years with a T-
Score ≤ -4 and has 
more than two fractures 
is prescribed teriparatide. 
 
 
21 
 
A postmenopausal woman diagnosed with 
osteoporosis with at least one vertebral 
fracture and NOT treated with a 
bisphosphonate, raloxifene or strontium 
ranelate  
is prescribed calcitonin.  
 
 
            1 
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9.3 Appendix 3 
MATosteo[19] 
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Medication Assessment Tool for use in osteoporosis/osteopenia (MATOsteo) – 
Draft 1 
 
 
 
Patient Code:                                                                                    
 
Date and setting:  
 
 
Key for the six answer categories: 
 
NA Not applicable 
Yes Standard is adhered to in eligible patients 
No(J) No, but justified 
No(U) No, unjustified 
IDQ Insufficient data to address the qualifying 
statement 
IDS Insufficient data to address the standard 
statement 
 
 
Definitions: 
Osteoporosis … is defined as a value of bone mineral density at least 2.5 standard 
deviations below the young adult mean (T-score < - 2.5). 
 
Osteopenia … is defined as a value of bone mineral density between 1 and 2.5 standard 
deviations below the young adult mean (T-score < - 1 and > - 2.5).  
 
DEXA scan Dual-energy X-ray absorptiometry is a method to assess the bone mineral 
density. The result is expressed in relation to the young adult mean (T-score) in 
standard deviation units.  
 
BMD Bone mineral density (g/cm2) = Bone mineral content (g/cm) / width at the 
scanned line (W)  
 
References:  
1 Scottish Intercollegiate Guidelines Network (SIGN). Management of Osteoporosis 71 (April 2004 Update) 
 
2 National Institute for Clinical Excellence (NICE). Alendronate, etidronate, risedronate, raloxifene, strontium ranelate for 
the primary prevention of osteoporotic fragility fractures in postmenopausal women Technology Appraisal TA160, 
October 2008 
 
3 National Institute for Clinical Excellence (NICE). Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and 
teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Technology 
Appraisal TA161, October 2008 
 
4 Summary of the 2002 Canadian Guidelines for the Diagnosis and Management of Osteoporosis (2005 Update) 
 
5 British National Formulary (BNF) 56, September 2008 
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 NA  Yes No 
(J) 
No 
(U) 
ID
Q 
 
ID
s 
Ref 
 
 
 Diagnosis of osteoporosis/osteopenia   
 
 1 A patient with a diagnosis of 
osteoporosis  
has a recorded DEXA scan to confirm 
osteoporosis 
 
[Justification for not being assessed by DEXA 
scan to confirm osteoporosis 
Patient > 60 years and > 2 vertebral fractures imply a 
diagnosis of osteoporosis or  
a postmenopausal woman ≥ 75 years and two or more 
independent clinical risk factors for fracture or indicators 
of low BMD]  
 
 


           1,2,3 
 
 2 Measurement of the BMD by DEXA scan  
is performed at least at the two specific sites 
– namely, anteroposterior spine and hip. 
 
           1 
 
 
 Calcium and vitamin D supplementation  
 
 3 A patient with a recorded diagnosis of 
osteoporosis 
is prescribed supplementary calcium (  
vitamin D).  
 
[Justification for non-prescribing calcium and vitamin D: 
There is a record that the patient has an adequate dietary 
intake of calcium and no vitamin D deficiency.] 
 
 
 
 
 
 
 
 
 
 
 
 
           1 
 
Independent clinical 
risk factors  
Indicators for low 
BMD 
 low body mass 
index defined as 
less than 22 
kg/m² 
 parental history of 
hip fracture, 
 ankylosing 
spondylitis 
 alcohol intake of 
4 or more units/d 
 Crohn’s disease  rheumatoid 
arthritis  
 conditions that 
result in 
prolonged 
immobility 
 
 untreated 
premature 
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 4 A patient with a recorded diagnosis of 
osteoPENIA  
is prescribed supplementary calcium (  
vitamin D) for the prevention of 
osteoporosis.  
 
[Justification for non-prescribing calcium and vitamin D: 
There is a record that the patient has an adequate 
dietary intake of calcium and no vitamin D deficiency.] 
 
          4 
 
 5 A patient with confirmed vitamin D 
deficiency or aged > 65  
is prescribed vitamin D.  
 
           1 
 
 6 A patient with osteoporosis  
is treated with an antiresorptive/ 
osteoanabolic agent (bisphosphonate, 
strontium ranelate, raloxifene, teriparatide, 
calcitonin) 
 
           1,2,5 
 
 7 A patient prescribed supplementary 
calcium  
is prescribed a daily dose of 500 – 1500 mg 
calcium.  
 
 
           1,4 
 
 8 A patient prescribed vitamin D  
is prescribed a daily dose of 10 – 20 µg (400 
- 800 IU) vitamin D.  
 
           1 
 
 9 A patient with osteoporosis and NOT 
prescribed  any of the following: 
bisphosphonates, raloxifene, strontium 
ranelate, teriparatide or calcitonin  
is prescribed ≥1000mg calcium plus 800 IU 
vitamin D per day 
 
 
           1 
 
 10 A patient with a recorded diagnosis of 
osteoporosis 
is prescribed an oral bisphosphonate as 
first-line therapy. 
 
Recorded reasons for non-conformance (justification): 
__________________________________________ 
 
 
 
           1,4 
 
 11 A patient with a recorded diagnosis of 
osteoPENIA  
is prescribed an oral bisphosphonate as 
first-line therapy.  
 
Recorded reasons for non-conformance (justification): 
__________________________________________ 
           4 
 
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
148 
 
  
12 
 
A patient prescribed  any of the 
following: bisphosphonates, raloxifene, 
strontium ranelate,  calcitonin or 
teriparatide 
has no contraindication on record (see 
below) 
[Contraindications to bisphosphonates are: 
 oesophageal strictures or achalasia 
 inability to remain upright for > 30 min after 
ingestion  
 hypocalcaemia 
 osteomalacia (etidronate)  
 moderate renal impairment (CrCl <  35 
mL/min)  
 pregnancy and breast feeding]  
 Contraindications to raloxifene are: 
 past/present venous thromboembolic 
events 
 hepatic impairment 
 cholestasis  
 severe renal impairment (CrCl < 10 
mL/min)  
 endometrial cancer 
 uterine bleeding 
 pregnancy and breast feeding 
 Contraindications to strontium ranelate are: 
 pregnancy and breast feeding 
 hypersensitivity 
 Contraindications to calcitonin are: 
 hypocalcaemia 
 hypersensitivity 
[Contraindications to teriparatide are: 
 pre-existing hypercalcaemia 
 skeletal malignancies or bone metastases 
 metabolic bone diseases 
 including Paget’s disease and 
hyperparathyroidism 
 unexplained raised alkaline phosphatase 
 previous radiation therapy to the skeleton] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1,2,5 
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13 A patient receiving treatment for 
osteoporosis/osteopenia 
is prescribed a standard dose regimen.   
              

           1,5 
14 A patient with osteoporosis on 
bisphosphonate therapy  
is on the preferred choice* 
* 1- Alendronate, 2-risedronate, 3-
intermittent cyclical etidronate 
         [Preferred order as shown in the drug 
history] 
           2,3 
 
 Prevention 
(in 
osteopenia) 
 Treatment 
(of 
osteoporosis
) 
Postmenopausal Osteoporosis 
 Alendronic acid 
  5 mg daily PO   10 mg daily or 70 mg  
once weekly PO 
 Disodium etidronate 
  400 mg for 14 days 
PO; 1,25 g calcium 
carbonate for 76 days 
PO 
  400 mg for 14 days 
PO, 1,25 g calcium 
carbonate for 76 days PO 
 Ibandronic acid (not in guidelines)  
   150 mg once a month 
PO  
or 3 mg every 3 months 
IV  
 Risedronate sodium  
  5 mg daily PO   5 mg daily PO  
or 35 mg weekly PO  
 Calcitonin  
   200 units daily 
intranasally 
 
 Raloxifene  
  60 mg daily PO   60 mg daily PO 
 Strontium ranelate 
   2 g daily PO 
 Teriparatide 
   20 micrograms daily, 
for a maximum duration 
of treatment of 18 months 
 
Osteoporosis in men 
 Alendronic acid 
   10 mg daily PO 
Glucocorticoid-induced Osteoporosis 
 Alendronic acid  
  5 mg daily PO    5 mg daily PO  
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15 A patient who is on long-term 
glucocorticoid therapy 
(> 7.5 mg prednisolone or 
equivalents for > 3 months) 
is prescribed a bisphosphonate.  
 
 
            1 
16 A postmenopausal woman 
prescribed strontium ranelate has 
an identifiable reason for not being 
prescribed a bisphosphonate 
  
Reasons for non-use of bisphosphonates are 
 contraindication to bisphosphonates 
(see 12) 
 inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
 intolerance to bisphosphonates 
(see12)] 
 
            2 
17 
A postmenopausal woman 
prescribed raloxifene  
is receiving it for secondary 
prevention and has an identifiable 
reason for not being prescribed a 
bisphosphonate  
 
[Reasons for non-use of bisphosphonates are 
 contraindication to bisphosphonates 
(see 12) 
 inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
 intolerance to bisphosphonates (see 
12)] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            3 
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18 A patient prescribed teriparatide is 
prescribed it for secondary 
prevention and meets at least one 
of the following 2 criteria 
 has a reason to avoid 
bisphosphonates (See 12) 
 has an intolerance to 
strontium ranelate 
o persistent nausea 
o persistent diarrhoea 
And has DEXA scan assessment that 
puts them in one the following groups 
 
 aged ≥ 65 years with a T-
Score ≤ -4 SD 
 aged ≥ 65 years with a T-
Score ≤ -3.5 SD and 
has more than two 
fractures 
 aged 55-64 years with a T-
Score ≤ -4 and has 
more than two fractures 
 
            3 
19 A patient prescribed calcitonin is 
prescribed it for secondary prevention 
after bisphosphonate, raloxifene or 
strontium ranelate have been tried or 
have reasons for excluding from 
consideration 
 
[Reasons for non-use of bisphosphonates are 
 contraindication to bisphosphonates 
(see 12) 
 inability to comply with the 
recommendations for use of 
bisphosphonates (see 12) 
 intolerance to bisphosphonates (see 
12)] 
 
[Reasons for non-use of strontium ranelate  
are: 
 Contraindication to strontium 
ranelate (see 10)] 
 
[Reasons for non-use of raloxifene are: 
 Contraindication to raloxifene] 
 
 
 
            1 
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9.4 Appendix 4 
Database protocol 
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CRITERION 1 
 
 
Step What? How? 
 
Step 1 
 
Identify patients 
with a diagnosis of 
osteoporosis who 
have been 
assessed by DEXA 
scan 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
 ‘Osteoporosis’ for criterion 1 
 ‘DXA’ for criterion 2 
 ‘DEXA IDS’ for criterion 3 
Press ‘view’ 
Sort patients by ‘Osteoporosis’ 
Delete patients who are not osteoporotic (0) 
 
 
Step 2 
 
Store results in a 
Microsoft Excel®  
spreadsheet 
 
 
Export results to Microsoft Excel® 
Sort all results by applying the ‘sort descending’ 
function 
Delete first row (containing ‘c1’, ‘d1’, ‘c2’…) 
 
 
 
 
Step 3 
 
Create a new table 
in Microsoft 
Access® containing 
results from step 2  
 
 
Select ‘Tables’, ‘new’, ‘import table’ in order to 
import the table created in step 2  
Select ‘First Row Contains Headings’ during the 
process of importing 
Name table ‘OS and DEXA’ 
 
 
Step 4 
 
Prepare justification 
search for “No”-
results 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
 ‘Osteoporosis’ for criterion 1 
 ‘>=60 years’ for criterion 2 
 ‘Vertebral’ for criterion 3 
 ‘>=75 years’ for criterion 4 
 ‘Female’ for criterion 5 
 ‘ICR IND BMD LOW’ for criterion 6 
Press ‘view’ 
 
 
 
A patient with a diagnosis of osteoporosis has  
been assessed by DEXA scan 
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Step 5 
 
Identify patients 
with osteoporosis, 
no DEXA scan, >= 
60 years and at 
least two vertebral 
fractures 
(Justification A) 
 
Create new query by using ‘design view’ 
Link ‘tbl_temp’ and table ‘OS and DEXA’ via 
patientKey. 
Apply ‘patientKey’, c1[1], c2 [0] (table ‘OS an 
DEXA’), c1 [1], c2 [1],c3 [1] (‘tbl_temp’) 
Run query 1 
Export results to Microsoft Excel® 
For patients with ‘1’ in field c3 (‘tbl_temp’): 
Check manually if they sustained more than 2 
vertebral fractures by inspecting on the table 
‘Patients: NHS Read codes_QOF and MAT data 
items_tbl’ (use the search function) 
 0 or 1 vertebral fractures: No(U) 
 2 or more vertebral fractures No(J) 
 
 
Step 6 
 
Identify patients 
with osteoporosis, 
no DEXA scan, 
>=75 years, female 
and at least 2 ICRF 
or IND for low BMD 
(Justification B) 
 
Create new query by using ‘design view’ 
Link ‘tbl_temp’ and table ‘OS and DEXA’ via 
patient keys 
Apply ‘patientKey’, c2 [0] (table ‘OS an DEXA’), 
c4 [1], c5 [1], c6 [1] (‘tbl_temp’) 
Run query 2 
Export data to Microsoft Excel® 
For patients with ‘1’ in field c3 (‘tbl_temp’): 
Check manually if they show 2 or more ICRF 
IND BMD by inspecting on the table ‘Patients: 
NHS Read codes_QOF and MAT data items_tbl’ 
(use the search function) 
 0 or 1 ICRF IND BMD: No(U) 
 2 or more ICRF IND BMD No(J) 
Remaining patients with osteoporosis but no 
DEXA scan: No(U) 
 
 
Step 7  
 
Interpret results 
from step 2 (stored 
in Microsoft Excel®) 
 
 
 Osteoporosis 1, DXA 0 and DEXA IDS 1: 
=IDS 
 Osteoporosis 1, DXA 1 and DEXA IDS 0: 
=YES 
 Osteoporosis 1, DXA 0 and DEXA IDS 0:  
      See step 5 and 6 for justifications 
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CRITERION 2 
 
 
Step What? How? 
 
Step 1 
 
Identify patients 
with a 
measured BMD 
by DEXA scan 
measured on 
two specific 
sites 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
 ‘Hip scan’ for criterion 1 
 ‘Lumbar scan’ for criterion 2 
Press ‘view’ 
Create a new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1[1], c2[1], d1, d2 
In ‘SQL view’ change ‘and’ to ‘or’ → 
[(((tbl_temp.c1)="1")) OR (((tbl_temp.c2)="1"));] 
 
 
Step 2 
 
Identify Yes, 
No(U) 
 
Export results to Microsoft Excel® 
 Patients with a DEXA scan performed on 
two specific sites at the same day!= Yes 
 Patients with a DEXA scan performed on 
only one site or with DEXA scans 
performed on two specific sites but not 
at the same day= No(U) 
 No(J)=0 (there is no justification for non-
adherence) 
 
Step 3 Identify IDS, 
IDQ 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
 ‘C2IDSdxa’ for criterion 1 
 ‘DEXA IDS’ (is IDQ for this criteria!) for criterion 
2 
Press ‘view’ 
Create a new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1[1], c2[1] 
In ‘SQL view’ change ‘and’ to ‘or’ → 
[(((tbl_temp.c1)="1")) OR (((tbl_temp.c2)="1"));] 
Export results to Microsoft Excel® 
 IDS= number of patients marked with 1 in 
column c1 
 IDQ= number of patients marked with 1 in 
column c2 
 
Measurement of the BMD by DEXA scan 
Is performed at least at the two specific sites – namely anteroposterior spine 
and hip 
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CRITERION 3 
 
 
Step What? How? 
 
Step 1 
 
Identify patients 
with a diagnosis of 
osteoporosis 
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
 
 
Step 2 
 
Create a table 
containing patients 
with a diagnosis of 
osteoporosis 
 
Use Microsoft Access® 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel® document ‘CLY OS’ and 
rename field c1 to ‘Osteoporosis’ (Table ‘CLY 
OS’) 
 
 
Step 3 
 
Identify patients 
with a diagnosis of 
osteoporosis who 
are prescribed 
supplementary 
calcium 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
 
 ‘Supplement’ for 
criterion 1 
Press ‘view’ 
Create new query by using 
‘desing view’ 
Select ‘tbl_temp’ and table 
‘CLY OS’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’, 
osteoporosis [1] (Table ‘CLY 
OS’) and d1 [not like “0”] 
(‘tbl_temp’) 
Run query 1  
 Number of ‘Yes’ 
results 
 
 
 
 
 
 ‘Osteoporosis’ for criterion 1 
Press ‘view’ 
Sort patients by ‘Osteoporosis’ 
Delete patients who are not osteoporotic (0) 
Export results to Microsoft Excel®.  
Name document ‘CLY OS’ 
 
Patient with a recorded diagnosis of osteoporosis 
Is prescribed supplementary calcium (vitamin D) 
and hip 
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Step 4 
 
Identify patients 
with a diagnosis of 
osteoporosis who 
are not prescribed 
supplementary 
calcium 
 
Create new query by using ‘Find Unmatched 
Query Wizard’ 
Select table ‘CLY OS’ 
Press ‘next’ 
Select ‘Queries’ / ‘query 1’ 
Press ‘next’ 
Link tables via ‘patientKey’ 
Press ‘next’ 
Select ‘patientKey’ 
Press ‘next’ 
 Number of total ‘No’ results 
 
 
Step 5 
 
Search for 
justifications of non-
adherence 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ‘Adequate dietary intake of calcium’ 
for criterion 1 
 ‘Adequate dietary intake of vitamin 
D’ for criterion 2 
Create new query by using ‘desing view’ 
Select ‘tbl_temp’ and ‘CLY_OS Without 
Matching Query 2’ 
Link via ‘patientKey’ 
Apply ‘patientKey’, c1[1], c2[1] 
In ‘SQL view’ change AND to OR between c1 
and c2 
Run query 3 
 Number of justified non-adherence= 
No(J) 
 Number of unjustified non-adherence= 
Number of total No-results- No(J)= 
No(U) 
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CRITERION 4 
 
Step What? How? 
 
Step 1 
 
Identify patients 
with a diagnosis of 
osteopenia 
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
 
 
Step 2 
 
Create a table 
containing patients 
with a diagnosis of 
osteopenia 
 
Use Microsoft Access® 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel® document ‘CLY ON’ and 
rename field c1 to ‘Osteopenia’ (Table ‘CLY ON’) 
 
 
Step 3 
 
Identify patients 
with a diagnosis of 
osteopenia who are 
prescribed 
supplementary 
calcium 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
 
 ‘Supplement’ 
Press ‘view’ 
Create new query by using 
‘desing view’ 
Select ‘tbl_temp’ and table 
‘CLY ON’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’, 
osteopenia [1] (Table ‘CLY 
ON’) and d1 [not like “0”] 
(‘tbl_temp’) 
Run query 1  
 Number of ‘Yes’ 
results 
 
 
 
 
 
 
 
 
 ‘Osteopenia’ for criterion 1 
Press ‘view’ 
Sort patients by ‘Osteopenia’ 
Delete patients who are not osteopenic (0) 
Export results to Microsoft Excel®.  
Name document ‘CLY ON’ 
 
Patient with a recorded diagnosis of osteopenia 
Is prescribed supplementary calcium ( vitamin D) 
and hip 
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Step 4 
 
Identify patients 
with a diagnosis of 
osteopenia who are 
not prescribed 
supplementary 
calcium 
 
Create new query by using ‘Find Unmatched 
Query Wizard’ 
Select table ‘CLY ON’ 
Press ‘next’ 
Select queries/ ‘query 1’ 
Press ‘next’ 
Link tables via ‘patientKey’ 
Press ‘next’ 
Select ‘patientKey’ 
Press ‘next’ 
 Number of total ‘No’ results 
 
 
Step 5 
 
Search for 
justifications of non-
adherence 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ‘Adequate dietary intake of calcium’ 
for criterion 1 
 ‘Adequate dietary intake of vitamin 
D’ for criterion 2 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ and ‘CLY_ON Without 
Matching Query 2’ 
Link via ‘patientKey’ 
Apply ‘patientKey’, c1[1], c2[1] 
In ‘SQL view’ change AND to OR between c1 
and c2 
Run query 3 
 Number of justified non-adherence= 
No(J) 
 Number of unjustified non-adherence= 
Number of total No-results- No(J)= 
No(U) 
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CRITERION 5 
 
 
Step What? How? 
 
Step 1 
 
Identify patients with 
confirmed vitamin D 
deficiency or aged over 
65 
who are  prescribed 
vitamin D 
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read code’ field: 
 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1[1], c2 [1] 
In ‘SQL view’ change AND to OR between c1 
and c2 
Run query 1 
Export results to Microsoft Excel®.  
Name document ‘CLY patients over 65 or 
vitamin D deficiency’ 
 
 
Step 2 
 
Create a table 
containing patients aged 
65 or older 
 
Use Microsoft Access® 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel® document ‘CLY 
patients over 65’ and rename field c1 to 
‘>=65 years’ and c2 to ‘vd deficiency’ (table 
‘CLY patients over 65 or vitamin deficiency’) 
 
 
Step 3 
 
Identify patients aged 65 
years or older or with a 
confirmed vitamin d 
deficiency who are 
prescribed vitamin d 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
Create new 
query by using ‘design view’ 
Select ‘tbl_temp’ and table ‘CLY patients 
over 65 or vitamin deficiency’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’ (‘CLY patients over 65 or 
vitamin deficiency’) and d1 [not like “0”] 
(‘tbl_temp’) 
Run query 2 
Number of Yes results 
 ‘Supplement’ 
Press ‘view’ 
 ‘>=65 years’ for criterion 1 
 ‘Vitamin D deficiency’ for 
criterion 2 
A patient with confirmed vitamin D deficiency or aged 65 or older 
is prescribed vitamin D 
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Step 4 
 
Identify patients aged 65 
years or older or with a 
confirmed vitamin D 
deficiency who are not 
prescribed vitamin d  
 
Create new query by using ‘Find Unmatched 
Query Wizard’ 
Select table ’CLY patients over 65 or vitamin 
D deficiency’ 
Press ‘next’ 
Select queries/ query 2 
Press ‘next’ 
Link tables via ‘patientKey’ 
Press ‘next’ 
Select ‘patientkey’ 
Press ‘next’ 
 Number of total No results= No(U) as 
there is no justification for not 
prescribing vitamin d in this case 
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CRITERION 6 
 
Step What? How? 
 
Step 1 
 
Identify patients  treated with 
bisphosphonate, raloxifene, strontium 
ranelate, OR calcitonin 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select 
 ‘Osteoporosis’ for 
criterion 1 
 ‘Bisphosphonate’ for 
criterion 2 
 ‘strontium ranelate’ for 
criterion 3 
 ‘raloxifene’ for criterion 
4 
 ‘calcitonin’ for criterion 
5 
 
Sort patients by 
‘Osteoporosis’ 
Delete patients who are not 
osteoporotic (0) 
Sort patients by different 
treatments 
(bisphosphonates, strontium 
ranelate, raloxifene, 
calcitonin) 
Delete patients who are not 
receiving treatment (0) 
 
 
 
A patient with osteoporosis  
is treated with an antiresorptive/ osteoanabolic agent (bisphosphonate, 
strontium ranelate, raloxifene, teriparatide, calcitonin) 
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CRITERION 7 
 
 
Step What? How? 
 
Step 1 
 
Identify patients 
prescribed 
supplementary 
calcium  
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
 ‘supplement’ for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1, d1[not like “0”], c2, d2, c3 
Run query 1 
 
 
Step 2 
 
Identify number of 
Yes, No(J), No(U), 
IDS 
 
 
Export results of ‘step 1’ to Microsoft Excel® 
Inspect on the results 
 Patient prescribed a daily dose of 500-
1500 mg calcium= Yes 
 Patient not prescribed a daily dose of 500-
1500 mg calcium= No(U) 
 documentation concerning dose, 
preparation and frequency not clear= IDS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient prescribed supplementary calcium  
Is prescribed a daily dose of 500-1500 mg calcium 
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CRITERION 8 
 
 
Step What? How? 
 
Step 1 
 
Identify patients who are prescribed 
vitamin D 
 
Use Microsoft Access® 
Create new query by using 
‘design view’ 
Select table: ‘Patients: Drug 
History_tbl’ 
Apply ‘drug name’: [like 
*Adcal D3* or like *Calceos* 
or like *Calcichew D3* or like 
*Cacit D3* or  like *Calfovit 
D3* or like *colecalciferol* or 
like *vitamin d*] 
Also show dose and 
frequency. 
Run query 1  
Export results to Microsoft 
Excel® 
 
Step 2 Identify patients who are prescribed a 
daily dose of 10 – 20 microgram (400 
– 800 IU) vitamin D (Standard) 
 
Possible drugs containing 10 micrograms 
(400 units) colecalciferol are the 
following: 
Adcal D3®, Calceos®, Calcichew D3® forte 
 
Possible drugs containing 11 micrograms 
(500 units) colecalciferol are the 
following: 
Cacit D3® 
 
Possible drugs containing 5 micrograms 
(200 units) colecalciferol are the 
following: 
Calcichew D3® 
 
Possible drugs containing 20 micrograms 
(800 units) colecalciferol are the 
following: 
Calfovit® 
 
Check manually if patients 
are receiving the appropriate 
dose regimen (especially 
focus on Calcichew D3, it is 
necessary to take it twice a 
day!) 
 
Patient prescribed vitamin D 
Is prescribed a daily dose of 10 – 20 microgram (400 – 800 IU) vitamin D 
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CRITERION 9  
 
 
Step What? How? 
 
Step 1 
 
Identify patients 
with osteoporosis 
and NOT 
prescribed 
bisphosphonates, 
raloxifene, 
strontium ranelate 
or calcitonin  
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
 ‘Osteoporosis’ for criterion 1 
 ‘Bisphosphonate’ for criterion 2 
 ‘strontium ranelate’ for criterion 3 
 ‘raloxifene’ for criterion 4 
 ‘calcitonin’ for criterion 5 
Press ‘view’ 
Create new query by using ‘design view’ 
Select  ‘tbl_temp’ 
Apply ‘patientKey’, c1 [1], c2 [0], c3 [0], c4 [0], c5 
[0] 
Run query 1 
 
 
Step 2 
 
Preparation for 
step 3 
 
Export results to Microsoft Excel® 
Select ‘File’, ‘Export’ and follow the process. 
Name document ‘Patient OS no (BP_ ralox_ 
stront_ calc)’ 
 
 
Step 3 
 
Create a table in 
Microsoft Access® 
containing data 
exported in step 2 
 
 
Use Microsoft Access® 
 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel® document ‘Patient OS no 
(BP_ ralox_ stront_ calc)’and rename field c1 to 
‘osteoporosis’, c2 to ‘bp (ex ibandro)’, c3 to 
‘strontium’, c4 to ‘raloxi’ and c5 to ‘calcito’ (table 
‘Criterion 9 search excluding ibandronic acid’) 
 
 
 
 
 
 
 
 
 
 
A patient with osteoporosis and NOT prescribed any of the following: 
bisphosphonates, raloxifene, strontium ranelate or calcitonin 
Is prescribed   1000 mg calcium plus 800 IU vitamin D per day. 
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Step 4 
 
Identify 
osteoporotic 
patients who are  
prescribed 
calcium and/ or 
vitamin D 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Drug’ field/ ‘group’: 
 
 
Step 5  
 
Identify patients 
with a diagnosis 
of osteoporosis 
and not treated 
bisphosphonates, 
raloxifene, 
strontium ranelate 
or calcitonin who 
are prescribed 
>=1000 mg 
calcium 800 IU 
vitamin D per day 
 
 
Create new query by using ‘design view’ 
Select table ‘Criterion 9 search excluding 
ibandronic acid’ and query ‘CLY OS on 
supplement’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’ (table ‘Criterion 9 search 
excluding ibandronic acid’) and d1, c2, c3, d2 
Run query 3 (query ‘Criterion 9 Yes Results’) 
Export data to Microsoft Excel® and check 
manually if the correct dose is prescribed.  
 only calcium is prescribed or only vitamin d 
is prescribed or the wrong dose is 
prescribed= No(U) 
 the correct dose is prescribed= Yes 
 documented date is not clear concerning 
dose, preparation, frequency= IDS 
 
 
Step 6  
 
Identify patients 
with a diagnosis 
of osteoporosis 
and not treated 
bisphosphonates, 
raloxifene, 
strontium ranelate 
or calcitonin who 
are not 
prescribed 
>=1000 mg 
calcium 800 IU 
vitamin d per day 
 
 
Create new query by using ‘Find Unmatched 
Query Wizard’ 
Select table ‘Criterion 9 Search excluding 
ibandronic acid’ 
Press ‘next’ 
Select queries/ query ‘Criterion 9 Yes Results’ 
Press ‘next’ 
Link tables via ‘patientKey’ 
Press ‘next’ 
Select ‘patientKey’ 
Press ‘next’ 
 Number additional No results= No(U) as 
there is no justification for not prescribing 
calcium and or vitamin d in this case or 
prescribing it in another dose 
 
 ‘supplement’ for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ and table ‘CLY OS’ (was 
created in Criterion 3, Step 2) 
Link tables via ‘patientKey’ 
Apply ‘patientKey’, osteoporosis [1] (Table ‘CLY 
OS’) and d1 [not like “0”] (‘tbl_temp’) 
Run query 2 (query ‘CLY OS on supplement’) 
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CRITERION 10 
 
 
Step What? How? 
 
Step 1 
 
Identify patients with a diagnosis 
of osteoporosis who are 
prescribed an oral 
bisphosphonate (alendronic 
acid, disodium etidronate, 
risedronate sodium) as first-line 
therapy  
 
Drugs containing oral 
bisphosphonates are the following: 
Alendronic acid (Fosamax®, 
Fosavance®), disodium etidronate 
(Didronel PMO®), risedronate 
sodium (Actonel®) 
 
 
 
 
 
 
 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select  
 ‘Bisphosphonate’ for 
criterion 1 
 ‘Osteoporosis’ for 
criterion 2 
 ‘raloxifene’ for criterion 
3 
 ‘strontium ranelate’ for 
criterion 4 
 ‘calcitonin’ for criterion 
5 
 ‘teriparatide’ for 
criterion 6 
Sort patients by 
‘osteoporosis’ 
Delete patients who are not 
osteoporotic (0) 
Sort patients by each 
treatment  
Delete patients who are not 
receiving any treatment (0) 
Export results to Microsoft 
Excel® 
Inspect on results, focus on 
the date: identify patients 
who were prescribed a 
bisphosphonate at first 
 
 
 
Patient with a recorded diagnosis of osteoporosis 
Is prescribed an oral bisphosphonate as first-line therapy 
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CRITERION 11 
 
Step What? How? 
 
Step 1 
 
Identify patients with a diagnosis 
of osteopenia who are 
prescribed an oral 
bisphosphonate (alendronic 
acid, disodium etidronate, 
risedronate sodium) as first-line 
therapy  
 
Drugs containing oral 
bisphosphonates are the following: 
Alendronic acid (Fosamax®, 
Fosavance®), disodium etidronate 
(Didronel PMO®), risedronate 
sodium (Actonel®) 
 
 
 
 
 
 
 
 
 
 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select  
 ‘Bisphosphonate’ for 
criterion 1 
 ‘Osteopenia’ for 
criterion 2 
 ‘raloxifene’ for criterion 
3 
 ‘strontium ranelate’ for 
criterion 4 
 ‘calcitonin’ for criterion 
5 
 ‘teriparatide’ for 
criterion 6 
Sort patients by ‘osteopenia’ 
Delete patients who are not 
osteopenic (0) 
Sort patients by each 
treatment  
Delete patients who are not 
receiving any treatment (0) 
Export results to Microsoft 
Excel® 
Inspect on results, focus on 
the date: identify patients 
who were prescribed a 
bisphosphonate at first 
 
 
 
Patient with a recorded diagnosis of osteopenia 
Is prescribed an oral bisphosphonate as first-line therapy 
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CRITERION 12 
 
Step What? How? 
 
Step 1 
 
Identify patients  who are prescribed 
bisphosphonates, raloxifene, strontium 
ranelate, cacitonin or teriparatide 
 
 
Use form ‘Query maker’ in 
Microsoft Access® 
Select 
 ‘Osteopenia’ for 
criterion 1 
 ‘Bisphosphonate’ for 
criterion 2 
 ‘strontium ranelate’ for 
criterion 3 
 ‘raloxifene’ for criterion 
4 
 ‘calcitonin’ for criterion 
5 
 ‘teriparatide’ for 
criterion 6 
 
Sort patients by ‘Osteopenia’’ 
Delete patients who are not 
osteopenic (0) 
Sort patients by different 
treatments (bisphosphonates, 
strontium ranelate, raloxifene, 
calcitonin) 
Delete patients who are not 
receiving treatment (0) 
Export results to Microsoft 
Excel ® 
Add patients receiving 
treatment and identified in 
criterion 6 
 
A patient prescribed  any of the following: bisphosphonates, raloxifene, 
strontium ranelate,  calcitonin or teriparatide 
has no contraindication on record 
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Step 2 Check for contraindications Use form ‘Query maker’ in 
Microsoft Access® 
Select 
 ‘Contraindication to 
Bisphosphonate’ for 
criterion 1 
 ‘Contraindication to 
strontium ranelate’ for 
criterion 2 
 ‘Contraindication to 
raloxifene’ for criterion 3 
 ‘Contraindication to 
calcitonin’ for criterion 4 
 ‘Contraindication to 
teriparatide’ for criterion 
5 
 
Delete ‘0’ results 
 
Check patients with ‘1’ results 
if they receive the agent for 
which a contraindication was 
recorded. If necessary mark 
them as No(U) 
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CRITERION 13 
 
 
Step What? How? 
 
Step 1 
 
Prepare for 
identifying main 
patient groups 
(female+ 
osteoporosis, 
postmenopausal+ 
osteoporosis, 
postmenopausal+ 
osteopenia, male+ 
osteoporosis) 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
 ‘Postmenopausal’ for criterion 1  
 ‘Osteoporosis’ for criterion 2 
 ‘Osteopenia’ for criterion 3 
 ‘Female’ for criterion 4 
 ‘Male’ for criterion 5 
 
Step 2 
 
Identify female 
patients with a 
diagnosis of 
osteoporosis and 
create a table in 
Microsof Access® 
containing these 
patients 
 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c4 [1], c2 [1] 
Run and save query 1 (‘Female Osteoporosis’) 
Select ‘File’, ‘Export’ to Microsoft Excel® by 
following the process. Name document ‘Female 
OS’ 
 
Step 3 
 
Identify 
postmenopausal  
patients with a 
diagnosis of 
osteoporosis and 
create a table in 
Microsoft Access® 
containing these 
patients 
 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1 [1], c2 [1] 
Run and save query 2 (‘postmenopausal 
osteoporosis’) 
Select ‘File’, ‘Export’ to Microsoft Excel® by 
following the process. Name document 
‘Postmenopausal OS’ 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel® document ‘Female 
OS’and rename field c4 to ‘female’ and c2 to 
‘Osteoporosis’ (table ‘Female Osteoporosis’) 
 
Press ‘view’ 
 
A patient receiving treatment for osteoporosis/ osteopenia 
is prescribed a standard dose regimen 
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Step 4 
 
Identify 
postmenopausal  
patients with a 
diagnosis of 
osteopenia and 
create a table in 
Microsof Access® 
containing these 
patients 
 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1 [1], c3 [1] 
Run and save query 3 (‘Postmenopausal 
Osteopenia’) 
Select ‘File’, ‘Export’ to Microsoft Excel® by 
following the process.  
Name document ‘Postmenopausal ON’ 
 
Step 5 
 
Identify male 
patients with a 
diagnosis of 
osteoporosis and 
create a table in 
Microsof Access® 
containing these 
patients 
 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c5 [1], c2 [1] 
Run and save query 4 (‘male osteoporosis’) 
Select ‘File’, ‘Export’ to Microsoft Excel® by 
following the process.  
Name document ‘Male OS’ 
 
Step 6 
 
Identify patients 
prescribed daily 2g 
PO strontium 
ranelate    
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘drug’ field/ ‘group’: 
 ‘Strontium ranelate’ for criterion 1 
Press ‘view’ 
Create new 
query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1 [not like “0”], d1, c2, d2, 
c3 
Run query 5 (query ‘Patient prescribed 
strontium ranelate’) 
Export data to Microsoft Excel® and check 
 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel® document ‘Male OS’ and 
rename field c5 to ‘Male’ and c2 to ‘Osteoporosis’ 
(table ‘Male Osteoporosis’) 
 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel® document 
‘Postmenopausal ON’ and rename field c1 to 
‘postmenopausal’ and c3 to ‘osteopenia’ (table 
‘Postmenopausal Osteopenia’) 
 
Select ‘Tables’, ‘New’, ‘Import Table’ 
Import Microsoft Excel® document 
‘Postmenopausal OS’and rename field c1 to 
‘postmenopausal’ and c2 to ‘Osteoporosis’  
(table ‘Postmenopausal Osteoporosis’) 
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manually if they are prescribed 2g PO daily.  
Create new query by using design view 
Select table ‘Postmenopausal Osteoporosis’ 
and query ‘Patient prescribed strontium 
ranelate’ 
Link tables via ‘patientKeys’ 
Apply patient keys 
Run query 6 
Apply ‘patientKey’  
 prescribed 2g PO daily and 
postmenopausal woman with 
osteoporosis= Yes 
 not prescribed 2g PO daily or not 
postmenopausal woman with 
osteoporosis= No(U) 
 recorded data not clear=IDS 
 No(J)=0… there is no justification for 
prescribing another dose or prescribing 
to another patient group 
 
 
Step 7 
 
Identify patients 
prescribed daily 
60mg PO raloxifene  
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘drug’ field/ ‘group’: 
 ‘Raloxifene’ for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1 [not like “0”], d1, c2, d2, 
c3 
Run query 7 (query ‘Patient prescribed 
raloxifene’) 
Export data to Microsoft Excel® and check 
manually if they are prescribed 60mg PO daily.  
Create new query by using ‘design view’ 
Select table ‘Postmenopausal Osteoporosis’ 
and query ‘Patient prescribed raloxifene’ 
Link tables via ‘patientKey’ 
Apply ‘patientKey’ 
Run query 8 
 prescribed 60mg PO daily and 
postmenopausal woman with 
osteoporosis= Yes 
 not prescribed 60mg PO daily or not 
postmenopausal woman with 
osteoporosis= No(U) 
 recorded data not clear=IDS 
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Step 8 
 
Identify patients 
prescribed 
teriparatide (20 
micrograms daily, 
for a maximum 
duration of 
treatment of 18 
months) 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘drug’ field/ ‘group’: 
 ‘Teriparatide’ for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select tbl_temp 
Apply ‘patientKey’, c1 [not like “0”], d1, c2, d2, 
c3 
Run Query 9 (Query ‘Patient prescribed 
teriparatide’) 
Export data to Microsoft Excel® and check 
manually if they are prescribed 20 micrograms 
daily, for a maximum duration of treatment of 18 
months.  
Create new query by using design view 
Select Table ‘Patients: NHS Read codes_QOF 
and MAT data items_tbl’ and Query ‘Patient 
prescribed teriparatide’ 
Link tables via patient keys 
Apply ‘patient keys’ and ‘mat data item’ [male] 
Run Query 10 
 prescribed 20 micrograms daily, for a 
maximum duration of treatment of 18 
months and not male = Yes 
 not prescribed 20 micrograms daily, for a 
maximum duration of treatment of 18 
months or male= No(U) 
 recorded data not clear=IDS 
 
 
Step 9 
 
Identify patients 
prescribed 
calcitonin (200 units 
daily intranasally) 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in drug field/ group: 
 Calcitonin for criterion 1 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ 
Apply ‘patientKey’, c1 [not like “0”], d1, c2, d2, 
c3 
Run query 11 (query ‘Patient prescribed 
calcitonin’) 
Export data to Microsoft Excel® and check 
manually if they are prescribed 200 units 
intranasally.  
Create new query by using ‘design view’ 
Select table ‘Postmenopausal Osteoporosis’ 
and query ‘Patient prescribed calcitonin’ 
Link tables via ‘patientKey’ 
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Apply ‘patientKey’ 
Run query 12 
 prescribed 200 units intranasally and 
postmenopausal woman with 
osteoporosis= Yes  
 not prescribed 200 units intranasally or 
not postmenopausal woman with 
osteoporosis= No(U) 
 recorded data not clear=IDS 
 
Step 10  
 
Identify patients 
prescribed  a 
standard dose 
regimen for 
bisphophonates 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘drug’ field/ ‘group’: 
 BP 
Press ‘view’ 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ and ‘Patients: NHS Read 
codes_QOF and MAT data items_tbl’ 
Apply ‘patientKey’, c1, c2, c3,d3 (‘tbl_temp’) 
and mat data item [male] (table ‘Patients: NHS 
Read codes_QOF and MAT data items_tbl’) 
Run query 13 
Export results to Microsoft Excel® and check 
manually if patients are prescribed the correct 
dose regimen: 
 Alendronic acid: 10mg po. Justification 
for not being prescribed 
10mg:glucocorticoid induced 
osteoporosis and prescribed 5mg po 
 Disodium etidronate: 400mg for 14 days 
PO, 1.25g calcium carbonate for 76 days 
PO (only if glucocorticoid induced 
osteoporosis) 
 Risedronate sodium 5mg daily PO (only 
if glucocorticoid induced osteoporosis) 
 
Create new query by using ‘design view’ 
Select ‘tbl_temp’ and ‘Patients: NHS Read 
codes_QOF and MAT data items_tbl’ 
Apply ‘patientKey’, c1, c2, c3,d3 (‘tbl_temp’) 
and mat data item [female] (table ‘Patients: 
NHS Read codes_QOF and MAT data 
items_tbl’) 
Run query 14 
Export results to Microsoft Excel® and check 
manually if patients are prescribed the correct 
dose regimen: 
 Alendronic acid: 10mg po daily, or 70 mg 
one weekly PO. Justification for not 
being prescribed 10mg or 70 mg once 
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weekly PO: glucocorticoid induced 
osteoporosis or osteopenia and 
prescribed 5mg PO. 
 Disodium etidronate: 400mg for 14 days 
PO, 1.25g calcium carbonate for 76 days 
PO  
 Risedronate sodium 5mg daily PO or 35 
mg weekly PO (only if osteoporosis) 
Count only one result per patient. Delete 
results for ibandronic acid. 
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CRITERION 14 
 
 
Step What? How? 
 
Step 1 
 
Drugs containing 
bisphosphonates are the 
following: 
 
Alendronic acid (Fosamax®, 
Fosavance®), disodium 
etidronate (Didronel PMO®), 
risedronate sodium (Actonel®) 
 
 
Use form ‘Query maker’ in Microsoft 
Access® 
Select in ‘Read Code’ field 
 ‘Osteoporosis’ for criterion 1 
 ‘Bisphosphonate’ for criterion 
2 
Press ‘view’ 
Delete patients who are not 
osteoporotic (0)  
Delete patients who are not 
prescribed a bisphosphonate (0) 
Sort patients by alendronate 
Export results to Excel® 
Check patients receiving a 
bisphosphonate if they are on the 
preferred choice by searching the 
‘general information’ table 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A patient with osteoporosis on bisphosphonate therapy  
is on the preferred choice* 
* 1- Alendronate, 2-risedronate, 3-intermittent cyclical etidronate 
         [Preferred order as shown in the drug history] 
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CRITERION 15 
 
Step What? How? 
 
Step 1 
 
Identify patients 
who are on long-
term 
glucocorticoid 
therapy  and 
prescribed a 
bisphosphonate 
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
 ‘long-term steroid’ for criterion 1 
 ‘bisphosphonates’ for criterion 2 
Press ‘view’ 
Sort patients by ‘long-term steroids’ 
Delete patients who do not receive a long-term 
treatment with steroids (0) 
Export results to Microsoft Excel 
Inspect on ‘Bisphosphonates’ column: 
 ‘1’= YES 
 ‘0’= NO (possible justification: see criterion 
12 ‘reasons to avoid bisphoshonates) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient who is on long-term glucocorticoid therapy (≥ 7.5 mg prednisolone or 
equivalents for ≥ 3 months) 
Is prescribed a bisphosphonate 
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CRITERION 16 
 
Step What? How? 
 
Step 1 
 
Identify 
postmenopausal 
women receiving 
strontium ranelate 
 
Check if there is a 
reason recorded 
for not receiving a 
bisphosphonate 
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
 ‘postmenopausal’ for criterion 1 
 ‘strontium ranelate’ for criterion 2 
Press ‘view’ 
Sort patients by ‘postmenopausal’ 
Delete those who are not postmenopausal (0) 
Delete patients who do not receive strontium 
ranelate  (0) 
Export results to Microsoft Excel and check if 
patients, who are prescribed strontium ranelate 
have an identifiable reason for not being 
prescribed a bisphosphonate by searching the 
‘general information’ table.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A postmenopausal woman prescribed strontium ranelate has an 
identifiable reason for not being prescribed a bisphosphonate 
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CRITERION 17 
 
Step What? How? 
 
Step 1 
 
Identify 
postmenopausal 
women receiving  
raloxifene  
 
Check if there is a 
reason recorded 
for not receiving a 
bisphosphonate 
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
 ‘postmenopausal’ for criterion 1 
 ‘raloxifene’ for criterion 2 
Press ‘view’ 
Sort patients by ‘postmenopausal’ 
Delete those who are not postmenopausal (0) 
Delete patients who do not receive raloxifene   (0) 
Export results to Microsoft Excel and check if 
patients, who are prescribed raloxifene have an 
identifiable reason for not being prescribed a 
bisphosphonate by searching the ‘general 
information’ table.  
 
A postmenopausal woman prescribed raloxifene  
is receiving it for secondary prevention and has an identifiable reason for not 
being prescribed a bisphosphonate  
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CRITERION 18 
 
 
 
Step What? How? 
 
Step 1 
 
Identify patients  
receiving  
teriparatide 
 
Check if the 
standard is 
adhered to 
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
 ‘teriparatide’ for criterion 1 
Press ‘view’ 
Sort patients by ‘teriparatide’ 
Delete those who do not receive teriparatide (0) 
Export results to Microsoft Excel and check if 
patients, who are prescribed teriparatide meet the 
criteria listed above by searching the patient 
record 
 
A patient prescribed teriparatide is prescribed it for secondary prevention 
and meets at least one of the following 2 criteria 
 has a reason to avoid bisphosphonates (See 12) 
 has an intolerance to strontium ranelate 
o persistent nausea 
o persistent diarrhoea 
And has DEXA scan assessment that puts them in one the following groups 
 
 aged ≥ 65 years with a T-Score ≤ -4 SD 
 aged ≥ 65 years with a T-Score ≤ -3.5 SD and 
has more than two fractures 
 aged 55-64 years with a T-Score ≤ -4 and has 
more than two fractures 
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CRITERION 19 
 
 
 
 
 
 
 
Step What? How? 
 
Step 1 
 
Identify patients  
receiving 
calcitonin 
 
Check if standard 
is adhered to 
 
 
Use form ‘Query maker’ in Microsoft Access® 
Select in ‘Read Code’ field: 
 ‘calcitonin’ for criterion 1 
Press ‘view’ 
Sort patients by ‘calcitonin’ 
Delete those who do not receive calcitonin (0) 
Export results to Microsoft Excel and check if 
patients, who are prescribed calcitonin meet the 
criteria listed above by searching the patient 
record 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A patient prescribed calcitonin is prescribed it for secondary prevention 
after bisphosphonate, raloxifene or strontium ranelate have been tried or 
have reasons for excluding from consideration 
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9.5 Appendix 5 
Instructions query builder 
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Instructions Query maker 
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What is the query maker? 
The query maker is a Microsoft Access® form developed by Tobias Dreischulte 
and Ian Thompson. Its’ purpose is to simplify and accelerate the process of data 
analysis when applying a MAT. 
 
How to use the query maker: 
When you open the database, the ‘Database window’ will appear. To open the 
query maker click on ‘Forms’ in the ‘object bar’ and double-click on 
‘frm_query_maker’: 
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When you open the form, three fields (Read code, Investigation, Drugs) with drop down 
menus appear: 
 
 
 
 
For building a query just select your criteria in the drop down menu. It is not possible to 
use more than one field at the same time.  
 
Example 1 
Your question is: 
“How many men in the examined population are diagnosed with osteoporosis and 75 
years or older?” 
 
Look in the drop down menus in which field the information you need is provided (in our 
example it is provided in the Read Code field.) Then select  ‘Male’ for criterion 1, 
‘Osteoporosis’ for criterion 2 and >= 75 years (for criterion 3) and click on the ‘view’ button: 
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A table will appear showing the results of your question. The table will automatically be 
named ‘tbl_temp: Table’ and contain 1 and 0 for each criteria selected in the previous step. 
1 means ‘Yes’ and 0 means ‘No’. That means you can also tell which patient is not male, is 
not suffering from osteoporosis or is not older than 75 years: 
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The second column shows the patient identifier (patient key). Columns c1, c2, c3, etc. 
present the results of the criteria selected in the previous step for each patient. In our 
example c1 shows if a patient is male, c2 if the patient has a diagnosis of osteoporosis and 
c3 the age of the patient.  Columns d1, d2, d3, etc. present the date of the data entry. 
 
You can now sort the data in ‘tbl_temp: Table’ by selecting a column and clicking on the 
‘Sort Ascending’ or the ‘Sort Descending’ icon. You can find those icons in the toolbar 
above:  
 
 
Results without use for your question can be deleted by selecting the row and pressing the 
‘Delete Record’ icon. You can find this icon in the toolbar above: 
 
 
It is also possible to export the results to Microsoft Excel® by selecting ‘File’ and ‘Export’. 
 
To show only the patients who fully adhere to your question (how many of my patients are 
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male, 75 years or older and suffer from osteoporosis?) you can run a query. Therefore, 
minimize ‘tbl_temp: Table’ and the form and open the ‘database window’. Then select 
‘Queries’ and ‘New’ by clicking on the icons.  
 
 
A dialog field will appear. Select ‘Desing View’ and ‘OK’. 
 
 
 
 
 
Add tbl_temp. The following window will appear: 
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In the small ‘tbl_temp’ field you can tell the program what to show after running the query. 
For solving our example (Example 1) we would select patientKey, c1 (male), c2 
(osteoporosis) and c3 (75 years or older) by double clicking and writing 1 in the ‘criteria’ 
row to tell the software that it shall only show the ‘yes- results’. Then run the query by 
pressing the ‘Run’ icon, which you can find in the toolbar above:  
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Your results could for example look like this: 
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It means the dataset contains of 4 male patients with osteoporosis and 75 years or older. 
It is important to now save your results and export them to Microsoft Excel®. Be aware 
that once you built a new query with the query maker (means select criteria in the drop 
down menu of the form and press view) tbl_ temp changes- the results of your former 
question will not be there anymore.  
 
How does the query maker work? 
There are four important tables and two important queries, which are necessary for the 
function of the fields.  
The ‘Read Code’ field accesses to the table ‘Patients: NHS Read codes_QOF and MAT 
data items_tbl’ and the query ‘qry_MAT’. 
The ‘Investigations’ field accesses to the table ‘Patients: Investigations_tbl’ and the query 
‘qry_investigation_list’. 
The ‘Drugs’ field accesses to the table ‘Patients: Drug History_tbl’ and the table ‘Master: 
Drug list_tbl’. 
If you change anything in the format of this tables and queries, the tool will not work 
anymore! It is important no to rename columns, etc.!  
 
 
What do I have to do to before importing my dataset into the tool? 
Go threw your MAT criterion by criterion and identify the terms you will have to ask for 
when doing your analysis (e.g. in the example above this terms would be male, 
osteoporosis and 75 years or older). Make a list of those and decide which data should be 
shown in which field afterwards. Then produce your three main tables.  
  
How to produce the main tables and import them into the tool 
For the ‘Read Code’ field: 
1. Identify READ Codes for diagnosis, clinical conditions, drugs and 
investigations which will be included in the project and create a table in 
Microsoft Excel®: 
 
 
Draw them from a complete list of READ Codes (provided  in the research standard 
folder on your desktop). Also, check http://www.scimp.scot.nhs.uk/coding 
_guidance.html. At this website, you can find out if a QOF (Quality outcome 
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framework) for the disease your MAT is about exist. If so Read Codes for use are 
defined, you have to adopt them for creating MAT data items.  
Inspect the READ Codes of the dataset you want to analyze and add additional 
ones to your table.  
Create MAT Data item (term summarizing different READ Codes with the same 
meaning) for each subset of READ Codes, e.g.: 
 
 
READ Code 
 
 
Description 
 
MAT Data item 
 
N3305 
 
Drug-induced osteoporosis 
 
Osteoporosis 
 
N330C 
 
Osteoporosis localized spine 
 
Osteoporosis 
 
 
2. Create the Table ‘Patients: NHS Read codes_QOF and MAT data items_tbl’ 
Copy the training tool and rename it for your purposes. Open your tool and select 
‘Tables’ in the ‘object bar’. Click with the right mouse button at ‘Patients: NHS Read 
codes_QOF and MAT data items_tbl’ and select ‘Export…’: 
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The following dialog field will appear: 
 
Choose where you want to save the table and select in the ‘Save as type’ drop 
down ‘Microsoft Excel 97-2003’. Click ‘Export’. Go back to your tool in Microsoft 
Access and open the table ‘Patients: NHS Read codes_QOF and MAT data 
items_tbl’. Then mark all the data stored in this table and click the ‘Delete Record’ 
icon: 
  
 Click the ‘Save’ icon and close the table. 
 
Open the Microsoft Excel® document containing your exported table. Mark all the 
date stored in this document and delete it, but keep the row headings as they are. 
Now store the date you want to analyze in your table by copying and pasting. It 
might be necessary to put data other than Read Codes, like age or sex, in the 
ReadCode column. If you have to use the same data for more data items you will 
have to add a letter in the Read Code field, e.g.: 
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PatientKey 
 
 
ReadCode 
 
MAT Data item 
 
DateRecorded 
 
1103.C8746.Patient 
 
 
21 
 
10 years or 
older 
 
24/01/2005  
 
1105.C8746.Patient 
 
 
21+ 
 
20 years or 
older 
 
17/07/2002 
  
The important columns are patient key, READ Code, MAT Data item and date. The 
DateRecorded column does not necessarily have to contain data.  
Save the table when you are finished and go back to your tool. Select ‘Tables’ in the 
‘object bar’. Then select ‘New’ by clicking on the icon in the toolbar above.  The 
following dialog field will appear: 
 
Select ‘Import Table’ and click ok. Chose the table you created in Microsoft Excel. 
The following dialog field will appear: 
A Pharmaceutical Care Model on Osteoporosis: Targeting patient groups 
 
 
196 
 
 
Select ‘Show Worksheets’ and ‘Next’. The following dialog field will appear: 
 
 Select ‘First Row Contains Column Headings’ and ‘Next’. The following  dialog 
field will appear: 
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Select ‘In an Existing Table’ and in the drop down menu ‘Patients: NHS  Read 
codes_QOF and MAT data items_tbl’. Then click ‘Next’. The following dialog field will 
appear: 
  
 Select ‘Finish’. 
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For the ‘Drugs’ field: 
1. Create the Table ‘Patients: Drug History_tbl’ 
Export the ‘Patients: Drug History_tbl’ like explained above. Then delete all the 
records in both the exported document and the table in Microsoft Access®. 
Create the table in Microsoft Excel® by storing the data into the exported document.  
 
 
PatientKey 
 
 
drug_name 
 
drug_category 
 
preparation 
 
dose 
 
frequency 
 
1035.C8746.Patient 
 
Omeprazole 
 
PPI 
 
CAPS 10MG 
 
1 Cap 
 
In the morning 
 
 
1033.C8746.Patient 
 
Furosemide 
 
Loop diuretics 
 
TABS 40MG 
 
2 Tabs 
 
In the morning 
 
  
 Import the data into your tool the same way you did it for the table  before. Import it 
into the table ‘Patients: Drug History_tbl’. 
 
2. Create the Table ‘Master: Drug list_tbl’ 
Export the ‘Master: Drug list_tbl’ like explained above. Then delete all the records in 
both the exported document and the table in Microsoft Access®. 
Create the table in Microsoft Excel® containing brand, drug, drug group drug 
category, disease surrogate and data source like explained above.  The column 
‘drug’ has to contain the same data, which is stored in the column ‘drug_name’ in, 
the ‘Patient: Drug History_tbl’. The column ‘drug_catagory’ has to contain the same 
data, which is stored in the column ‘drug_category’ in, the ‘Patient: Drug 
History_tbl’.  
For importing the data into your tool follow the same procedure than before.  Import 
into the table ‘Master: Drug list_tbl’.  
 
For the ‘Investigations’ field: 
1. Create the table ‘Patients: Investigations_tbl’ 
Export the ‘Patients: Investigations_tbl’ like explained above. Then delete all the 
records in both the exported document and the table in Microsoft Access®. 
Create MAT Data item for each subset of values.  
Create the table in Microsoft Excel® data item, value, unit of measure, date 
recorded.   
e.g.: 
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The data stored in the ‘value’ column has to be a value- otherwise the tool will not 
work anymore. For importing the data into your tool follow the same procedure than 
before. Import into the table ‘Patients: Investigations_tbl’.  
 
 
Before using the tool the first time 
Open and close ‘Master: Drug list_tbl’, ‘qry_MAT’ and ‘qry_investigations_list’ once.  Now 
you are ready to start. Good luck with your data analysis! 
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